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MUltIPle SCleRoSIS: GeneRal IntRoDUCtIon
Multiple Sclerosis (MS) is the most common chronic (non-traumatic) disabling neurological 
disease in young adults1. It was first described in detail by Jean-Marie Charcot in 1868 
as a rare disease, but nowadays MS has a prevalence of 0.1-0.2 percent in the Western 
European population2. Females are twice as often affected compared to males1. The average 
age at onset is 30 years. The majority of patients (85%) presents initially with an acute or 
subacute episode of focal neurological deficits (most frequently affecting the optic nerve, 
brainstem/cerebellum, spinal cord or cerebral hemispheres)3. The symptoms often diminish 
over several weeks (sometimes full recovery occurs). This first episode is called Clinically 
Isolated Syndrome (CIS). Of these CIS patients around 30-70 percent will develop MS with 
a relapsing remitting course (RRMS), with full or partial recovery from these relapses4,5. In a 
substantial part of the RRMS patients, the phase of relapses and remissions is followed by 
slowly progressive increase of neurological disability (Secondary Progressive MS (SPMS)6. 
A minority of MS patients (10-15%) will not experience any relapses, but show disease 
progression from onset (Primary Progressive MS (PPMS))6,7. See figure 1 for schematic 
illustration of the course of the different types of MS.  
Figure 1: Schematic illustration of the course of the different types of MS. The X-axis represents time 
and the Y-axis represents neurological disability. RR = relapsing remitting, PP = primary progressive, SP 
= secondary progressive, PR = progressive relapsing.
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The disease course is highly variable between MS patients: in addition to the differences 
between subtypes indicated above, timing and nature of the neurological complaints are 
heterogeneous between individual patients with the same disease subtype. Symptoms can 
vary from decreased vision to (temporary) blindness, paresis and/or sensory disturbances 
in the limbs, cognitive complaints and mood disorders, clumsiness in the limbs to diplopia. 
These symptoms are caused by lesions in respectively the optic nerve, brain or spinal 
cord, cerebellum and brainstem. Quantification of these symptoms is difficult due to this 
variety of neurological symptoms and lack of one outcome-parameter comprising the full 
scope of MS. In our center we use the Multiple Sclerosis Functional Composite (MSFC) 
(assessing ambulatory function, upper limb function and (parts of) cognitive function)8 and 
the Expanded Disability Status Scale (EDSS). The EDSS uses information from neurological 
examination to evaluate the following seven neurological functional systems: visual, 
brainstem, pyramidal, sensory, cerebellar, bladder/bowel and cerebral function9. The EDSS 
is internationally the most commonly used outcome parameter, however, no single measure 
reflects the entire scope of disability (necessitating a combination of other, more functional, 
outcome parameters such as the MSFC)10. In general, disability accumulates during the 
disease course and patients with a longer disease duration experience more symptoms. 
The degree and speed of disability is highly variable. Some MS patients will only have mild 
or no complaints during their lifetime, while others are in need of a wheelchair within a year 
after disease onset4. This uncertainty on prognosis due to this heterogeneity (unknown time 
and place of new complaints and the accompanied disability) places an enormous burden on 
often young MS patients. From observational studies we already established some clinical 
indicators for a fast disability accumulation: a primary progressive disease course, a rapid 
deterioration in the first years after disease onset, a higher initial relapse rate, a shorter 
interval to the second relapse and a higher EDSS score at 5 years1,11-13. In addition to these 
clinical prognostic markers, more and more evidence from long-follow-up studies indicates 
that MRI parameters early in the disease may have additional prognostic value for disability 
after 20 years: T2 lesion volume at disease onset and increases of this T2 lesion burden 
within the first 5 years are correlated with disability after 20 years5.
Pathophysiology
Although the exact etiology of MS is unknown, it is generally thought that MS is an auto-
immune complex trait, resulting from an interplay between environmental factors and 
genes1. It is characterized by focal lesions in the central nervous system (brain and spinal 
cord) that can be observed postmortem by histopathological examination and in vivo using 
Magnetic Resonance Imaging (MRI). These lesions are scattered throughout the brain 
and spinal cord involving the white and grey matter. Only a small proportion of the new 
inflammatory lesions gives rise to neurological symptoms14, the remaining new lesions 
remain clinically silent. 
11
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The commonly accepted hypothesis is that these lesions are caused by an increase in auto-
reactive T cells that generate an inappropriate inflammatory response against myelin or 
oligodendrocytes1. After the initial inflammatory response remyelination occurs, but also 
gliosis. 
The pathology of MS is not restricted to lesions only. Also abnormalities in the normal 
appearing white matter (and grey matter) have been demonstrated, together with axonal 
loss. Axonal loss can be visualized by MRI by assessing the volume of the brain. In MS 
patients this volume declines faster than in normal aging people (a higher atrophy rate). This 
has been demonstrated in all stages of MS and it occurs not only during the inflammatory 
response, but also independent from the inflammation14. 
therapy
Therapy in MS is aimed on reducing relapses and slowing disease progression, since no 
curative treatment for MS is available. These Disease Modifying Therapies (DMTs) are 
only effective in the relapsing phase of the disease. No DMTs are available for secondary 
or primary progressive MS patients. The available therapies for RRMS are Interferons 
(Interferon Beta 1a and Interferon Beta 1b), Glatiramer acetate and since a couple of years 
Natalizumab has been added. These DMTs modestly succeeded in decreasing the number 
of relapses and (partially) inhibit the formation of new T2 lesions (and T1 gadolinium 
enhancing lesions) on MRI-scans15-20. In CIS patients DMT can delay a second relapse20. 
In RRMS patients Interferon has been demonstrated to delay clinical disability, however, 
the true long-term effects need to be determined in future studies20-22. Interferons and 
glatiramer acetate show comparable effectiveness and the same route of administration 
(requires frequent subcutaneous or intramuscular injections). Natalizumab (a monoclonal 
antibody against alpha-4-integrin, administered as monthly intravenous infusions) is more 
effective, however it is used as a second line drug due to the occasional occurrence of 
progressive multifocal leucoencephalopathy23. Recently oral drugs have been studied. One 
of them (Fingolimod) showed a higher effectiveness of this drug on reducing relapses and 
new lesions on MRI, when compared to the current first line drugs (intramuscular interferon 
beta 1a)24. Fingolimod has become recently available in the Netherlands as a second line 
oral disease modifying therapy. Longterm effects of these DMTs are still lacking.
DIaGnoSIS oF MUltIPle SCleRoSIS
Relapsing MS usually starts with an acute onset of neurological complaints, such as sensory 
disturbances, unilateral optic neuritis, diplopia, limb weakness, clumsiness, gait ataxia or 
bladder or bowel symptoms, but also cognitive impairment. This first episode in which a 
12
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patient presents neurological symptoms due to demyelination is called: clinically isolated 
syndrome (CIS). Only 30-70% of these patients will develop MS later in their lives4,5. No single 
diagnostic test for MS exists. The diagnosis of MS requires dissemination in time and place, 
as was described in 1983 by Poser25 and other causes of the clinical condition should be 
excluded. Dissemination in time (DIT) using the Poser criteria is defined as the occurrence of 
new neurological complaints lasting at least 24 hours and starting at least 30 days after the 
onset of the first episode. Dissemination in space (DIS) is defined as two different areas of 
the central nervous system that are affected, as detected by clinical (and paraclinical) signs 
and symptoms. If patients fulfilled clinically dissemination in time and space (had a second 
relapse, on a new location) the diagnosis: clinically definite MS (CDMS) could be made. 
Since 2001 Magnetic Resonance imaging (MRI) criteria of brain and spinal cord are allowed 
as evidence for dissemination in space and dissemination in time, facilitating early diagnosis 
and early treatment with disease modifying therapy26-30. In 2010 the International Panel on 
Diagnosis of MS set out the most recent diagnostic criteria30. Compared to previous criteria, 
these criteria are easier to use and in some patients the diagnosis can be made on one brain 
MRI scan only. Please see table 1 for a summary of the most recent diagnostic criteria. 
GenetICS oF MUltIPle SCleRoSIS 
MS is considered to be a complex auto-immune disease, in which an interplay of genetic 
and environmental factors is thought to cause the disease. The prevalence of MS varies 
considerably over the world, with the highest prevalence of more than 30 per 100,000 in 
northern Europe, southern Australia and North America2. Increasing latitude (distance from 
equator) correlates with increasing prevalence and incidence. This is possibly due to a lower 
exposure to sunlight in these countries and lower Vitamin D3 levels31-33. Also several viruses 
have been implicated in the pathogenesis of MS (Epstein-Barr virus has the most reliable 
epidemiological and laboratory data related to MS susceptibility)34,35.
Although it is hypothesized that environmental factors contribute significantly to MS 
susceptibility, the majority of these environmental factors are still unidentified. In this thesis 
we focus on genetic factors in MS.
13
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table 1: The revised McDonald 2010 criteria for diagnosis of MS30.
Clinical Presentation Additional Data Needed for MS diagnosis
≥2 attacks; objective clinical evidence 
of ≥2 lesions or objective clinical 
evidence of 1 lesion with reasonable 
historical evidence of a prior attack
None
≥2 attacks, objective clinical evidence 
of 1 lesion
Dissemination in space, demonstrated by ≥1 T2 lesion in 
at least 2 of 4 MS-typical regions of CNS (periventricular, 
juxtacortical, infratentorial or spinal cord); or await a further 
clinical attack implicating a different CNS site 
1 attack; objective clinical evidence 
of ≥2 lesions
Dissemination in time, demonstrated by: Simultaneous 
presence of asymptomatic gadolinium enhancing and 
non-enhancing lesions at any time; or a new T2 and/
or gadolinium-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline scan; 
or await a second clinical attack
1 attack; objective clinical evidence 
of 1 lesion (Clinically Isolated 
Syndrome (CIS))
Dissemination in space and time, demonstrated by: For DIS: 
≥1 T2 lesion in at least 2 of 4 MS typical regions of the CNS 
(periventricular, juxtacortical, infratentorial or spinal cord); 
or await a seond clinical attack implicating a different CNS 
site; and for DIT: Simultaneous presence of asymptomatic 
gadolinium enhancing and nonenhancing lesions at any 
time; or a new T2 and/or gadolinium-enhancing lesion(s) on 
follow-up MRI, irrespective of its timing with reference to a 
baseline scan; or await a second clinical attack.
Insidious neurological progression 
suggestive of Primary Progressive MS 
(PPMS)
One year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the following 
criteria:
1. Evidence for DIS in the brain based on ≥1 T2 lesion in the 
MS characteristic regions (periventricular, juxtacortical or 
infratentorial).
2. Evidence for DIS in the spinal cord based on ≥2 T2 lesions 
in the cord.
3. Positive CSF (isoelectric focusing evidence of oligoclonal 
bands and/or elevated IgG index)
Genetic role in MS susceptibility
Familial clustering of MS cases has been demonstrated in several studies36-40. Recurrence in 
monozygotic twins is >20%41. First degree relatives have a higher risk (~2%) of developing 
MS than the general population (0.1%). The risk correlates with the amount of shared genes 
with the affected family member. MS is a complex genetic disease, that is characterized 
by modest disease risk heritability and additionally gene-environment interactions35,42. The 
strongest gene effect, involved in MS susceptibility and already discovered in the mid-1970s, 
stems from the HLA-DRB1*1501 allele43,44. 
After decennia using (often underpowered) linkage and candidate gene studies to determine 
the heritability of MS (with little further progress), the past five years several Genome 
14
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Wide Association Studies (GWAS) were performed. GWAS studies are able to assess large 
quantities of Single Nucleotide Polymorphisms (SNPs) (300.000 – 500.000) at once and when 
performed in large groups of MS patients, this high-throughput-technique is able to detect 
SNPs with a modest effect on MS susceptibility. SNPs are DNA sequence variations occurring 
when a single nucleotide in the genome differs between people, of which some variations 
are associated with a higher risk on developing MS. Several GWAS were performed in large 
sets of MS patients and identified several loci related to MS susceptibility with “genome-wide 
significance” (cut off p-value of < 5 x 10-7)45-50. All of these risk alleles are common, exert only 
modest individual effects on risk (odds ratios 1.1-1.3) and act seemingly independently51. 
Please see table 2 for a list of risk alleles associated with MS susceptibility. 
effect of genes on MS phenotype
Multiple Sclerosis is characterized by enormous variations in phenotype expression. Not 
only clinically: e.g. symptoms that can affect the entire body and varying rate of disability 
accumulation, but also paraclinically. When assessed by MRI: several areas of the brain 
and spinal cord are affected in varying degrees. The biological factors that underlie this 
heterogeneity are poorly understood. The current hypothesis is that disease progression 
and other phenotypic variability of MS are influenced by genetic and non-genetic factors52.
Studies in families with multiple MS patients provided evidence for a familial effect on disease 
course, age at onset and disease progression53-56. Moreover, pathological studies on these 
lesions in MS show four distinct, but overlapping histological types57. The histopathological 
appearances are generally similar between lesions from each patient, but differ between 
patients, indicating heterogeneity in pathology between patients57.
Before the “GWAS-era”, several genes (APOE, IL1RN, MHC class II and IL1B) were implicated 
to be related to disease severity, however effect sizes and size of study populations were 
small and results were often ambiguous58-60. Most of these genotype-phenotype associations 
await confirmation in different datasets. 
15
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table 2: Established non-MHC MS susceptibility genes.86
Susceptibility gene rs-number OR estimate
VCAM1 rs11581062 1.12
PLEK rs7595037 1.11
MERTK rs17174870 1.11
SP140 rs10201872 1.14
EOMES rs11129295 1.11
CD86 rs9282641 1.21
IL12B rs2546890 1.11
BACH2 rs12212193 1.09
THEMIS rs802734 1.10
MYB rs11154801 1.13
IL22RA2 rs17066096 1.14
TAGAP rs1738074 1.13
ZNF746 rs354033 1.11
MYC rs4410871 1.11
PVT1 rs2019960 1.12
HHEX rs7923837 1.10
CLECL1 rs10466829 1.09
ZFP36L1 rs4902647 1.11
BATF rs2300603 1.11
GALC rs2119704 1.22
MALT1 rs7238078 1.12
TNFSF14 rs1077667 1.16
MPV17L2 rs874628 1.11
DKKL1 rs2303759 1.11
CYP24A1 rs2248359 1.12
MAPK1 rs2283792 1.10
SCO2 rs140522 1.10
MMEL1 rs4648356 1.14
EV15 rs11810217 1.15
RGS1 rs1323292 1.12
C1orf106 rs7522462 1.11
CBLB rs2028597 1.13
IL7 rs1520333 1.10
IL2RA rs3118470 1.12
TMEM39A rs2293370 1.13
IL12A rs2243123 1.08
NFKB1 rs228614 1.09
IL7RA rs6897932 1.11
PTGER4 rs4613763 1.20
ZMIZ1 rs1250550 1.10
CD6 rs650258 1.12
CXCR5 rs6309023 1.12
TNFRSF1A rs1800693 1.12
CYP27B1 rs12368653 1.10
ARL6IP4 rs949143 1.08
SOX8 rs2744148 1.12
CLEC16A rs7200786 1.15
IRF8 rs13333054 1.11
STAT3 rs9891119 1.11
RPS6KB1 rs180515 1.09
TYK2 rs8112449 1.08
CD40 rs2425752 1.11
TNFRSF6B rs6062314 1.16
Intergenic rs13192841 1.10
Intergenic rs669607 1.13
Intergenic rs12466022 1.11
16
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IMaGInG MUltIPle SCleRoSIS
brain MRI
MS lesions can be visualized using Magnetic Resonance Imaging (MRI) and have greatly 
improved the sensitivity and specificity of the diagnostic MS criteria by detecting clinically 
silent lesions28. The typical MS lesions are especially apparent on T2-weighted images as 
hyperintense (bright) spots. However, T2 lesions do not have pathological specificity and 
are also present in normal ageing and other neurological diseases. The MS lesions may 
be pathologically characterized by inflammation, demyelination, gliosis, edema or axonal 
loss 61,62. New T2 lesions are considered a subclinical marker for MS disease activity, and 
their numbers are moderately correlated with relapse frequency. To distinguish active and 
inactive inflammatory lesions, gadolinium-based contrast agents are administered. Lesions 
that appear bright on T1 weighted MR images after contrast administration (gadolinium 
enhancing lesions), reflect disruption of the blood brain barrier due to acute inflammation. 
On the same T1 weighted images without prior injection of contrast agent, dark spots are 
commonly found in MS patients. These spots are called hypo-intense lesions (also: black 
holes). These T1 hypo-intense lesions are indicative of extensive brain tissue damage, but 
may also arise as a result of inflammation related edema. 
Although the entrance of MRI in the field of MS has increased the diagnostic possibilities, 
the relation between MRI abnormalities and disability remain limited: this has often been 
referred to as the “clinico-radiological paradox”63. The number and volume of lesions 
are frequently used in monitoring disease evolution and assess treatment efficacy in 
MS, even though an ambiguous relationship between the extent of lesions and clinical 
disability appears64,65. It has been shown that focal lesions only partially explain disability. 
Apart from focal lesions, a higher atrophy rate of the brain is present in MS patients in all 
stages of the disease, when compared to healthy controls66. This brain volume loss due 
to neurodegeneration is better correlated to disability change and can be calculated using 
standard T1 weighted images. However, still no full explanation for the clinico-radiological 
paradox has been demonstrated. Another possible explanation for this paradox could 
be the presence of diffuse changes in the white matter and grey matter lesions (difficult 
to visualize using the conventional MRI sequences). New MRI techniques such as DIR 
(detecting grey matter lesions in the cortex and basal ganglia)67, MR spectroscopy, diffusion 
tensor, magnetization transfer and functional MRI are currently being studied to assess their 
ability to detect these less visible changes in the MS brain, that may explain the disease 
progression. Finally, the location of lesions within the brain have been found to be related to 
disease disability and might explain part of the clinico-radiological paradox (box 1)68. 
17
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box 1: lesion Probability Mapping
Lesion location within the brain is highly variable between MS patients. Although there 
are some predeliction sites such as the periventricular, juxtacortical and infratentorial 
region, it has been demonstrated that the distribution is highly variable between 
patients. Within families, however, a higher concordance has been observed in lesion 
location69. It is hypothesized that lesion location determines symptomatology (and is 
able to explain part of the clinico-radiological paradox). To determine whether lesion 
location is genetically determined (see chapter 3.2) we used the Lesion Probability 
Mapping (LPM) method. This method enables us to assess relations between genotype 
and lesion location without a priori dividing the brain into a number of regions. For all 
patients T2 lesion-maps are generated. On these maps the lesions are outlined and 
groups with a certain genotype could be compared to the rest of the patients not carrying 
this genotype. All lesion masks of patients carrying a certain genotype were stacked and 
one mask was created indicating for every voxel the frequency of the presence of a 
lesion for these patients. For every voxel we assessed whether the patients carrying a 
certain genotype have a significantly higher probability of having a lesion in this voxel 
compared to patients not carrying the genotype. 
Spinal cord MRI
Abnormalities in the spinal cord (focal lesions and diffuse abnormalities) are found in 
the majority of established MS patients (>90%)70. In MS patients, lesions are usually less 
than two vertebral segments in length, mostly located in the cervical cord71. These lesions 
can be visualized using MRI scan of the spinal cord, using conventional cardiac triggered 
sagittal PD and T2-weighted dual echo spin echo sequences. Spinal cord lesions may 
occur independently of MS brain abnormalities72. Moreover a small proportion of CDMS 
patients (less than 5%) does have abnormalities in the spinal cord, but does not exhibit 
abnormalities in the brain73. It has been suggested that a subgroup of MS patients might 
be more susceptible to a high amount of spinal cord lesions and few brain lesions, while 
others have extensive brain lesions and no spinal cord lesions. This heterogeneity is not well 
understood. Not only focal abnormalities are present in MS, but also spinal cord atrophy and 
diffuse abnormalities can be present66. 
The importance of spinal cord lesions on diagnosing MS has been accepted by MS experts, as 
is reflected in the most recent diagnostic criteria30. In CIS patients often asymptomatic spinal 
cord lesions are found (prevalence around 30-40%)74,75 and spinal cord imaging is useful for 
several reasons. First, in spinal cord CIS, spinal cord MRI can rule out compressive spinal 
cord disease and characterize intrinsic spinal cord lesions. Second, in brain CIS, the finding 
of asymptomatic spinal cord lesions is of additional value in demonstrating dissemination 
18
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in space. Finally, CIS patients with asymptomatic spinal cord lesions more often convert to 
clinically definite MS than patients without spinal cord lesions74. Although spinal cord MRI 
can be useful in diagnosing MS, it was found less suitable for monitoring dissemination in 
time using previous diagnostic criteria, as brain MRI shows more new lesions over time than 
spinal cord MRI73. 
Spinal cord parameters have been found to be associated with disability. About 30% of new 
lesions in the spinal cord cause symptoms, compared to only 6% of new brain MRI lesions73. 
The number of focal lesions within the spinal cord correlates weakly with the degree of 
disability (mainly associated with bladder symptoms and walking disability)72,76. Mounting 
evidence points out that diffuse abnormalities may be more predictive of disability77. Diffuse 
abnormalities have been found to be associated with higher disability and a progressive 
disease course72,78,79. However, these diffuse abnormalities are only present in a minority 
of MS patients. In contrast, spinal cord atrophy is a more frequent finding in MS and has 
been found to be an important factor leading to irreversible disability77,80,81. No correlation 
was found between the extent of focal lesions (in brain and spinal cord) and cord atrophy, 
indicating that cord atrophy might be an independent feature of MS 82-85.
 
aIMS anD oUtlIne oF tHIS tHeSIS
As has become clear from the previous paragraphs, the heterogeneity in MS is enormous, 
not only clinically (symptoms throughout the entire body and disability ranging from no 
complaints until death due to MS), but also paraclinically (a huge variety in lesion location 
throughout the brain and the spinal cord). Knowledge on factors involved in MS phenotype 
is important (especially early in the disease). This knowledge may enable us to identify 
patients susceptible for early disability accumulation. These patients might benefit more 
from early treatment with a more aggressive disease modifying therapy. While in patients 
with an expected benign disease course, disease modifying therapy could be postponed or 
maybe not started at all. This would increase the cost-effectiveness of disease modifying 
therapy and prevent “unnecessary” adverse events. Moreover, from a patient perspective, 
an earlier diagnosis of MS and a more accurate prediction on what to expect in the future, 
can be valuable for patients. This knowledge might help (often young) patients in planning 
their lives and may reduce the high degree of uncertainty that MS patients are faced with 
nowadays. Ultimately, knowledge of the processes underlying disease progression may lead 
to new treatment strategies. 
So far, few clinical parameters have been found to have some prognostic value in patients: 
age at onset, disease subtype (progressive onset) and high relapse frequency early in the 
disease1,11-13. Additional markers that could be assessed early in the disease are needed. 
19
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Information on the genetic background of several phenotypic differences is still scarce, 
however several studies imply a genetic influence on these differences. Of these phenotypic 
differences, disease progression and the speed of disability accumulation are considered 
as (one of) the most important measures related to the prognosis of the patient. We 
hypothesize that genetic information and spinal cord parameters (lesions and atrophy of 
the spinal cord) can explain part of the phenotypic heterogeneity of MS, especially disease 
progression and speed of disability accumulation. Can we identify endophenotypes, using 
genetic information, spinal cord MRI variables in combination with clinical hallmarks?
Both biomarkers (genetic information and MRI hallmarks) may be proven valuable, based on 
their own characteristics. While genetic information possibly reflects a predisposition for a 
certain aspect of disease phenotype, it has the advantage of remaining constant over time 
and the possibility to assess this early in the disease. In addition, imaging variables (such as 
spinal MRI features) however changes over time and visualizes the regions of the central 
nervous system that are affected. These characteristics may provide crucial information on 
the evolving disease and the speed of disability accumulation.
In chapter 2 we assessed the genetic effect on disease clinical phenotype. In chapter 2.1 
we test our hypothesis that disease severity is caused by a combination of genes in addition 
to several clinical factors. In a large group of well characterized MS patients, we genotyped 
around 80 SNPs. This genetic information was added to a statistical model to test whether 
the prediction of disease severity could be improved in addition to established clinical 
predictive variables.
In chapter 2.2 we examined the role of the Interleukin 7 Receptor gene. This gene has 
been found to be associated with the risk of MS. The genetic variation (single nucleotide 
polymorphism (SNP)) that has the highest association with MS susceptibility is causing 
changes on mRNA level. We hypothesized that the function of Interleukin 7 Receptor in the 
inflammatory process might also lead to disease modifying capacities. 
As mentioned above, disease severity is thought to be caused predominantly by the 
neurodegenerative part of MS, while the inflammatory process is more relevant in relapse 
occurrence and development of new lesions. However, only one MS susceptibility gene with 
a direct role in neurodegeneration has been found up till now: the KIF1B gene. This gene 
was found in three different populations associated with MS susceptibility. In chapter 2.3 we 
examine whether this KIF1B-gene has a role in some of the neurodegenerative phenotypes 
of MS (atrophy rate, disability accumulation in the long run). 
In chapter 3 we tried to assess the genetic role in lesion distribution in MS. It is described 
that lesion location is one parameter that might indirectly affect disease severity, as some 
lesions in clinical relevant areas of the central nervous system, are more likely to cause more 
complaints. Several studies have suggested a genetic role in the lesion distribution. First in 
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chapter 3.1 we assessed the genetic role in distribution of lesions between the brain and 
the spinal cord. 
Second, in chapter 3.2 we tried to see whether lesion distribution within the brain could be 
explained by genotype of a group of selected genes that are thought to be related to MS. 
In chapter 4 we assessed the clinical relevance of spinal cord lesions on diagnosing MS 
(chapter 4.1) using the new diagnostic criteria. Furthermore we assessed the relevance of 
upper cervical cord atrophy and other clinical and MRI features (brain and spinal cord) to 
predict disease severity (chapter 4.2).
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Chapter 2.1
abstract
background: Multiple sclerosis (MS) is a heterogeneous neurological disease with varying 
degrees of severity. The common hypothesis is that susceptibility to MS and its phenotype 
are caused by a combination of environmental and genetic factors. The genetic part exerts 
its effect through several genes each having modest effects. 
objectives: We evaluated whether disease severity could be predicted by a model based 
on clinical data and data from a DNA chip. The DNA chip was designed containing several 
single nucleotide polymorphisms (SNPs) in 44 genes, previously described to be associated 
with MS.
Methods: A total of 605 patients with Multiple Sclerosis were included in this analysis, 
using gender, onset type and age at onset as clinical covariates. We correlated 80 single 
nucleotide polymorphisms to the degree of disease severity using the following three 
outcome measures: linear Multiple Sclerosis Severity Score (MSSS), dichotomous MSSS 
(using a cut-off point of 2.5) and time to reach EDSS 6. 
Results: Sixty-nine single nucleotide polymorphisms were included in the analysis. No 
individual single nucleotide polymorphism showed a significant association; however, a 
combination of single nucleotide polymorphisms significantly improved the prediction of 
disease severity in addition to the clinical variables. In all three models the Interleukin 2 
gene was included, confirming a previously reported modest effect on disease severity. The 
highest power was obtained using the dichotomized MSSS as outcome. 
Conclusions: Several single nucleotide polymorphisms showed their added predictive value 
over the clinical data in the predictive models. These results support our hypothesis that 
disease severity is determined by clinical variables and genetic influences (through several 
genes with small effects) in concert.
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Introduction
Multiple Sclerosis (MS) is a presumed auto-immune disease affecting the central nervous 
system, characterized by demyelination and neurodegeneration. The clinical disease course 
is highly variable; some patients remain without significant functional loss for many years, 
while others become wheelchair-bound within a short period of time1. As different treatment 
options have become available (with varying efficacy and side-effects) the identification of 
patients prone to develop high disability within a short period, has become highly relevant. 
However, predictors for future disability are scarce.
Susceptibility and disease progression in MS is believed to be conferred by the interplay 
of genetic and environmental factors. The major histocompatibiliy complex (MHC) class II 
region on chromosome 6 was found to be highly associated with susceptibility to MS. In 
addition, a few single nucleotide polymorphisms (SNPs) showed genome-wide significance 
of association with small effect sizes to MS susceptibility2-4. The current opinion is that in 
addition to these genes, several other genes, each exerting a small effect on susceptibility 
to MS remain to be discovered5. Much effort has been put into unravelling the genetic and 
environmental influences on disease susceptibility, but less attention has been given to 
causes of disease variability and severity. The current hypothesis is that disease progression 
and other phenotypic variability of MS are influenced by genetic and non-genetic factors6. 
Earlier studies have reported intrafamilial concordance for certain phenotypes: disease 
course, disease severity and age at onset7-11. Several genes (APOE, IL1RN, MHC class II and 
IL1B) have been studied in relation to disease severity, however effect sizes were small and 
results were ambiguous12-14. Recently, alleles at the HLA-DRB1 locus have quite convincingly 
been shown to affect disease severity15-16. HLA-DRB1 alleles are also found associated with 
the development of antibodies against interferon-beta therapy and magnetic resonance 
imaging (MRI) parameters, possibly exerting an effect on disease course17-19. 
Determining the genetic influence on the disease process is important to gain insight into 
the pathophysiological mechanisms involved, and may suggest therapeutic approaches 
more readily than identifying genes involved in disease susceptibility12. Clinical predictors 
of disease severity were already identified, the most important being onset type (relapsing 
versus progressive), age at onset and gender. 
We hypothesize that a combination of genes might improve the prediction of expected 
disease severity over purely clinical variables and designed a DNA chip to address this theory.
In this study we evaluated the additional prognostic value of genetic information of a DNA 
chip, containing a set of candidate genes, previously correlated to MS (either susceptibility 
or phenotypes) over available demographics and clinical characteristics, aiming to improve 
the prediction of the expected disease severity for future patients. 
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Material and methods
Study participants:
A total of 605 unrelated Dutch Caucasian patients were selected retrospectively from natural 
history studies conducted at the MS Center at the VU University Medical Center (VUmc) 
in Amsterdam. The selection was based on the availability of DNA, clinical assessment of 
disability and the confirmed diagnosis of MS. No inclusion criteria for disability status, 
age, gender or onsettype were applied during selection of data for analysis. This study was 
carried out with the approval of the Medical Ethics Committee of the VUmc and informed 
consent was obtained from all participants. Patients were all diagnosed with MS according 
to Poser or McDonald criteria20-21. Clinical data were collected retrospectively including age, 
gender, onsettype, disease course, age at onset and duration of the disease. Disability status 
was determined for all subjects by using Kurtzke’s Expanded Disability Status Scale (EDSS)22. 
These scores were not acquired during relapses.
Since no single golden standard for disease severity exists, we considered two outcomes 
for the patients: the Multiple Sclerosis Severity Score (MSSS) and time to reach EDSS 6, a 
clinically relevant endpoint, indicating that assistance for walking is required. We calculated 
the global MSSS from EDSS scores and disease duration at the time of patients’ last visit 
as described earlier23. The global MSSS denotes the speed of disability accumulation of an 
individual patient compared with a large patient cohort.
Selection of SnPs:
SNPs were selected based on involvement in MS pathogenesis, prognosis or response to 
treatment, published in literature before July 2007. The polymorphisms were confirmed 
and associated to an identifier by using dbSNP database (www.ncbi.nlm.nih.gov/SNP). 
Nucleotide sequences for the design of allele-specific probes and PCR primers were retrieved 
from the SNPper database (http://snpper.chip.org/bio) and NCBI database (www.ncbi.nlm.
nih.gov/SNP). Sequence specific probes and primers were designed by using the software 
Primer3, which is freely available at http://frodo.wi.mit.edu/. Gene names were applied 
according to the HUGO Gene Nomenclature Committee.
Genotyping:
Genomic DNA was isolated from anti-coagulated blood with DNAzol reagent (Molecular 
Research Center, Inc., Cincinnati, OH). Genotyping was carried out using a newly developed 
low-density DNA microarray based on allele-specific probes. The design, fabrication, 
validation and analysis of the arrays were performed following the procedure described 
earlier with minor modifications24. 
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Variable selection:
We employed feature selection to identify the most important and predictive features in 
the models to be analyzed. This approach of variable filtering is based on the marginal 
association between each variable (SNP or clinical variable) and phenotype, as variables are 
typically filtered on the basis of a p-value cut-off from a univariate analysis.
The following outcome measures for disease severity were applied in our study: the time 
to reach EDSS 6 and MSSS. The MSSS outcome was employed in two ways: as a continuous 
outcome measure and after dichotomization, using a cut-off point of MSSS 2.5. The purpose 
of the latter approach was to compare relatively benign patients to more severely affected 
patients. 
For the continuous MSSS we used the non-parametric Kruskal-Wallis (KW) test. For the 
dichotomized MSSS, the Chi-Square test was used. For time to reach EDSS 6 groups were 
compared by logrank tests.
To correct for multiple testing False Discovery Rate (FDR) according to Benjamini and 
Hockberg was applied25. The corrected number represents the expected proportion false 
discoveries for a given p-value cut-off. We used cut-off 0.05 after FDR correction. 
Additionally, we tested the association of the SNPs included on the chip with onsettype 
(relapsing vs progressive onset) with a Chi-Square statistic on contingency tables. P-values 
were adjusted using the FDR as described above. 
Predictive models:
HelixTree® software (Golden Helix, Inc., Bozeman, MT, USA) was used to calculate allelic 
association between different groups and deviations from Hardy-Weinberg Equilibrium 
(HWE). The same software calculated linkage disequilibrium among SNPs. In order to filter 
the SNPs included in the analyses, those SNPs that were monomorphic and those with 
minor allele frequency below 5% in our studied population were removed from the analysis. 
In addition, when a complete linkage disequilibrium among SNPs was observed (r2 >0.8) 
only the one with the lowest p value for allelic association between SNPs and phenotypes 
was included in the regression model. Multivariate prognostic models were constructed for 
the following outcomes: continuous MSSS, dichotomous MSSS with the cut-off point of 2.5 
and time to reach EDSS 6, using linear regression model, logistic regression model and Cox-
regression model respectively, using SPSS version 15.0 (SPSS Inc. Headquarters, Chicago, IL, 
USA) and R packages Design (Harrell, 2001) and Stats (R Development Core Team, 2008).
First clinical variables (age at onset, gender and onsettype) were included as independent 
variables in all models. Secondly, backward selection was applied to select the SNPs that 
contributed to the model to increase the predictive power.
The goodness of fit of the model was evaluated using Hosmer-Lemeshow statistic and the 
accuracy was assessed by calculating the bootstrap area under the Receiver Operating 
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Characteristic (ROC) curve (AUC) with 95% confidence intervals. Bootstrapping on the 
model’s AUC was conducted 500 times using 100% random sampling by replacement, using 
R package Boot. To measure the impact of the SNPs and variables included in the logistic 
regression model of the analyzed phenotypes, the sensitivity, specificity, and positive 
likelihood ratio (LR+ = sensitivity / (1-specificity)) were computed by means of ROC curves. 
AUC – ROC curves of the models based on clinical variables alone and clinical variables plus 
SNPs were compared by using the method by Delong et al.26 implemented in the software 
Analyse-it (Analyse-it Software Ltd. Leeds, UK). The goodness of fit of the models based on 
clinical variables alone and clinical variables plus SNPs, was compared using a Likelihood 
Ratio Test and Akaike’s Information Criteria (AIC)27. Both analyses were performed using R 
statistical software.
Results
Patient characteristics
Our patient group (n=605) reflects a representative MS population, with approximately 35% 
male and 17% primary progressive MS patients (see table 1). Eighty-six out of 605 patients 
(14.2%) from the study population had MSSS values < 2.5 indicating a relatively benign 
disease course.
SnP selection
Eighty validated polymorphisms located in 44 different genes were studied on a DNA chip 
(see supplementary table 1 for the complete list). Five SNPs were monomorphic and 6 
had a minor allele frequency below five percent. These eleven SNPs were excluded prior to 
univariate analysis. Finally, 69 SNPs were included in the analyses. 
Univariate analysis on SnPs in relation to severity outcome-measures
We first determined the correlations of the individual SNPs to the outcome measures: 
MSSS, time to reach EDSS 6 and dichotomous MSSS using MSSS 2.5 as a cut-off point. The 
raw p-values and corrected p-values of the SNPs are noted in supplementary table 2. No 
SNP remained significantly associated after correcting for multiple testing. 
effect of SnPs on onsettype
The analysis of the effect of the different SNPs on the onsettype did not reveal any significant 
association after correcting for multiple testing.
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table 1: Patient characteristics. Patient demographics and clinical characteristics divided in MS 
subtypes. 
All RR SP PP
Total number of patients 605 310 190 105
Gender (n; % Male) 219 (36.2) 96 (31.0) 78 (41.1) 45 (42.9)
Mean age at onset (SD) 32.4 (9.5) 30.4 (8.0) 30.6 (8.8) 41.6 (9.5)
Mean disease duration (SD) 13.1 (8.3) 9.7 (5.9) 18.2 (9.3) 13.8 (7.6)
Median EDSS (Interquartile range) 4.0 (3.5) 3.0 (2.0) 6.5 (1.5) 6.5 (3.5)
Median MSSS (Interquartile range) 5.6 (4.7) 3.9 (3.7) 7.9 (3.7) 7.3 (3.3)
Number of patients that reached EDSS 6 (%) 234 (38.7) 27 (8.7) 147 (77.4) 60 (57.1)
Median time to reach EDSS 6 in months 
(Interquartile range)
103 (105) 102 (83) 114 (121) 84 (91)
EDSS: Expanded Disability Status Scale; MSSS: Multiple Sclerosis Severity Score; PP: primary 
progressive; RR: relapsing remitting; SD: standard deviation, SP: secondary progressive.
Multivariate prognostic models on disease severity:
The linear model (MSSS) returns two non-zero coefficients for the SNPs, both originating 
from the IL2 SNP rs2069763, in addition to the clinical variables (see table 2). The Cox-
regression analysis returns nine non-zero coefficients for the SNPs. However, all coefficients 
are close to zero or the 95%-confidence interval include 1 (see table 3). 
table 2: Predictive model using MSSS as a continuous outcome variable (linear regression). Indicator 
variables have been created for the categorical predictors. The reference group for gender is “female”, 
the reference group for onsettype is “relapsing”, and the reference group for IL2 (rs2069763) is “GG”.
Indicator 
variable
b-coefficient 
(unstandardized)
β-coefficient 
(standardized)
95% Confidence 
interval for 
b-coefficient 
(unstandardized)
Significance
age at onset 0.05 0.17 0.02-0.07 0.0001
Gender Male 0.51 0.09 0.09-0.93 0.0183
onsettype Progressive 0.94 0.13 0.34-1.53 0.0021
Il2 (rs2069763) GT 
TT 
-0.51 -0.10 -0.95- -0.08 0.02
-1.00 -0.13 -1.65- -0.08 0.0027
When using the model for the dichotomous outcome of the MSSS (with a cut-off point of 
2.5) three clinical covariates and six SNPs were included in the model (see table 4). 
The linear regression corrected R-square is 0.088 and the Cox regression R-square is 0.02. 
The R-square for the logistic regression is 0.219, indicating a higher predictive power for the 
logistic regression model using the dichotomous outcome, although these are not directly 
comparable. Therefore, only for the dichotomous model ROC curves are obtained to test the 
additive value of the SNPs over the clinical data relevant to disability accumulation. 
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table 3: Predictive model using survival analysis on time to reach EDSS = 6 (Cox-regression).
β-coefficient oR 95% Confidence 
interval for oR
Significance
age at onset 0.03 1.033 1.02-1.05 <0.001
Gender
Male vs female 0.28 1.32 1.01-1.73 0.046
nDUFS7 (rs2074897)
AG vs GG
AA vs GG
-0.05 0.96 0.69-1.33
0.030
0.786
0.36 1.44 0.99-2.08 0.054
aDaMtS14 (rs4747075)
AG vs GG
AA vs GG
-0.54
0.001
0.58 0.42-0.80 0.001
-0.53 0.59 0.39-0.89 0.011
FaS (rs2234978)
CT vs CC
TT vs CC
0.25
0.016
1.28 0.97-1.70 0.086
0.60 1.83 1.19-2.82 0.006
Il2 (rs2069762)
TG vs TT
GG vs TT
0.28
0.008
1.33 1.00-1.75 0.044
0.70 2.02 1.23-3.31 0.005
SPP1 (rs2853744)
GT vsGG 0.58 1.78 1.18-2.67 0.006
Figure 1 shows ROC curves obtained with the “clinical model” and the “clinical-genotypic 
model”. The clinical model includes age at onset, onsettype and gender. While the clinical-
genotypic model includes the selected SNPs (see table 4) in addition to the clinical 
parameters. The curve obtained from the clinical-genotypic model shows a sensitivity of 
37% with specificity of 95.3% and an LR+ of 7.9 (AUC=0.78), whilst the clinical model had a 
sensitivity of 27.4% with specificity of 95.3% and an LR+ of 5.8 (AUC=0.68).
By including genetic information (SNPs) in the model, a significant improvement in predictive 
power was obtained as calculated by means of the AIC and the Likelihood Ratio Test. The 
Likelihood Ratio Test showed that the model including SNPs fits the data significantly better 
than the model based on clinical variables only (X2=46.89, df=10, p<0.0001). In addition 
to this, the model including SNPs showed a lower AIC than that based on clinical variables 
only (443.9 vs 470.7). The multivariate model combining clinical data and genotypic data 
significantly predicted the severity of the disease (model X2=78.8, p< 0.001). The model 
discriminated well between patients who had mild and more severe forms of the disease 
(AUC = 0.78, bootstrap 95% CI 0.75-0.84). 
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table 4: Predictive model using dichotomous MSSS as outcome measure (threshold is set on MSSS 
< 2.5) (logistic regression).
β-coefficient oR 95% Confidence 
interval for oR
Significance
age at onset 0.05 1.05 1.02-1.08 0.004
Gender
Male vs female 0.70 2.02 1.14-3.57 0.015
onsettype
Progressive vs relapsing 1.55 4.69 1.32-16.63 0.017
noS2 (rs1137933)
AG vs GG
AA vs GG
-0.63 0.53 0.32-0.89
0.005
0.016
-1.41 0.24 0.09-0.67 0.006
PItPnC1 (rs1318)
AG vs AA
GG vs AA
-0.81 0.45 0.27-0.75
0.009
0.002
-0.53 0.59 0.18-1.95 0.387
Il2 (rs2069763)
GT vs GG
TT vs GG
-0.94 0.39 0.22-0.70
0.004
0.001
-0.98 0.38 0.17-0.84 0.016
CCl5 (rs2107538)
CT vs CC
TT vs CC
0.71 2.04 1.12-3.70
0.062
0.020
0.38 1.47 0.38-5.67 0.576
Il1Rn (rs423904)
CT/TT vs CC -0.52 0.60 0.36-0.99 0.047
PnMt (rs876493)
GG vs AA/AG -0.65 0.52 0.29-0.92 0.025
Figure 1: ROC curves for the “clinical model” and the “clinical-genotypic model”. The clinical model 
includes the following variables: age at onset, gender and onsettype. The clinical-genotypic model 
includes the variables mentioned in Table 4. The “clinical model” had a AUC of 0.68 and the clinical-
genotypic model had a AUC of 0.78. The Likelihood Ratio Test showed that the model including SNPs 
fits the data significantly better than the model based on clinical variables only (X2=46.89, df=10, 
p<0.0001).
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Discussion
As expected, we could not detect one major SNP / gene related to disease severity in our 
study. The current hypothesis concerning susceptibility genes and MS is based on the 
assumption that multiple genes exert a small effect on developing MS on top of the major 
influence of HLA-DRB1*1501. Our hypothesis was based on transferring this assumption 
to genes involved in disease progression. We therefore developed an instrument to detect 
these effects and built predictive models including several SNPs in addition to relevant 
clinical parameters.
We tested three different predictive models based on different outcome measures, as no 
single golden standard has been described in literature. 
Our results show that a combination of SNPs increases the predictive value of the models. 
Different genes were included in the different models, showing in general small individual 
effects on the outcome. The most prominent gene, included in all 3 models with 
moderately high coefficients encodes for interleukin-2 (IL-2). IL-2 (T cell growth factor) 
is an immunoregulatory cytokine important for the T cell homeostasis and is involved 
in the regulation of auto-immunity28-30. Previously this gene was found to be related to 
susceptibility to MS31 and genetic differences in this gene were found between relapsing 
remitting MS patients and secondary progressive MS patients31-32. Interestingly, Daclizumab, 
a humanized monoclonal antibody (mAb) that blocks the binding of interleukin-2 to the 
interleukin-2 receptor alpha unit (IL-2R-alpha chain; CD25), has shown to be effective in 
most patients who experienced persistent MS disease activity with first-line therapy33. 
Moreover, in secondary progressive MS patients heightened levels of IL-2 were reported 
and CSF concentrations of IL-2 were correlated with the degree of disability in patients with 
clinically active patients34. Genetic variation within the IL-2 gene is likely to modify disease 
progression. 
Interestingly, rs3135388 (a surrogate marker for HLA-DRB1*1501) did not show any effect 
on disease severity in any of the models. This contrasts other studies that have shown that 
carriers of the HLA-DRB1*1501 had a more severe disease course using an extreme-outcome-
strategy16. When applying the same strategy and definitions to our patient group, sample 
sizes of the benign and severe MS patient groups were too small to test this hypothesis. 
The most convincing model with the highest predictive power and the highest coefficients 
was the dichotomous model on the MSSS. The dichotomous model on the MSSS 
discriminates benign patients from the more severely disabled patients, by using a cut-off 
point of MSSS 2.5 (equivalent to an EDSS of three or lower at 15 years of disease duration; 
the common definition of benign MS). A dichotomous model might be more sensitive in 
detecting the small effects of the SNPs, however the survival model (time to reach EDSS 6) 
and the linear MSSS model provide more detailed information on the speed of disability 
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accumulation and on the severity of the disability. Unfortunately in our study only 38.7% of 
the patients reached the EDSS of 6, thereby limiting the power of survival analysis. Although 
we tried to lower the chance of overfitting of our predictive model, our findings should be 
further explored and confirmed in a different cohort of MS patients, preferably with a longer 
disease duration.
To improve the prediction on disability, selection of the right SNPs is essential. Our selection of 
SNPs was based on a heterogeneously reported association between this gene and multiple 
sclerosis susceptibility or phenotypes. The selection of SNPs was performed in the “pre- 
Genome-Wide Association Study (GWAS)- era”. Using information from recently published 
data of genes influencing disease phenotype35 could substantially improve our SNP selection 
in search of predictive models. Baranzini et al showed that MSSS was associated with genes, 
relatively new to MS literature. These genes are involved in cellular mechanisms such as 
protein amino acid N-linked glycosylation, cellular respiration and embryonic development. 
This study illustrates that disease-modifying genes are not necessarily identical to disease 
susceptibility genes35. 
More and more evidence points towards a predictive value of MRI parameters early in the 
disease for disability later on36. Including these early MRI parameters in the predictive model 
could improve the predictive value on future disability accumulation. Moreover inclusion of 
yet to be discovered genes and maybe environmental factors might increase the explained 
variance in disease severity. 
In summary, we showed in a relatively large sample of well characterised patients that in 
addition to clinical variables, genetic information is valuable to improve the prediction of 
disease severity in MS. However, to more precisely estimate the true genetic influence on 
disability accumulation in MS, replication of our results is key.
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Supplementary table 1: SNPs included on the DNA chip. MAF=minor allele frequency in our sample. 
Gene rs-number Chromosome Polymorphism MaF
ADAMTS14 * rs4747075 10q22 A/G 0.29
ADAMTS14 rs7081273 10q22 C/G 0.35
ADAMTS14 rs4746060 10q22 C/T 0.09
BTNL2 * rs2076530 6p21.3 A/G 0.23
CACNG4 rs4790896 17q24 C/T 0.41
CCDC46 rs987931 17q24 G/T 0.34
CCL5 rs2280788 17q11.2-q12              C/G 0.03**
CCL5 rs2107538 17q11.2-q12               C/T 0.19
CCR5 rs333 3p21 -/+ 0.10
CD24 rs8734 6q21 C/T 0.00**
CIITA rs3087456 16p13 A/G 0.26
CNTF rs1800169 11q12 A/G 0.13
CRYAB rs14133 11q21-q23 C/G 0.26
CRYAB rs762550 11q21-q23 A/G 0.37
CTLA4 rs231775 2q33 A/G 0.37
CTLA4 rs5742909 2q33 C/T 0.08
EBF1 rs1368297 5q34 A/T 0.38
FAS rs1800682 10q23 C/T 0.45
FAS rs3781202 10q23 C/T 0.40
FAS rs2234978 10q23 C/T 0.31
GABBR1 rs1805057 6p21.3 A/G 0.00**
HELZ rs2363846 17q24 C/T 0.49
HLA * rs2395166 6p21.3 C/T 0.47
HLA-DRA rs2213584 6p21.3 C/T 0.41
HLA rs2227139 6p21.3 C/T 0.41
HLA-DRA rs3135388 6p21.3 C/T 0.31
HLA rs9268458 6p21.3 A/C 0.18
HLA * rs6457594 6p21.3 A/G 0.39
HLA-DRA rs2395182 6p21.3 G/T 0.39
HLA-DRA rs2239802 6p21.3 C/G 0.39
HSPB2 rs2234702 11q21-q23 C/G 0.00**
IFNAR1 rs2257167 21q22 C/G 0.11
IFNGR2 rs9808753 21q22 A/G 0.15
IL1B rs1799916 2q14 G/T 0.00**
IL1B rs1143627 2q14 C/T 0.34
IL1B rs1143634 2q14 C/T 0.27
IL1RN rs419598 2q12-q14 C/T 0.27
IL1RN 2073 C/T 2q12-q14 C/T 0.27
IL2 rs2069763 4q26-27 G/T 0.36
IL2 rs2069762 4q26-27 G/T 0.25
IL4R rs1801275 16p12 A/G 0.23
IL7R rs11567685 5p13 C/T 0.25
IL7R rs7718919 5p13 G/T 0.14
IL7R rs11567686 5p13 A/G 0.35
IL10 * rs1800896 1q32 A/G 0.50
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MC1R rs1805009 16q24 C/G 0.02**
MC1R rs1805006 16q24 A/C 0.01**
MEFV rs28940577 16p13.3 A/G 0.00**
MOG rs3130250 6p22 A/G 0.20
MOG rs3130253 6p22 A/G 0.11
NDUFA7 rs2288414 19p13.2 C/G 0.03**
NDUFA7 rs561 19p13.2 A/G 0.18
NDUFS5 rs2889683 1p34.2 C/T 0.30
NDUFS5 rs6981 1p34.2 A/G 0.06
NDUFS7 rs2074897 19p13.3 A/G 0.49
NFKBIL1 rs3130062 6p21.3 C/T 0.15
NOS2 rs1137933 17q11.2 C/T 0.24
NOS2 rs2779248 17q11.2 C/T 0.40
NOTCH4 rs367398 6p21.3 A/G 0.21
PDCD1 rs11568821 2q37 A/G 0.11
PITPNC1 rs1318 17q24 C/T 0.20
PITPNC1 rs2365403 17q24 C/G 0.17
PNMT rs876493 17q11-q23 C/T 0.42
PRKCA rs7220007 17q24 A/G 0.48
PRKCA rs887797 17q24 C/T 0.29
PRKCA rs2078153 17q24 C/G 0.23
PRKCA * rs3890137 17q24 A/G 0.36
PTPN22 rs2476601 1p13 A/G 0.10
PTPRC rs17612648 1q31 C/G 0.02**
PTPRC rs4915154 1q31 A/G 0.01**
SPP1 rs1126616 4q21 C/T 0.23
SPP1 rs1126772 4q21 A/G 0.19
SPP1 rs2853744 4q21 G/T 0.05
SPP1 rs9138 4q21 A/C 0.24
SPP1 rs4754 4q21 C/T 0.24
TNF rs1800629 6p21.3 A/G 0.17
TNFSF10 rs1131568*** 3q26 A/G 0.34
UCP2 rs659366 11q13 C/T 0.36
VDR rs1544410 12q13 A/G 0.40
VDR rs731236 12q13 C/T 0.39
* Deviation from Hardy Weinberg proportions with p < 0.05.
**Excluded from analyses due to minor allele frequency < 0.05
*** Previously rs-number: rs9880164.
See list of abbreviations on page 181
42
Chapter 2.1
Supplementary table 2: Results of univariate analysis before and after correction for multiple testing. 
Significant values are printed in bold.
Gene rs-number
p-value 
logrank 
test on 
time to 
reach 
eDDS6
Corrected 
p-value 
(FDR) 
logrank 
test on 
time to 
reach 
eDDS6
p-value 
(kruskal 
Wallis) 
on linear 
MSSS
Corrected 
p-value 
(FDR) on 
linear 
MSSS 
p-value 
(ChiSquare) 
on 
dichotomous 
MSSS 
Corrected 
p-value on 
ChiSquare on 
dichotomous 
MSSS 
ADAMTS14 rs4747075 0.02 0.52 0.02 0.60 0.09 0.86
ADAMTS14 rs4746060 0.11 0.64 0.38 0.84 0.16 0.87
ADAMTS14 rs7081273 0.03 0.55 0.19 0.68 0.30 0.87
BTNL2 rs2076530 0.58 0.97 0.50 0.88 0.30 0.87
CACNG4 rs4790896 0.78 0.97 0.61 0.91 0.55 0.97
CCDC46 rs987931 0.17 0.66 0.62 0.92 0.46 0.97
CIITA rs3087456 0.87 0.97 0.87 0.93 0.94 0.97
CCL5 rs2107538 0.19 0.66 0.21 0.68 0.04 0.47
CCR5 rs333 0.33 0.82 0.42 0.84 0.61 0.97
CNTF rs1800169 0.83 0.97 0.72 0.93 0.59 0.97
CRYAB rs762550 0.30 0.80 0.83 0.93 0.66 0.97
CRYAB rs14133 0.98 1.00 0.71 0.93 0.74 0.97
CTLA4 rs5742909 0.85 0.97 0.18 0.68 0.11 0.87
CTLA4 rs231775 0.27 0.80 0.44 0.85 0.64 0.97
EBF1 rs1368297 0.86 0.97 0.93 0.96 0.71 0.97
FAS rs2234978 0.01 0.52 0.47 0.85 0.49 0.97
FAS rs1800682 0.99 1.00 0.81 0.93 0.64 0.97
FAS rs3781202 0.83 0.97 0.97 0.97 0.85 0.97
HELZ rs2363846 0.52 0.97 0.21 0.68 0.55 0.97
HLA-DRA rs3135388 0.32 0.82 0.12 0.65 0.25 0.87
HLA rs2395166 0.12 0.64 0.20 0.68 0.96 0.97
HLA rs9268458 0.29 0.80 0.36 0.84 0.51 0.97
HLA-DRA rs2213584 0.66 0.97 0.38 0.84 0.54 0.97
HLA rs2227139 0.70 0.97 0.43 0.84 0.65 0.97
HLA rs6457594 0.69 0.97 0.47 0.85 0.71 0.97
HLA-DRA rs2395182 0.30 0.80 0.06 0.65 0.16 0.87
HLA-DRA rs2239802 0.24 0.76 0.06 0.65 0.16 0.87
IFNAR1 rs2257167 0.15 0.64 0.10 0.65 <0.01 0.10
IFNGR2 rs9808753 0.11 0.64 0.08 0.65 0.12 0.87
IKBL rs3130062 0.71 0.97 0.41 0.84 0.30 0.87
IL1B rs1143627 0.06 0.55 0.10 0.65 0.83 0.97
IL1B rs1143634 0.94 1.00 0.76 0.93 0.64 0.97
IL1RN 2073 C/T 0.78 0.97 0.89 0.93 0.18 0.87
IL1RN rs419598 0.72 0.97 0.96 0.97 0.20 0.87
IL2 rs2069763 0.05 0.55 0.01 0.49 0.01 0.12
IL2 rs2069762 0.07 0.55 0.17 0.68 0.97 0.97
IL4 rs1801275 0.06 0.55 0.42 0.84 0.67 0.97
IL7R rs11567685 0.05 0.55 0.08 0.65 0.32 0.87
IL7R rs7718919 0.61 0.97 0.25 0.69 0.75 0.97
IL7R rs11567686 0.67 0.97 0.66 0.93 0.90 0.97
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IL10 rs1800896 0.14 0.64 0.22 0.69 0.83 0.97
MOG rs3130250 0.18 0.66 0.11 0.65 0.61 0.97
MOG rs3130253 0.36 0.86 0.12 0.65 0.91 0.97
NDUFA7 rs561 0.80 0.97 0.86 0.93 0.26 0.87
NDUFS5 rs6981 0.47 0.97 0.20 0.68 0.26 0.87
NDUFS5 rs2889683 0.24 0.76 0.38 0.84 0.61 0.97
NDUFS7 rs2074897 0.07 0.55 0.19 0.68 0.81 0.97
NOS2 rs1137933 0.47 0.97 0.42 0.84 <0.01 0.12
NOS2 rs2779248 0.85 0.97 0.60 0.91 0.38 0.97
NOTCH4 rs367398 0.70 0.97 0.87 0.93 0.96 0.97
PDCD1 rs11568821 0.85 0.97 0.61 0.91 0.75 0.97
PITPNC1 rs1318 0.19 0.66 0.10 0.65 0.01 0.12
PITPNC1 rs2365403 0.84 0.97 0.83 0.93 0.24 0.87
PNMT rs876493 0.38 0.87 0.30 0.80 0.01 0.19
PRKCA rs887797 0.84 0.97 0.25 0.69 0.35 0.93
PRKCA rs3890137 0.13 0.64 0.69 0.93 0.80 0.97
PRKCA rs2078153 0.69 0.97 0.83 0.93 0.90 0.97
PRKCA rs7220007 0.90 0.98 0.70 0.93 0.85 0.97
PTPN22 rs2476601 0.51 0.97 0.81 0.93 0.64 0.97
SPP1 rs2853744 0.09 0.64 0.10 0.65 0.59 0.97
SPP1 rs4754 0.76 0.97 0.51 0.88 0.65 0.97
SPP1 rs9138 0.74 0.97 0.56 0.90 0.67 0.97
SPP1 rs1126616 0.77 0.97 0.55 0.90 0.68 0.97
SPP1 rs1126772 0.99 1.00 0.78 0.93 0.94 0.97
TNF rs1800629 1.00 1.00 0.54 0.90 0.27 0.87
TNFSF10 rs1131568 0.82 0.97 0.24 0.69 0.18 0.87
UCP2 rs659366 0.95 1.00 0.84 0.93 0.26 0.87
VDR rs731236 0.65 0.97 0.87 0.93 0.84 0.97
VDR rs1544410 0.85 0.97 0.79 0.93 0.95 0.97
See list of abbreviations on page 181
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abstract
background: The Interleukin 7 Receptor (IL7R) has been recognized as a susceptibility gene 
for Multiple Sclerosis (MS). Analysis of rs6897932 (the most strongly MS-associated Single 
Nucleotide Polymorphism (SNP)), showed effects of genotype on the relative expression of 
membrane-bound to total amount of IL7R mRNA. 
objective: We assessed the relevance of IL7R on MS phenotype (including clinical and 
magnetic resonance imaging (MRI) parameters) at DNA and mRNA level in Dutch patients 
with MS. 
Methods: Genotype of rs6897932 was analyzed in 697 MS patients and 174 healthy controls. 
The relevance of genotype and carriership of the C-allele on MS phenotype (disease activity 
and severity, using clinical and MRI parameters) was assessed. In addition, relative gene 
expression of membrane-bound to total IL7R mRNA, was analyzed with respect to disease 
phenotype in a subgroup of 95 patients with early relapsing MS.
Results: In particular, homozygosity for the risk-allele is a risk factor for MS in our population 
(ORCC vs CT and TT=1.65 (95% CI: 1.18 – 2.30), two-sided p=0.004). However, no effect of genotype 
or the relative expression of membrane-bound IL7R (presence of exon 6-7) to total amount 
of IL7R mRNA (presence of exon 4-5) was found on MS phenotype. 
Discussion: Homozygosity for the IL7R exon 6 rs6897932 C allele is associated with a higher 
risk for MS in our Dutch population. No effect was found of genotype or mRNA expression 
on disease phenotype. 
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Introduction
The demyelinating neurodegenerative disease Multiple Sclerosis (MS) is the most common 
cause of chronic neurological disease in young adults1. Evidence indicates a complex 
interplay of genetic and environmental factors in the predisposition to this disease2-4. 
The strongest and most consistent genetic component is the Major Histocompatibility 
Complex (MHC) HLA-DRB1*1501-DQB1*0602 haplotype5. More recently, several non-MHC 
Single Nucleotide Polymorphisms (SNPs) were found, showing a more modest effect on 
susceptibility6-10. One of the SNPs identified and confirmed in several cohorts is rs6897932, 
located in exon 6 of the Interleukin 7 Receptor (IL7R) gene on chromosome 5p138-15. In 
linkage studies the chromosome 5p12-14 region was related to MS susceptibility. A role 
for the IL7R-gene in MS susceptibility was furthermore suggested because of its function in 
survival and proliferation of T and B cells16. For its action the cytokine IL-7 depends on the 
expression of its corresponding receptor on the cell surface (IL-7R)17,18. Two isoforms of the 
IL-7R receptor exist, a membrane-bound and a soluble isoform. 
The SNP with the strongest association within the IL7R gene, identified by the whole genome 
association studies and haplotype analysis, was rs6897932 (a non-synonymous SNP, leading 
to a coding change (T244I))9. In vitro analysis shows that the ‘C’ allele augments an exonic 
silencer resulting in an approximately two-fold increase in the skipping of exon 6 when 
compared with the ‘T’ allele, leading to increased production of the soluble form of IL-7R8.
In the family of cytokines and cytokine receptors, alternative splicing of pre-mRNA is a 
widespread regulatory mechanism that has been demonstrated to be involved in the control 
of gene expression influencing both cell development and cell activation17,19.
Due to the functional consequences of this polymorphism it can be postulated that this SNP 
not only has an influence on disease susceptibility, but may also affect the disease course: 
patients carrying the risk allele might have a more active disease. To our knowledge no other 
studies have addressed the possible effect of IL7R polymorphisms and relative expression 
levels combined in one study on MS disease course.
In this study our aim is to assess the importance of this IL7R SNP (rs6897932) in MS 
susceptibility in a Dutch population. Secondly, we study the relevance of this SNP (on 
DNA and mRNA level) on the disease course (measured by clinical and imaging outcome 
parameters). 
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Material and Methods
Subjects
We sampled 697 patients from MS natural history studies at the MS Center of the VU 
University Medical Center, Amsterdam, the Netherlands. Dutch Caucasian patients only 
were included based on availability of at least one clinical assessment of disability using the 
Expanded Disability Status Scale (EDSS) and the availability of DNA material. Patients had a 
diagnosis of MS according to McDonald criteria20 or Poser criteria21, depending on the time 
of data acquisition. Patients that presented with a first relapse with symptoms suggestive for 
demyelination that lasted at least 24 hours, however that do not fulfill the McDonald criteria 
at their most recent follow-up were also included (Clinically Isolated Syndrome (CIS))20. We 
included 174 unrelated Dutch Caucasian healthy controls in this study. This group was also 
incorporated (and described) in the study by Schrijver et al.22
This study was carried out with the approval of the Medical Ethical Committee of the VUmc 
and informed consent was obtained from all participants. 
MS-phenotype
For all patients the following clinical data on disease severity were collected: age at disease 
onset, most recent EDSS23 scores, Multiple Sclerosis Severity Scales (MSSS)24 and time to 
reach EDSS = 6 (a clinically relevant time-point indicating when a patient requires help in 
walking). When available Multiple Sclerosis Functional Composite (MSFC) scores25 were 
collected and used as secondary outcomes of disease severity. The MSFC is a composite 
score consisting of three separate tests, the Timed 25-Foot Walk (T25FW), the 9-hole Peg 
Test (9HPT) and the Paced Auditory Serial Addition Test (PASAT). Testing was performed 
under standardized conditions and tests were practiced at least once before baseline 
assessment. In patients that were followed up annually from disease onset up to at least 
2 years (n=210), the following disease activity measures were collected: occurrence of 
new relapses, use of disease modifying therapy (DMT) and the number of intravenously 
administered methylprednisolone treatment courses. 
Patient selection sub study on expression analysis:
For this sub study we selected a group of 95 relapse-onset patients from our total MS 
(DNA) cohort (n=697). This selection was based on the availability of mRNA. These patients 
were all sampled from one of our ongoing prospective natural history studies in early MS 
patients. Patients eligible for this study presented with CIS or were diagnosed with MS 
within the previous 6 months. RNA was collected at baseline and an MRI scan of the brain 
was performed at baseline and after two years of follow-up. At annual follow-up visits the 
above described measures of disease severity and disease activity were collected. 
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Genotyping
Genomic DNA was isolated from anticoagulated blood using DNAzol reagent (Molecular 
Research Center, Inc, Cincinnati, Ohio). The single nucleotide polymorphism (SNP) in exon 6 of 
the interleukin 7 receptor gene (IL7R) (dbSNP rs ID: rs6897932; HGVS nomenclature version 
2.0: NG_009567.1:g.22585C>T) was analyzed using the C___2025977_10 predesigned and 
validated Taqman Genotyping Assay on Demand from Applied Biosystems (Foster City, CA, 
USA).
expression analysis
Blood samples were collected using PaxGene RNA tubes followed by standard processing 
according to the manufacturers instructions. Automated RNA isolation was performed, 
within 3 months after freezing on the BioRobot MDX (Qiagen). The cDNA synthesis was 
performed with the SuperScript III First-Strand Synthesis System (Invitrogen) according 
to the manufacturer’s conditions. The total RNA input per reaction was 100 ng using a 
reverse IL7R primer (5’-TTC TTG GTT TCT TAC AAA GAT GTT CC-3’) complementary to exon 
7. Quantitative PCR was performed in duplicate on the ABI7300 with Platinum Quantitative 
PCR supermix-UDG w/Rox (Invitrogen). Quantitative analysis was done with the ABI7500 
software. 
The amounts of total (membrane-bound plus soluble) IL7R and membrane-bound form 
of IL7R mRNA were measured by assaying Hs00233682_m1 for exons 4–5 enabling the 
detection of total IL7R cDNA, and via Hs00904814_m1 spanning exons 6–7 reflecting only 
membrane-bound IL7R. Results are normalized to the expression level of ‘housekeeping 
gene’ glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to correct for experimental 
variations. Gene expression results were analyzed using the 2-ΔΔCt method for relative 
quantification26. The relative expression of membrane-bound IL7R to total amount of IL7R 
mRNA was expressed as a ‘fold-change’ value.
Magnetic Resonance Imaging (MRI)
Per protocol MRI scans were performed at baseline and at year 2 for patients from our 
ongoing natural history study in early MS. Scans were acquired either on 1.0 Tesla or 1.5 
Tesla (Siemens AG, Erlangen, Germany) scanners with standard head coils, using standard 
2D conventional or fast spin-echo Proton Density (PD) - and T2-weighted images (TR: 2200-
3000 ms, TE: 20-30 & 80-100 ms) with slice thicknesses of 3-5 mm, a maximum gap between 
slices of 0.5 mm, and an in-plane resolution of 1x1 mm2. The number and volume of T2 
weighted lesions, T1 hypo-intense lesions and gadolinium-enhancing T1 weighted lesions 
on brain MRI were assessed and compared to baseline. The lesions were identified by an 
independent rater, blinded for IL7R expression results and clinical data. 
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Disease severity on MRI was assessed by measuring the T1 hypo-intense lesion volume and 
the T2 lesion volume at baseline and after two years of follow-up. We used the following 
disease activity MRI parameters: number of new T2 lesions at follow-up and volume of T1 
gadolinium enhancing lesions. 
Baseline scans were performed on the day of blood sampling for patients included in the 
expression analysis.
Statistical analysis
The annualized relapse rate and rate of intravenous methylprednisolone treatment courses 
were calculated from the most recent available data by dividing the total number of relapses 
and respectively the number of methylprednisolone-courses by the total follow-up duration. 
Clinically relevant changes in EDSS and MSFC were assessed according to generally accepted 
guidelines27,28.
Hardy–Weinberg equilibrium (HWE) was evaluated using Pearson’s goodness-of-fit χ2 test 
(degree of freedom= 1) for genotyping results. Genotype distribution and allele frequencies 
were compared between healthy controls and MS subjects using Pearson Chi-Square testing 
and Fisher’s exact test respectively; odds ratios were calculated including 95% confidence 
intervals using the best fitted genetic model (recessive, dominant or additive). 
To test for significant differences in MS phenotype, the parameters of disease severity and 
disease activity (clinically and using MRI parameters) were compared for every genotype 
using Kruskal Wallis Test; differences between carriers and non-carriers of the risk-allele 
were assessed using the Mann Whitney Test. In addition, multivariate regression analysis 
was performed to correct the results for relevant clinical parameters (disease duration, 
gender, use of disease modifying therapy, age and onset type).
The 2 -ΔΔCT method was used to calculate the relative change in gene expression of 
membrane-bound to total IL7R mRNA. We assessed whether there were differences in the 
relative expression of membrane-bound to total IL7R mRNA between genotypes using the 
Kruskal Wallis Test. Differences in membrane-bound to total IL7R expression between groups 
for baseline characteristics (clinically and using MRI parameters) were tested with Mann-
Whitney, Kruskal-Wallis and Spearman test where appropriate. Moreover, multivariate 
regression analysis was performed to correct the results for relevant clinical parameters 
(disease duration, gender, age, use of disease modifying therapy and onset type).
For the time to first relapse and time to reach EDSS = 6, we constructed Kaplan-Meier curves 
and with log-rank we tested differences between dichotomized levels of membrane-bound 
to total IL7R expression and between genotypes. All reported p-values are based on two-
tailed significance tests. The threshold for significance was set at 0.01. For all statistical 
procedures SPSS 15.0 for Windows was used.
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Results
Patients
A total of 697 unrelated, Dutch Caucasian patients were included in the DNA analysis. The 
median disease duration was 10.8 years (IQR: 10.5 years). The median EDSS was 4.0 (IQR: 
4.0) (see table 1 for more patient characteristics). MSFC results were available for 441 
patients (data not shown).
Clinical data on disease activity was prospectively collected for 210 relapse-onset patients 
from disease onset (median follow-up 6 years). Some 57.1% of patients used Disease 
Modifying Therapy (DMT) during follow-up. The median relapse rate in this group was 0.47. 
The median number of treatment courses with methylprednisolone per year was 0.12 (for 
more details on this subgroup see Supplementary table 1 for patient characteristics). 
The control subjects (n=174) consisted of 97 females (55.7%) and had a mean age of 46.5 
years.
table 1: Patient characteristics. 
all (n=697) RR (n=367) SP (n=192) PP (n=111) CIS (n=27)
Gender (n; % Male) 250 (35.9%) 112 (30.5%) 79 (41.1%) 49 (44.1%) 10 (37.0%)
Median age at onset (IQR) 32.1 (13.6) 29.9 (11.4) 29.8 (11.2) 42.1 (13.6) 39.6 (11.0)
Median disease duration at most 
recent visit (IQR)
10.8 (10.5) 8.2 (7.8) 17.1 (10.8) 12.2 (10.3) 4.1 (3.3)
Median EDSS at most recent visit 
(IQR)
4.0 (4.0) 3.0 (2.0) 7.0 (1.5) 6.5 (3.0) 2.0 (2.0)
Number of patients that reached 
EDSS 6 (%) 
249 (35.7%) 32 (8.7%) 151 (78.6%) 64 (57.7%) 2 (7.4%)
Median time to reach EDSS 6 in 
years (IQR)
8.5 (9.0) 8.8 (7.4) 9.4 (10.6) 6.6 (7.3) 0.3 (*)
Median T2 lesion volume at 
baseline-scan in mm3 (IQR) (n=226)
1649 (3380) 1861 (3523) 3027 (5344) 2180 (3330) 607 (1259)
Median T1 hypo-intense lesion 
volume at baseline scan in mm3 
(IQR) (n=226)
101 (333) 94 (326) 140 (573) 183 (687) 86 (171)
Median number of new T2 lesions 
at follow-up two years after 
baseline scan (IQR) (n=182) 
4 (7) 4 (9) 2 (14) 2 (5) 1 (4)
SD= standard deviation; MSSS= Multiple Sclerosis Severity Scale at final clinical follow-up; EDSS= 
Extended Disability Status Scale. IQR: Interquartile range.
* Only based on 2 patients (0 and 8 months, no interquartile range could be calculated).
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association of genotype of rs6897932 (Il7R) and susceptibility to MS 
Genotype-frequencies in the healthy controls and in the total MS patient group did not 
deviate from Hardy Weinberg Equilibrium (p>0.01). Genotype frequencies in MS patients 
were distributed as follows: CC 58.4%, CT 35.0% and TT 6.6%. In our MS patient cohort the 
frequency of the risk-allele C is 75.8% and in our healthy control cohort 67.8%. 
Genotype distribution was significantly different between healthy controls and MS 
patients (Pearson Chi-Square p<0.01). The recessive model fitted best (CC vs CT and TT) 
and conferred an increased risk of disease for homozygous carriers of the ‘C’ allele (0.58 vs 
0.46, OR: 1.65 (95% confidence interval: 1.18 – 2.30), p=0.004). Homozygosity for the risk-
allele is a risk factor for MS development in our population. Genotype frequencies, odds 
ratios and 95% confidence-intervals were calculated (see table 2). Stratification for disease 
subtype revealed that the association of this SNP with MS is predominantly present in the 
secondary progressive (SP) MS patient group (see table 2). Carriership of the risk-allele was 
significantly more frequent in SP MS patients, when compared to healthy controls. The pre-
study power of this susceptibility study is approximately 20% to detect a OR of 1.2 when 
comparing carriers of the CC genotype compared to the CT and TT genotype.
association of rs6897932 (Il7R) and MS phenotype
EDSS was obtained of all 697 patients. A brain MRI scan was available from 226 patients 
at baseline and from 182 (80%) patients at follow-up after two years (see table 1). See 
supplementary table 2 for patientcharacteristics of the subgroup of which an MRI was 
available. No association could be detected between genotype of rs6897932 and disease 
severity (clinically and using MRI parameters). There was also no association of genotype 
with disease activity measures (using clinical and MRI parameters) (see table 3). After 
correction for disease duration, gender and onset type no significant differences were found. 
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Il7R gene expression profiles and MS characteristics. 
For 95 patients mRNA was available and IL7R mRNA expression profiles (the relative 
expression of membrane-bound IL7R (presence of exon 6-7) to total amount of IL7R mRNA 
(presence of exon 4-5)) were determined. These early MS patients had a median disease 
duration at baseline of 7 months (IQR: 10.3), a median EDSS of 2.5 (IQR: 1.5) and 51.6% of 
patients used DMT during follow-up. Baseline MRI scans were available for 93 patients. 
Two patients were lost to follow-up before the second year and an additional 15 patients did 
not have a follow-up MRI scan of the brain after 2 years.
In this substudy 61.1% of the MS patients were homozygous for the ‘C’ risk allele, while 
32.6% carried the CT genotype and 6.3% of our patients was homozygous for the T-allele. 
This distribution did not deviate from the original cohort. No association of genotypes of 
rs6897932 and the relative expression of membrane-bound IL7R to total amount of IL7R 
mRNA were found.
There were no differences observed in relative expression of membrane-bound IL7R to total 
amount of IL7R mRNA between patients that received an intravenous treatment course 
with methylprednisolone or experienced a relapse in the 3 months preceding the blood 
withdrawal compared to patients that did not experience such an event in the previous 
3 months. Furthermore, no association was found between MS phenotype (clinically and 
using MRI scans of the brain) at the time of blood withdrawal and relative gene expression 
of membrane-bound to total IL-7R mRNA. Also, the membrane-bound to total IL-7R 
expression ratio neither predicted disease activity, nor did it predict disease severity using 
clinical parameters (after a median follow-up duration of 4 years and 4 months) and MRI 
parameters of the brain, also when controlled for use of disease modifying therapy, gender, 
age, onsettype and disease duration. The pre-study power of our study to detect a clinically 
relevant difference of 0.5 point on the MSSS is approximately 50%.
Discussion
We present here the results on the effect of IL7R SNP rs6897932 and expression of 
alternatively spliced IL7R mRNAs on clinical disease course in a large and well documented 
Dutch MS patient group. We confirm the relevance of the genotype of the exon 6 SNP: 
rs6897932 on MS susceptibility in our Dutch MS population. Especially the homozygote C 
(risk-allele) genotype is associated with MS susceptibility in our study, possibly indicating 
a dose-dependent-effect. Although an effect of heterozygotes can not be excluded due 
to the small OR (~1.2) as calculated in previous studies8,9,13. Although the power of our 
susceptibility study is relatively low (20%), due to the low number of healthy controls, the 
allele frequencies of the risk C allele in our MS population and healthy controls are however 
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similar to other MS studies9,14. Moreover, the genotype distribution in our healthy controls 
is similar to a study with Dutch controls (n=465)29, strengthening the robustness of our 
positive association of the CC genotype and MS susceptibility.
In accordance with a previous study11, the association of this SNP with MS suscepibility 
is predominantly driven by the genotype distribution in our SP MS patients. Because of 
this overrepresentation of the risk allele in the generally more disabled MS patients, we 
postulated that the same C-allele is not only involved in disease susceptibility, but may also 
be involved in MS disease progression and severity. However, we did not find a correlation 
between genotype and disease severity. Previous studies demonstrated no effect of this IL7R 
SNP (and other susceptibility SNPs) on markers of disease severity in large cohorts8,30. We 
confirm this observation in our study in Dutch MS patients, by using more extensive disease 
severity markers (including imaging parameters) in a well documented MS population. 
In addition, we show in our relapse-onset cohort that genotype is not related to disease 
activity parameters in early MS. More and more evidence points towards different genetic 
influence on MS severity compared to MS susceptibility31. Genes involved in MS severity are 
often involved in different processes than genes found related to MS susceptibility. However, 
modest effects of some genes might be present in both MS susceptibility and MS severity32. 
HLA-DR15, for example, was associated with a lower age of onset in MS33 and with female 
sex34. Furthermore, carriers of DRB1*1501 presented with higher numbers of focal brain 
lesions at the time of initial presentation in the Optic Neuritis Treatment Trial35 and were 
associated with disease severity inferred by HMR spectroscopy and MRI measures36. 
Because mRNA might be a more direct reflection of the time-dependent biological relevance 
of the IL7R receptor, we hypothesized that the membrane-bound to total IL-7R expression 
ratio would be associated with disease phenotype at the moment of blood withdrawal 
or influence the future disease course. However, no association was found between the 
expression profiles and MS phenotype (disease severity and disease activity) in our study. 
Moreover, surprisingly, no association was found between different genotypes for SNP 
rs6897932 and the membrane-bound to total IL7R expression. These expression results 
contradict previous results to some extent, as the association of the C major allele with 
alternative splicing of exon 6, leading to more soluble compared to membrane-bound IL7R 
was seen in a study of 94 healthy controls8, but not in a study of 24 MS subjects11. This might 
be due to the fact that we used whole blood mRNA in stead of peripheral blood mononuclear 
cells (PBMCs). Differences in mRNA profiles have been described within different blood 
types37. Although we excluded that a recent relapse or prednisolone treatment (common 
in early MS) would influence the relative expression of membrane-bound to total IL7R 
mRNA, we cannot exclude other possible confounding factors. Also, the effect of disease 
modifying drugs on measures of disease-severity has not been taken into account in any of 
the reported studies.
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Although we showed no influence of mRNA expression on disease phenotype in our 
homogenous group of early MS patients, this may change later on in the disease (since 
analysis showed evidence for a role in disease susceptibility in secondary progressive MS). 
Unfortunately no mRNA was collected from secondary progressive MS patients or healthy 
controls. Maybe mRNA expression would serve more as an indicator of disease severity 
as opposed to a predictor for disease phenotype. Future studies comparing early patients 
to patients in a more advanced stage of MS would be interesting and should preferably 
incorporate studies on protein level as well. Because knowledge on disease progression 
might be very important in developing future treatment in order to prevent disability 
accumulation, more studies (including genetic and environmental factors) are warranted to 
elucidate the mechanisms involved in disease progression. 
In conclusion, we confirm the relevance of rs6897932 in MS susceptibility. Considering this 
and previous publications8-15 IL7R is firmly established as a (modest) genetic contributor to 
MS susceptibility. No effect of this polymorphism was found on disease phenotype (disease 
severity and disease activity). Due to the described effect of this SNP on mRNA expression 
and the overrepresentation of the risk-allele in the more severely disabled MS patients 
(secondary progressive MS), we studied the effect on disease severity and activity. However, 
no effect was found of the genotype and the membrane-bound to total IL7R expression ratio 
on MS phenotype. 
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Supplementary table 1: Characteristics of patients (n=210) included in substudy on relationship 
genotype of rs6897932 and MS disease activity.
MS subtype (n=210)
CIS
RR
SP
27
173
10
Gender (% Male) 31.4%
Median disease duration in years at most recent visit (IQR) 5.9 (3.4)
Median EDSS at most recent visit (IQR) 2.5 (2.0)
% of patients ever used disease modifying treatment 
Most recent disease modifying treatment:
Interferons
Glatiramer acetate
Natalizumab
Other (Mitoxantrone, Fingolimod)
57.1%
81 (38.5%)
19 (9%)
15 (7.1%)
5 (2.5%)
Median annual number of relapses during follow-up (IQR) 0.47 (0.47)
Median annual number of intravenous methylprednisolone treatments during 
follow-up (IQR).
0.12 (0.31)
Genotype distribution
% CC
% CT
% TT
57.1
35.2
7.6
Supplementary table 2: Characteristics of patients (n=226) with MRI variables available, included in 
study on relationship genotype of rs6897932 and MS disease activity and disease severity.
MS subtype (n=226)
CIS
RR
SP
PP
26
165
10
25
Gender (% Male) 34.5%
Median disease duration in years at most recent visit (IQR) 6.0 (3.3)
Median EDSS at most recent visit (IQR) 2.5 (1.6)
% of patients ever used disease modifying treatment 
Most recent disease modifying treatment:
Interferons
Glatiramer acetate
Natalizumab
Other (Mitoxantrone, Fingolimod)
52.2%
81 (35.8%)
18 (8.0%)
14 (6.2%)
5 (2.2%)
Genotype distribution
% CC
% CT
% TT
55.8%
36.7%
7.5%
?
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Introduction
In search of genetic causes of Multiple Sclerosis (MS), a number of genes have consistently 
shown association with MS susceptibility in the past couple of years1. All of these identified 
genes are directly or indirectly involved with the inflammatory process. However, it has 
become increasingly clear that MS consists of both an inflammatory and a progressive 
neurodegenerative process2, which is e.g. illustrated by the fact that new and potent anti-
inflammatory drugs have been unable to halt neurodegeneration. The relation between 
episodes of inflammation and the neurodegenerative component characterized by 
irreversible axonal loss, are far from clear at this point. Some authors have argued that 
neurodegeneration is independent of inflammation, while others argue that the two 
components are closely associated and are actually interdependent2;3. The neurodegenerative 
component is clinically highly relevant since it is held predominantly responsible for disability 
accumulation, although several questions regarding this issue still remain2. Until recently 
no genetic marker for neurodegeneration in MS was identified. However, in 2008, it was 
reported for the first time that a “neurodegenerative gene”, i.e., the KIF1B rs10492972[C] 
variant, was associated with MS susceptibility4. KIF1B is involved in axonal transport of 
mitochondria and synaptic vesicle precursors. Dysregulation of axonal transport plays a role 
in several neurodegenerative diseases4. The authors suggested that KIF1B could be the first 
gene involved in MS susceptibility with a possible neurodegenerative effect4. Unfortunately, 
this finding could later not be confirmed in other samples5, but perhaps this SNP explains 
some of the neurodegenerative phenotypic differences between MS patients. 
Methods 
To assess the effect of this gene polymorphism on phenotype, the current study related 
genotype and carriership of the C-allele of rs10492972 to neurodegenerative markers in 
214 MS patients. These MS patients were selected from ongoing natural history studies in 
our MS center based on the availability of DNA and precise clinical characterization of the 
disease course and disease severity. First we assessed this in terms of clinical measures, 
using Multiple Sclerosis Severity Scores (MSSS) and Multiple Sclerosis Functional Composite 
Scores to assess disability. Secondly, by use of Magnetic Resonance Imaging (MRI) measures 
such as T1 hypo-intense lesion volume, T2 lesion volume, T1/T2-ratio and atrophy measures 
(normalized brain volume and percent brain volume change), which were available for 164 
of the 214 patients. The progression of both clinical and MRI measures was also analyzed 
at 2 years follow-up. Significance was tested using the Kruskal-Wallis-test for genotype 
comparisons and Mann-Whitney U test for carriership comparisons (p<0.05). Written 
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informed consent was obtained from all participants and the study was approved by the 
local ethics committee. 
Results
In our group of MS patients, 36.9% was male, 10.7% had a primary progressive disease 
course, 66.4% a relapsing remitting disease course, 19.2% a secondary progressive disease 
course and 3.7% a clinically isolated syndrome course, and the mean disease duration of 
our total group was 12 years. Median EDSS was 3.5. The C-(risk)-allele frequency in our 
cohort was 30.1%, which is comparable to the allele frequencies described by others4;5. The 
genotype-distribution was in H-W equilibrium. No association was found between carriership 
of the risk-allele or genotype of rs10492972 and the described neurodegenerative markers, 
neither on the clinical level, nor on MRI (for details see table 1). 
Discussion
Therefore, based on this dataset, we conclude that no evidence could be found for a 
determining influence of carriership of the risk allele or genotype of the KIF1B gene on 
any of the neurodegenerative phenotypic markers. This finding should be confirmed in a 
larger cohort to more definitively exclude an association. Furthermore it would be highly 
interesting to test the role of KIF1B in other diseases with neurodegenerative components.
In KIF1B -knockout mice more atrophy was observed when compared to wild-type mice6. 
In humans, however, no effect of carriership of the rs10492972[C] variant was observed in 
susceptibility to and disability accumulation in primary progressive MS patients7, nor in our 
study of a more general MS population. 
Although genetic susceptibility studies have consistently pointed towards the importance of 
inflammation in MS, the determining influence of genes on the neurodegenerative part of 
MS remains enigmatic. Different genetic markers within neurodegenerative pathways and 
their relationship to the MS phenotype, should be investigated in future studies.
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abstract
background: Multiple Sclerosis (MS) is a heterogeneous neurological disease with extensive 
variation with respect to the most affected central nervous system region (brain vs spinal 
cord). 
objective: To test the hypothesis that this variation in lesion location (brain vs spinal cord) 
might be (partially) genetically determined. 
Design: Candidate gene study. Setting: Academic research.
Patients: Patients were selected for the availability of DNA material, clinical variables, and 
brain and spinal cord magnetic resonance images (evaluating T2-weighted lesion load in the 
brain and the number of spinal cord lesions). 
Main outcome Measures: For genotyping we used a DNA chip, containing a set of genes 
mentioned in previous publications noting their relation to different phenotypes of MS. We 
assessed the association between brain and spinal cord abnormalities and the genotypes of 
the patients.
Results: One hundred fifty patients were included in the analysis. Five single- nucleotide 
polymorphisms within the Major Histocompatibility Complex region were associated with 
the number of focal abnormalities in the spinal cord. The most significant was rs3135388 
(surrogate marker for the HLA-DRB1*1501 allele). Carriers of HLA-DRB1*1501 had a median 
of 4 spinal cord lesions compared with 2 lesions for non-carriers (p<0.001). No significant 
association was noted between the single nucleotide polymorphisms and T2-weighted 
lesion load in the brain.
Conclusions: Carriership of HLA-DRB1*1501 (via rs3135388) was associated with the extent 
of focal abnormalities in the spinal cord. Spinal cord lesions might be an explanation for 
increased MS disease severity in patients carrying HLA-DRB1*1501.
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Introduction
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system, characterized 
by inflammation, demyelination and axonal loss in the brain and spinal cord. The current 
hypothesis is that MS is caused by a complex interplay of genetic and environmental factors. 
The genetic influence is characterized by the interaction of multiple genes that exert modest 
effects. The most striking among these is the association of the major histocompatibility 
complex (MHC) with MS susceptibility, which has consistently been reported over the past 
decades1.
Clinically, MS is a heterogeneous disease with a diverse spectrum of neurologic deficits and 
variable outcome. Some studies have focused on genetic predictors of disease phenotypes, 
such as disease severity, disease subtypes, magnetic resonance (MR) imaging characteristics 
and response to treatment, showing some effect of different genes1-8.
Besides clinical heterogeneity, considerable variation exists between patients regarding type 
and anatomic location of the lesions9,10. Varying degrees of involvement of the cerebrum, 
brainstem, cerebellum, and spinal cord have been described in post-mortem and MR imaging 
studies 11,12. This variability is unexplained, and much effort is being put in unravelling it. 
Several arguments point toward a genetic role in the regional distribution of lesions in 
the brain and spinal cord in MS. First, differences in pathologic manifestation of MS have 
been observed between Asian and Western populations. Asian-type MS is characterized 
by predominant involvement of the optic nerve and spinal cord, whereas Western type MS 
predominantly involves the brain. Genetic differences within the HLA region between these 
populations could underlie this variability3,13-16. Second, recent studies confirm a tendency 
of patients to develop relapses in the same locations, including spinal cord lesions17,18. This 
tendency for localized exacerbations could be genetically predetermined. Third, involvement 
of a genetic factor has already been demonstrated in lesion distribution in experimental 
autoimmune encephalomyelitis (an animal model that shows many similarities to MS). 
Butterfield et al. showed that in mouse experimental autoimmune encephalomyelitis the 
lesions in the brain and spinal cord were controlled by different quantitative trait loci19.
Many researchers have demonstrated the clinical relevance of spinal cord lesions in 
diagnosing MS and disability accumulation. However, we are unaware of any studies that 
included spinal cord MR imaging variables in genetic analyses, searching for genotype-
phenotype correlations.
In this study, we used a DNA-chip containing a set of single nucleotide polymorphisms 
(SNPs) in candidate genes to assess the genetic effect on regional lesion distribution in the 
brain and spinal cord as seen on MR imaging. The SNPs on this chip were selected based on 
published associations with MS pathogenesis, prognosis or response to treatment.
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Material and methods
Study participants:
Unrelated Dutch Caucasian patients were selected retrospectively from natural history 
studies conducted at the MS Center at the VU University Medical Center (VUmc) in 
Amsterdam, the Netherlands. Patients were selected for the availability of DNA material, 
as well as brain and spinal cord MR images, that fulfilled certain standardized requirements 
(described herein) and were obtained less than two years apart. The study was performed 
with the approval of the medical ethics committee of the VU University Medical Center and 
informed consent was obtained from all participants. Patients were diagnosed as having 
MS as ascertained using Poser or revised McDonald criteria20,21. For patients included in 
the analyses, clinical data were collected, including age, sex, type of disease, age at onset, 
disease course and duration of disease. Disability status was determined for all subjects 
using Kurtzke’s Expanded Disability Status Scale (EDSS)22 and, whenever available, the 
Multiple Sclerosis Functional Composite Scale (MSFC)23. 
Selection of SnPs:
Single-nucleotide polymorphisms were selected based on involvement in MS pathogenesis, 
prognosis or response to treatment, according to the literature published before July 2007. 
The polymorphisms were confirmed and associated with an identifier using dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP). Nucleotide sequences for the design of allele-specific 
probes and polymerase chain reaction primers were retrieved from the SNPper database 
(http://snpper.chip.org/bio). Sequence-specific probes and primers were designed using 
freely available Primer3 software (http://frodo.wi.mit.edu/).
If a polymorphism was not present in the database, position and sequences were established 
by performing a BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the data 
available in the literature. 
Genotyping 
Genomic DNA was isolated from anti-coagulated blood using DNAzol reagent (Molecular 
Research Center, Inc., Cincinnati, OH). Genotyping was performed using a newly developed 
low-density DNA microarray based on allele-specific probes. The design, fabrication, 
validation and analysis of the arrays were performed following the procedure described by 
Tejedor et al. with minor modifications24. 
brain MR Imaging
Magnetic Resonance Images were acquired on 1.0 Tesla or 1.5 Tesla systems (Siemens AG, 
Erlangen, Germany) with standard head coils, using 2D conventional or fast spin-echo Proton 
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Density-weighted and T2-weighted images (TR: 2200-3000 ms, TE: 20-30 & 80-100 ms) with 
section thicknesses of 3-5 mm, a maximum gap between sections of 0.5 mm, and an in-plane 
resolution of 1x1 mm2 . Lesions were identified by an expert reader and then outlined on 
the corresponding proton density-weighted image using home-developed semi-automated 
seed-growing software based on a local thresholding technique (Show_images)25. Lesion 
areas were multiplied by the intersection distance to obtain total T2-weighted brain lesion 
volume for each patient. 
Spinal cord MR Imaging:
Spinal cord scanning included a cardiac-triggered sagittal proton density-weighted and 
T2-weighted dual-echo spin echo sequence with a section-thickness of 3mm covering 
the whole spinal cord (TR: 2500 – 3000 ms, TE: 20-30 & 80-100 ms), with a gap between 
sections of 0.3 mm, and an in-plane resolution of 1x1 mm. From this sequence the number 
of focal lesions and the presence of diffuse abnormalities were scored by one experienced 
reader (CL). Diffuse abnormalities were defined as poorly delineated areas with increased 
signal intensity compared with the signal intensity of spinal cerebrospinal fluid best seen 
on proton density-weighted images26. Lesion volume was assessed in the spinal cord as the 
total number of focal pathologic segments involved (total extension of all spinal cord lesions 
over several corresponding vertebral segments). 
Statistical analysis:
First, the associations between the brain variable (T2-weighted lesion load) and the spinal 
cord variables (the number of focal lesions and the presence of diffuse abnormalities) were 
tested per SNP and per clinical variable. We used the non-parametric Spearman ρ rank 
correlation test, Kruskal-Wallis test, Mann Whitney test and χ² test as appropriate, applying 
the false discovery rate according to Benjamini and Hochberg27 to correct for multiple 
testing. The corrected number represents the expected proportion of false discoveries 
for a given p-value cut-off. We used the cut-off point of p<0.05 after false discovery rate 
correction. Spearman rank correlation coefficient was used to test the correlations between 
two scaled variables. 
Secondly, multivariate analysis by general linear models was performed on the associated 
SNPs (p<0.10 significance after correction for multiple testing). We used log-transformed 
brain T2-weighted lesion loads and the square-root-transformed number of focal 
abnormalities in the spinal cord to correct for significant clinical variables and the type of 
MR imaging system (1.0 T vs 1.5 T). 
All analyses were performed using commercially available software packages. These 
included SPSS (version 15; SPSS Inc., Chicago, IL, USA), Excel 2003 and HelixTree (Golden 
Helix, Inc., Bozeman, MT).
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Results 
Patient characteristics:
One hundred and fifty patients were included in the analysis. Our patient group reflects 
a representative population with MS, with 36.7% being male and 20.0% having primary 
progressive MS (table 1). Most patients (132/150) demonstrated abnormalities (mostly 
focal lesions) on spinal cord MR imaging, while all patients had abnormalities on brain MR 
imaging.
table 1: Patient demographic, clinical and Magnetic Resonance (MR) Imaging characteristics according 
to Multiple Sclerosis subtype.
all (n=150) RR (n=88) SP (n=32) PP (n=30)
Male sex, No. (%) 55 (36.7%) 26 (29.5%) 17 (53.1%) 12 (40.0%)
Age at MRI, y* 41.4 (11.2) 36.1 (9.2) 46.5 (8.9) 51.2 (9.8)
Disease duration, y* 7.1 (7.4) 4.4 (6.2) 12.8 (7.0) 9.2 (7.1)
Median EDSS (Interquartile range) 3.5 (2.5) 2.0 (2.0) 5.5 (2.5) 4.0 (3.0)
Brain T2-weighted lesion load (ml)* 7.7 (10.3) 4.9 (6.6) 16.2 (14.6) 7.0 (9.2)
Focal lesions in the spinal cord* 3.4 (3.0) 3.3 (2.8) 4.5 (3.9) 2.8 (2.3)
patients with diffuse abnormalities, No. (%) 20 (13.3) 9 (10.2) 6 (18.8) 5 (16.7)
*Data are given as mean (SD).
Genotyping:
In total, 80 SNPs in 44 genes were studied on the DNA chip. Twelve SNPs were excluded 
from further analysis (5 SNPs were monomorphic and 7 SNPs had a minor allele frequency 
< 5% (details are provided in supplementary table 1). Hardy-Weinberg equilibrium was 
calculated for all SNPs.
Correlation between lesion load in the brain and genotypes:
In the univariate analyses of T2 lesion load in the brain versus all SNPs on the DNA chip, 
the only suggestive correlation was rs2107538 (CCL5) (OMIM: 187011) (see table 2). Two 
clinical covariates were significant and were included in the general linear model for brain 
T2-weighted lesion load namely, disease duration and MS subtype. The type of MR imaging 
system (1.0 T vs 1.5 T) was not associated with T2-weighted lesion load in the brain. After 
inclusion of rs2107538 (CCL5) in the model that contained the clinical covariates, this SNP 
showed significant association with brain T2-weighted lesion load (p=0.03).
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Correlation between spinal cord abnormalities and genotypes:
Several MHC SNPs were found to be related to the number of focal spinal cord abnormalities 
(table 2). The most significant is SNP rs3135388. Carrier status of the A-allele (surrogate 
marker for HLA-DRB1*1501) was associated with significant more lesions in the spinal cord 
(Figure 1). The median number of focal abnormalities in carriers of HLA-DRB1*1501 (n=80) 
was 4 lesions and in non-carriers (n=70) was 2 lesions (p<0.001 Mann Whitney test).
When corrected for multiple testing, five SNPs within the MHC class II region (rs3135388, 
rs2395182, rs2239802, rs2227139 and rs2213584), remained significant and one SNP within 
the C2TA gene (Class II TransActivator) showed a suggestive result. The five HLA SNPs are in 
strong linkage disequilibrium.
In addition, the aforementioned MHC class II SNPs were also found to be correlated with 
a higher lesion volume in the spinal cord. Specifically carriership of HLA-DRB1*1501 was 
associated with more segments of the spinal cord affected by focal lesions (p=0.01, Mann 
Whitney test).
No clinical covariate (disease duration, age of patients, or MS subtype) was significantly 
correlated with the number of focal lesions in the spinal cord. No general linear model that 
included the five significantly associated MHC class II SNPs could be produced, because 
of the high level of collinearity owing to the high linkage disequilibrium (r2 ranging from 
0.33-0.99). Only rs3087456 (C2TA) (OMIM: 600005) showed a marginally significant p-value 
(p=0.05) in the general linear model that included rs3135388 (p=0.002). No association was 
observed between the presence of diffuse abnormalities and the evaluated SNPs.
table 2: Correlation by Kruskal Wallis test of Single-Nucleotide Polymorphisms (SNPs) with Magnetic 
Resonance Imaging variables.
SnP Gene P value Uncorrected P Value for 
association With lesion Volume in 
the Spinal Cord**
Uncorrected False disco-very 
rate corrected
no. of focal lesions in the spinal cord
rs3135388* MHC2 <0.001 0.03 0.02
rs2395182 * MHC2 0.001 0.03 0.003
rs2239802* MHC2 0.001 0.03 0.003
rs2227139* MHC2 0.002 0.03 0.005
rs2213584* MHC2 0.003 0.05 0.009
rs3087456 C2TA 0.009 0.10 0.18
t2-Weighted lesion load in the brain
rs2107538 CCL5 0.001 0.07 Not applicable
* These SNPs reside on three haplotype blocks with pair wise r2 values ranging from 0.33-0.99.
** Defined as the total number of segments affected by focal lesions.
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Figure 1: Carriership of Hla-DRb1*1501 and focal spinal cord lesions.
Scatterplot of focal spinal cord lesions for carriers and non-carriers of HLA-DRB1*1501 (measured as 
presence of A-allele of rs3135388). Carriers of HLA-DRB1*1501 had a median of 4 spinal cord lesions 
compared with 2 lesions for noncarriers (P < .001, Mann Whitney test). Line reflects the median 
number of focal abnormalities.
Comment
In the present candidate gene study, we observed an association between several SNPs 
within the MHC class II region and the number of focal abnormalities in the spinal cord. The 
most significant results were found for rs3135388. This SNP is a surrogate marker for the 
HLA-DRB1*1501 allele (r2 = 0.97)28. 
After correction for multiple testing, no genes were significantly related to T2-weighted 
lesion load in the brain. The MHC class II SNPs that were associated with more lesions in 
the spinal cord and with a higher lesion volume in the spinal cord do not seem to affect the 
presence of T2-weighted lesions in the brain.
Studies have unambiguously shown that HLA-DRB1*1501 strongly influences MS 
susceptibility6,29,30. There is some evidence that this haplotype might also be associated with 
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a more severe disease course1,4,6,31. Recent findings show a correlation between carriership 
of HLA-DRB1*1501 and Expanded Disability Status Scale scores using an extremes of 
outcome strategy (comparing severe and mild disability only)1. In our study we could not 
demonstrate a correlation between carriership of HLA-DRB1*1501 and Expanded Disability 
Status Scale scores. This might be because of the impossibility to perform the extremes of 
outcome analysis owing to a small sample size. However, findings from this study suggest 
that spinal cord lesions might be an additional explanation for the described relationship 
between HLA-DRB1*1501 and MS disease severity.
Abnormalities in the spinal cord correlate with the degree of disability and with the date of 
diagnosis32,33. In our study we also noticed a relation between EDSS scores and the number 
of focal abnormalities in the spinal cord (p=0.02, ρ=0.185). Future studies should include 
additional MR imaging variables of the spinal cord such as atrophy (cross-sectional area), as 
this variable might correlate better with clinical disability 34.
In a recent article, Okuda et al. showed in their patients that HLA-DRB1*1501 affects 
disease severity as measured by clinical variables and by brain MR imaging variables35. 
In our patients, we could not demonstrate this effect on T2-weighted lesion load in the 
brain or on cognitive function (using Paced Auditory Serial Addition Task scores)23. Post-
hoc power analysis detected a power of less than 25% to detect a T2-weighted lesion load 
difference of 1 ml, suggesting that a type II error cannot be ruled out. This also warrants 
careful interpretation of the suggestive positive finding of rs2107538 (CCL5) in association 
with brain T2-weighted lesion load, although previous findings have shown an influence of 
this gene on other MR imaging variables36.
Previous data were sometimes conflicting about the effect of HLA haplotypes on brain MR 
imaging features. Some studies found a relationship between HLA genotypes and brain MR 
imaging quantitative markers31,35, while other studies did not observe this effect of HLA-
DRB1*150131,37. In addition, no effect of HLA-DRB1*1501 was shown on lesion distribution 
within the brain using T1 and T2 lesion maps38.
To date we are unaware of any study that specifically relates HLA-DRB1*1501 to spinal cord 
abnormalities on MR imaging in a Caucasian population.
The molecular basis of the association with a greater involvement of the spinal cord in patients 
carrying the HLA-DRB1*1501 allele remains unknown. Major Histocompatibility Complex 
class II genes are involved in self versus non-self immune recognition39. These genes encode 
for polymorphic surface glycoproteins. Variability in this region may determine individual 
differences in T-cell responses. It is postulated that MHC class II may present variable central 
nervous system antigens to T cells, possibly producing different lesion distribution in animals 
and in humans40. 
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Moreover, Stromnes et al. reported different lesion distribution in the central nervous system 
(spinal cord vs brain parenchyma) in two mouse experimental autoimmune encephalitis 
models with different MHC strains 41. This was found to be mediated by variable preferential 
Myelin Oligodendrocyte Glycoprotein (MOG) epitope presentation and ultimately by 
an alternative ratio of T helper 17 to T helper 1. The present study indicates a different 
mechanism of lesion formation in the brain vs the spinal cord, with a possible indirect role of 
the MHC class II genes. The role of the genes on this mechanism is unclear. The translation 
of these findings from animal models to the human situation warrants further studies.
Because of the complexity of the MHC class II region (epistatic effects and high linkage 
disequilibrium), future studies using high-density HLA mapping are warranted to unravel 
the genetic influence on lesion distribution and determine the responsible HLA allele. 
In conclusion, this study demonstrates more focal lesions in the spinal cord among carriers 
of the HLA-DRB1*1501 allele. If confirmed in independent samples these observations may 
provide important insight in MS disease heterogeneity and its underlying mechanisms.
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Supplementary table 1: SNPs included on MS-chip. HWE = Hardy-Weinberg Equilibrium in our sample; 
MAF = minor allele frequency in our sample.
Gene rs-nr Chromosome Polymorphism HWE * MAF
ADAMTS14 rs4747075 10q22 A/G P<0.01 0.30
ADAMTS14 rs7081273 10q22 C/G n.s. 0.34
ADAMTS14 rs4746060 10q22 C/T n.s. 0.08
Apo I/Fas rs1800682 10q23 C/T n.s. 0.47
Apo I/Fas rs3781202 10q23 C/T P<0.01 0.40
Apo I/Fas rs2234978 10q23 C/T n.s. 0.31
BTNL2 rs2076530 6p21.3 A/G P<0.01 0.26
CIITA rs3087456 16p13 A/G n.s. 0.26
CACNG4 rs4790896 17q24 A/G n.s. 0.41
CCR5 rs333 3p21 -/+ n.s. 0.11
CD24 rs8734 6q21 C NA 0.00 §
CNTF rs1800169 11q12 A/G n.s. 0.12
CRYAB rs14133 11q21-q23 C/G n.s. 0.27
CRYAB rs762550 11q21-q23 A/G n.s. 0.42
CRYAB rs2234702 11q21-q23 C NA 0.00 §
CTLA4 rs231775 2q33 A/G n.s. 0.37
CTLA4 rs5742909 2q33 C/T n.s. 0.09
EBF rs1368297 5q34 A/T n.s. 0.38
GABBRA1 rs1805057 6p22 C NA 0.00 §
HELZ rs2363846 17q24 C/T n.s. 0.48
HLA rs2395166 6p21.3 C/T n.s. 0.47
HLA rs2213584 6p21.3 A/G n.s. 0.40
HLA rs2227139 6p21.3 C/T n.s. 0.40
HLA rs3135388 6p21.3 A/G n.s. 0.33
HLA rs9268458 6p21.3 A/C n.s. 0.20
HLA rs6457594 6p21.3 A/G P<0.01 0.40
HLA-DRA rs2395182 6p21.3 G/T n.s. 0.38
HLA-DRA rs2239802 6p21.3 C/G n.s. 0.38
IFNAR1 rs2257167 21q22 C/G n.s. 0.08
IFNGR2 rs9808753 21q22 A/G n.s. 0.14
IKBL rs3130062 6p21.3. C/T n.s. 0.18
IL10 rs1800896 1q32 A/G n.s. 0.46
IL1B rs1799916 2q14 A NA 0.00 §
IL1B rs1143627 2q14 A/G n.s. 0.34
IL1B rs1143634 2q14 C/T n.s. 0.23
IL1RN rs419598 2q12-q14 C/T n.s. 0.31
IL1RN 2073 C/T 2q12-q14 C/T n.s. 0.30
IL2 rs2069763 4q26 G/T n.s. 0.36
IL2 rs2069762 4q26 G/T n.s. 0.27
IL4R rs1801275 16p12 A/G n.s. 0.20
IL7R rs11567685 5p13 C/T n.s. 0.25
IL7R rs7718919 5p13 G/T n.s. 0.13
IL7R rs11567686 5p13 A/G n.s. 0.34
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MC1R rs1805009 16q24 C/G NA 0.01 §
MC1R rs1805006 16q24 A/C NA 0.00 §
MEFV rs28940577 16p13.3 A NA 0.00 §
MGC33887 rs987931 17q24 G/T n.s. 0.32
MOG rs3130250 6p22 A/G n.s. 0.19
MOG rs3130253 6p22 A/G n.s. 0.12
NDUFA7 rs2288414 19p13.2 C/G NA 0.03 §
NDUFA7 rs561 19p13.2 A/G n.s. 0.21
NDUFS5 rs2889683 1p34.2 C/T n.s. 0.31
NDUFS5 rs6981 1p34.2 A/G NA 0.04 §
NDUFS7 rs2074897 19p13.3 A/G P<0.01 0.47
NOS2A rs1137933 17q11.2 A/G n.s. 0.25
NOS2A rs2779248 17q11.2 C/T n.s. 0.39
NOTCH4 rs367398 6p21.3 A/G n.s. 0.16
PD-1 rs11568821 2q37 G/A n.s. 0.11
PITPNC1 rs1318 17q24 A/G n.s. 0.21
PITPNC1 rs2365403 17q24 C/G n.s. 0.18
PNMT rs876493 17q11-q23 A/G n.s. 0.39
PRKCA rs7220007 17q24 A/G n.s. 0.49
PRKCA rs887797 17q24 C/T n.s. 0.30
PRKCA rs2078153 17q24 C/G n.s. 0.23
PRKCA rs3890137 17q24 A/G n.s. 0.37
PTPN22 rs2476601 1p13 A/G n.s. 0.11
PTPRC rs17612648 1q31 C/G n.s. 0.03 §
PTPRC rs4915154 1q31 A/G n.s. 0.00 §
CCL5 rs2280788 17q11.2-q12 C/G n.s. 0.02 §
CCL5 rs2107538 17q11.2-q12 C/T n.s. 0.18
Spp1 rs1126616 4q21 C/T n.s. 0.23
Spp1 rs1126772 4q21 A/G n.s. 0.18
Spp1 rs2853744 4q21 G/T n.s. 0.05
Spp1 rs9138 4q21 A/C n.s. 0.24
Spp1 rs4754 4q21 C/T n.s. 0.24
TNF rs1800629 6p21.3 A/G n.s. 0.17
TNFSF10 rs1131568† 3q26 C/T n.s. 0.32
UCP2 rs659366 11q13 C/T n.s. 0.37
VDR rs1544410 12q13 A/G n.s. 0.48
VDR rs731236 12q13 A/G n.s. 0.48
* P-value of Hardy Weinberg equilibrium (HWE). A p-value < 0.01 indicates deviation from HWE. 
NA: not applicable. N.s.: not significant.
§ Excluded due to minor allele frequency below 5%.
† Previous rs-number: rs9880164.
See list of abbreviations on page 181
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abstract
background and Purpose: In MS, the total brain lesion volume and spatial distribution of 
lesions across the brain vary widely among individual patients. We hypothesized that spatial 
distribution may be partially driven by genetic predisposition and aimed to explore relations 
between candidate genes and the spatial distribution of white matter brain lesions in MS. 
Material and methods: Genotypes of 69 single nucleotide polymorphisms (SNPs) in 208 
MS patients were related to spatial distribution of T2 brain lesions. Lesions were manually 
outlined on magnetic resonance imaging scans and binary lesion masks were produced and 
registered to a common space. With Randomise software, the lesion masks were related 
to genotype using a voxelwise nonparametric General Linear Model approach, followed by 
clusterwise analysis. We used a DNA chip with SNPs selected from the literature on MS 
susceptibility, severity and phenotypes. 
Results: For eleven of these SNPs, one of the genotypes expressed significant clusters of 
increased or decreased lesion probability in varying, predominantly periventricular, brain 
regions. When statistically controlling the voxelwise analyses for effects of total brain 
lesion volume, only one SNP remained significant: rs2227139, located within the Major 
Histocompatibilty Complex (MHC) class II region. This SNP retained its periventricular cluster 
of significantly increased lesion probability for the heterozygote genotype. 
Conclusion: Heterozygosity of rs2227139 (MHC class II region) is associated with increased 
right frontal periventricular lesion probability (p<0.01). Ten other SNPs showed associations 
between genotype and spatial lesion distribution that are partly explained by total lesion 
volume.
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Introduction
Multiple Sclerosis (MS) is a multifocal inflammatory demyelinating disease of the central 
nervous system (CNS). MS lesions can be found throughout the entire CNS parenchyma, 
histopathologically characterized by inflammation, demyelination and axonal loss resulting 
in a highly variable clinical presentation. Lucchinetti et al. showed the histopathological 
heterogeneity of MS lesions among patients with MS, with a distinct homogeneity within 
each patient, which might partially depend on the immunogenetic background of the 
individual patient with MS.1,2 
The spatial distribution of MS lesions across the brain is not homogeneous, showing 
particularly high frequencies in the periventricular white matter. Moreover this spatial 
distribution is highly variable between patients.3-5 Lesion probability mapping (LPM) studies 
in combination with a nonparametric General Linear Model (GLM) approach have been 
proven useful in studying associations between lesion distribution and clinical disability 
parameters. This voxel-wise method does not require a priori assumptions. Previous studies 
showed differences in lesion distribution across disease subtypes and disability status,5-7 
as well as between different lesion subtypes: T1 gadolinium-enhancing lesions showed a 
spatial distribution differing from non-enhancing T2 lesions and from T1 hypointense lesions 
(“black holes”).8,9 
We hypothesized that spatial lesion distribution might depend on individual immunogenetic 
background. Although genotype has been shown to influence MS susceptibility in several 
studies,10-12 there are relatively few studies of genotype-phenotype associations in MS and 
positive results await confirmation in larger studies.13-18
We suspect a genetic influence on the anatomical distribution of MS lesions for three 
main reasons. First, studies confirm a tendency of patients to develop relapses in the same 
locations.19,20 Moreover, in relatives who both suffer from MS, lesions have been observed 
more frequently in similar locations.14 This tendency for localised exacerbations could 
be genetically predetermined. Second, in Experimental Autoimmune Encephalomyelitis 
(EAE) (the animal model used to study MS), involvement of a genetic factor was already 
demonstrated in lesion distribution. Butterfield et al. showed that in mice EAE the lesions in 
the spinal cord and brain were controlled by different quantitative trait loci.21 Third, recently 
we found that carriership of HLA-DRB1*1501 is associated with more lesions within the 
spinal cord, but not with the total lesion volume in the brain.22 This allele, also known to be 
involved in MS susceptibility, is hence suggested to specifically affect lesion development 
in the spinal cord, a particular region of the central nervous system. Similarly, lesion 
development in certain regions inside the brain may be partially dependent on genetic 
parameters. A recent study found that the HLA-DRB1*1501 allele did not exhibit an effect 
on lesion distribution.23 We hypothesized that an effect on lesion distribution may be even 
more likely for genes associated with disease phenotype. 
88
Chapter 3.2
To explore this hypothesis, the present study compared spatial lesion distribution on MRI 
between different genotypes of a set of genes -selected based on their potential contribution 
to phenotypes of MS-, in a large cohort of MS patients, by using LPM. 
Material and Methods
Patients
This cross-sectional study used clinical and genetic data and MRI scans of 208 Caucasian 
patients sampled from MS natural history studies at our center. Patients were included 
based on availability of brain MRI and DNA material. The selected patients are a subgroup 
of the patients in which the clinical correlates of brain lesion distribution were studied 
previously.7 All had a diagnosis of MS according to Poser criteria24, McDonald criteria25 or 
revised McDonald criteria26 depending on the date of data acquisition. Expanded Disability 
Status Scale (EDSS)27 scores were obtained within a median interval of 0.0 (IQR 0.0 – 4.8) 
months from MRI scanning. Approval by the local ethics review board was obtained and 
informed consent was obtained from all participants.
Selection of SNPs 
Pubmed (http://www.ncbi.nlm.nih.gov/sites/entrez) and genetic association (http://
geneticassociationdb.nih.gov/cgi-bin/tableview.cgi?table=geneview) databases were 
searched for genes and polymorphisms suggested to be involved in pathogenesis, prognosis 
and treatment response in MS. Resulting polymorphisms were confirmed and associated 
to an identifier by using dbsnp database (www.ncbi.nlm.nih.gov/SNP). Their frequency in 
the Caucasian population was assessed using the HapMap project (http://www.hapmap.
org/index.html.en). Nucleotide sequences for the design of allele-specific probes and PCR 
primers were retrieved in the SNPper database (http://snpper.chip.org/bio). Sequence 
specific probes and primers were designed using Primer3 software (freely available at 
http://frodo.wi.mit.edu/). If a polymorphism was not present in the database, position 
and sequences were established by performing a blast search (http://blast.ncbi.nlm.nih.
gov/Blast.cgi, ) using data available in the literature. SNPs within the MHC class II region 
were predominantly selected based on the described linkage disequilibrium with the HLA-
DRB1*1501 allele.28,29 All genetic databases were accessed in 2006. The SNP rs-numbers and 
gene symbols were actualized at February 9th 2009.
A total of 80 validated polymorphisms located in 44 different genes were finally chosen 
(Supplementary table 1). Eleven of these 80 SNPs were excluded: five because they were 
monomorphic, and six because they had a minor allele frequency below five percent. 
Deviations from Hardy-Weinberg equilibrium were determined by Chi-square testing. 
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Genotyping 
Genomic DNA was isolated from anti-coagulated blood with DNAzol reagent (Molecular 
Research Center, Inc., Cincinnati, OH). Genotyping was carried out using a previously 
described low-density DNA microarray based on allele-specific probes with minor 
modifications.30 
Image acquisition and creation of lesion masks 
Different image acquisition protocols were used for the different clinical studies from which 
our patients were sampled: we used 2D conventional or fast spin-echo PD- and T2- weighted 
images, acquired using either 1.0 Tesla (Siemens Magnetom Impact) (77.4% of patients) or 
1.5 Tesla (Siemens Magnetom Vision) (22.6%) scanners using standard head coils, with slice 
thicknesses of 3-5 mm, an in-plane resolution of 1x1 mm2, and a maximum inter-slice gap 
of 0.5 mm. On these images, lesions were identified by an expert reader, and then outlined 
using home-developed semi-automated seed-growing software (Show Images)31 based 
on a local thresholding technique, thus creating binary lesion masks. T2 weighted images 
were created from each patient’s T2 weighted image using Brain Extraction Tool (FSL).32 
We created a common space T2 template with 2x2x2 mm voxels by linearly registering all 
T2 brain images (allowing 12 degrees of freedom) to the ICBM brain (MNI-152) image,33 
using the registration tool FLIRT (part of the FMRIB software library (FSL)),34 followed by 
averaging and smoothing using a 4mm FWHM Gaussian kernel. In order to bring all lesion 
masks to this common space template, all individual T2 brain images were then registered 
to the common space T2 brain template (again using FLIRT with 12 degrees of freedom), 
and the registration matrices thus obtained were then applied to the corresponding binary 
lesion masks. Nearest-neighbour interpolation was used to generate individual lesion maps 
that showed lesion presence or absence for each voxel. Registration quality was ensured by 
visual inspection. To be able to investigate the effect of the global whole-brain lesion load, 
we calculated total brain lesion volume. To account for head size differences, lesion volumes 
were calculated in common space after registration (therefore representing relative lesion 
volumes). 
Statistical analysis 
Voxel- and clusterwise statistical inference was accomplished using the non-parametric 
Randomise method as implemented in FSL 4.0 (part of the FMRIB software library: FMRIB 
Analysis Group, University of Oxford, http://www.fmrib.ox.ac.uk), using a general linear 
model design to model each voxel independently from the other voxels (5000 permutations; 
cluster-forming threshold pseudo-t = 2, corresponding to voxelwise p-threshold = 0.01).34,35 
For each SNP, three comparisons were made to test the association of genotypes with 
voxelwise lesion probability, always comparing one genotype to the combination of both other 
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genotypes (i.e. the comparisons made were: homozygote frequent allele vs heterozygote 
and other homozygote; homozygote rare allele vs heterozygote and other homozygote; 
and heterozygote vs both homozygotes). The lesion masks of the patients carrying a certain 
genotype were put together and compared to the lesion masks of patients that did not carry 
this genotype. For each comparison we separately tested for both increased and decreased 
lesion probability associated with that genotype. 
Although SNP markers with low genotype frequencies may be of importance in complex trait 
disorders like MS, such markers can result in unreliable observations in voxelwise analyses. 
Therefore, homozygote genotypes with frequencies below 5% in our cohort were combined 
with the heterozygote genotype and compared to the other homozygote genotype. 
Because total brain lesion volume has been found to influence lesion distribution,7 the 
following two steps were taken. First, for genotypes showing significant clusters in the LPM 
analyses, these LPM analyses were repeated while statistically controlling for total brain 
lesion volume. Second, we investigated the effect of genotype on the total brain lesion 
volume at a patient level by directly comparing the total brain lesion volume between 
genotypes, while statistically controlling for disease duration (without taking anatomical 
distribution into account). 
Finally, for the LPM and total brain lesion volume analyses, we tested whether correction for 
disease duration affected the results by using general linear model (after logtransformation 
of the total lesion volume to obtain a normal distribution).
Results
Patient characteristics
Our cohort of 208 MS patients was representative of the general MS population regarding 
patient characteristics (table 1), with a slightly high proportion of primary progressive MS 
patients (19.2%). These patients had a quasi-symmetrical brain lesion distribution typical for 
MS (Figure 1), with the highest lesion frequencies in periventricular regions.
table 1: Patient characteristics per MS subgroup.
Total MS group: 
(n=208)
RR MS 
(n=126)
SP MS 
(n=42)
PP MS 
(n=40)
Gender; n (%) Male 77 (37%) 37 (29.4%) 25 (59.5%) 15 (37.5%)
Age in years; mean (SD) 41.1 (11.1) 35.6 (8.6) 47.8 (7.7) 51.6 (9.7)
Disease duration in years; median (IQR) 6.3 (10.1) 3.9 (7.8) 11.8 (12.2) 8.3 (9.5)
Lesion volume* (ml); median (IQR) 12.4 (35.5) 10.3 (22.9) 38.6 (102.4) 13.5 (40.0)
EDSS score; median (IQR) 3.5 (2.9) 2.0 (2.0) 6.0 (2.5) 4.5 (2.0)
* Lesion volumes were calculated in common space (therefore representing relative lesion volumes).
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Figure 1: Lesion frequency map for our group of 208 MS patients, indicating for every voxel the lesion 
frequency throughout our patient sample, showing a range from 1% (n=2 patients having a lesion in 
that voxel) through the maximum of 33% (n=69). For colour figure see page 187.
Correlations between genotype and spatial lesion distribution
Of the 69 SNPs analysed, 11 genotypes of 10 SNPs showed significant clusters of either 
increased or decreased lesion probability, predominantly in periventricular clusters, for one 
of the genotypes (Figures 2 and 3). All clusters were located periventricularly, abutting the 
frontal or occipital horn of the lateral ventricles, often in an asymmetrical configuration. 
An increased lesion probability, in different periventricular regions, was observed for 
the heterozygous genotype of three SNPs: rs2227139 (within the MHC class II region), 
rs2076530 (within butyrophilin-like 2 gene) and rs876493 (within phenylethanolamine 
N-methyltransferase gene). Furthermore, there were two SNPs in which the homozygous 
major allele was associated with a higher lesion probability; i.e., rs2107538 within the 
chemokine (C-C motif) ligand 5 (CCL5) and rs9808753 within the interferon gamma receptor 
2 (IFNGR2) gene (Figure 2).
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Figure 2: Association between increased lesion probability and genotype. Each row shows results for 
the comparison of one genotype compared to the other two. a: CC genotype of rs2107538 within 
the CCL5 gene (chemokine (C-C motif) ligand 5). b: AA genotype of rs9808753 within IFNGR2-gene 
(IFNGR2: interferon gamma receptor 2). C: AG genotype of rs2076530 within Butyrophilin-like 2 
gene (BTNL2) (MHC class II associated). D: AG genotype of rs876493 (within phenylethanolamine 
N-methyltransferase-gene). e: CT genotype of rs2227139 (within MHC class II region). F: CT genotype 
of rs2227139 (within MHC class II region), when statistically controlled for total T2 brain lesion volume.
Images show several axial slices of the T2-weighted template (the same slices in each case), with color 
overlay (indicating p-values) of the clusters in which local lesion probability was significantly increased. 
For colour figure see page 188.
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For six SNPs, a genotype was associated with a decreased lesion probability (for details 
on cluster location and genotypes see Figure 3). These six SNPs were located within the 
following genes: Butyrophilin-like 2 gene (BTNL2, MHC class II associated), Alpha B crystalline 
(CRYAB), NADH dehydrogenase (ubiquinone) Fe-S protein 7 (NDUFS7), Uncoupling protein 2 
(UCP2) and two SNPs within the TNF receptor superfamily, member 6 gene (also called FAS). 
When total brain lesion volume was included in the statistical model, only rs2227139 
(within the MHC class II region) retained a significant cluster in which the CT genotype was 
associated with an increased local lesion probability compared to the other two genotypes 
(Figure 2F).
This result of rs2227139 also remained after correction for disease duration.
To corroborate our findings, we calculated the voxelwise average lesion frequencies for each 
of the three genotypes of the SNP rs2227139, the only SNP that remained significant after 
controlling for total brain lesion volume. In the voxel with the maximum pseudo-t-value 
observed in the significant cluster (voxelwise pseudo-t = 4.1), a lesion was present in 29% 
(n=26 / 89) of the patients with the heterozygote genotype CT, compared to 16% (n= 12 / 77) 
of the patients with the CC genotype and 2% (n= 1 /42) of the patients with the TT genotype.
There were no genotypes of any SNP associated simultaneously with both a decreased 
lesion probability in one location and an increased lesion probability in another, indicating 
consistency of the observed relations across the brain. 
Influence of genotype on total brain lesion volume
We assessed whether genotype was directly related to total brain lesion volume for the 
SNPs with significant results in the clusterwise analysis. Of the 11 genotypes associated with 
an increased or decreased lesion probability at the described locations, six genotypes were 
significantly associated with total lesion volume in the brain (table 2). When we controlled 
these results for disease duration three SNPs were significantly associated with total lesion 
volume. The results were consistent with the LPM results- that is genotypes associated 
with a higher total brain lesion volume were also associated with an increased local lesion 
probability, and a decreased local lesion probability. 
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Figure 3: Association between decreased lesion probability and genotype. Each row shows results for 
the comparison of one genotype compared to the other two. a: CT genotype of rs3781202 (within 
FAS-gene: TNF receptor superfamily, member 6). b: TT genotype of rs2234978 (within FAS-gene: 
TNF receptor superfamily, member 6). C: GG genotype of rs2076530 within Butyrophilin-like 2 gene 
(BTNL2) (MHC class II associated). D: AA genotype of rs762550 within Alpha B crystallin gene. e: GG 
genotype of rs2074897 within NDUFS7-gene (NADH dehydrogenase (ubiquinone) Fe-S protein 7). 
F: CC genotype of rs659366 within UCP-2 gene (Uncoupling protein 2). 
Images show several axial slices of the T2-weighted template (the same slices in each case), with color 
overlay of the clusters in which local lesion probability was significantly decreased. For colour figure 
see page 189.
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table 2: Association of genotypes of the SNPs significant in LPM analyses with total T2 lesion volume in 
the brain. P-values of significant associations to total T2 lesion volume are printed in bold.
Gene Rs-number Mean whole brain t2 lesion 
volumes in ml (SD)
P-value of 
differences in total 
lesion volume 
between genotypes 
(Mann Whitney 
U-test)
p-value of 
differences in total 
lesion volume, 
corrected for disease 
duration (using GlM)Genotype of 
interest†
other 
genotypes
association with local increased local lesion probability in lPM analyses
BTNL2 rs2076530§ AG
32.0 (32.9)
AA and GG
23.8 (27.4)
0.04 0.05
CCL5 rs2107538 CC
28.2 (29.0)
CT and TT*
20.9 (28.1)
0.02 0.07
IFNGR2 rs9808753 AA 
28.5 (30.5)
AG and GG*
18.3 (22.6)
0.04 0.29
PNMT rs876493 AG
28.1 (29.0)
AA and GG
23.2 (28.6)
0.15 0.13
HLA rs2227139 CT
28.0 (29.9)
CC and TT
23.9 (28.0)
0.35 0.25
association with local decreased local lesion probability in lPM analyses
BTNL2 rs2076530§ GG 
18.7 (22.7)
AA and AG
26.6 (29.5)
0.13 0.04
CRYAB rs762550 AA 
19.8 (21.0)
AG and GG
27.0 (30.2)
0.28 0.30
FAS rs2234978 TT 
12.5 (14.7)
CC and CT 
27.1 (29.7)
0.02 0.06
FAS rs3781202 CT 
23.1 (28.5)
CC and TT
28.4 (29.1)
0.18 0.37
NDUFS7 rs2074897 GG 
18.4 (23.7)
AA and AG
28.2 (30.1)
<0.01 0.08
UCP2 rs659366 CC 
18.6 (23.1)
CT and TT
29.8 (31.1)
<0.01 <0.01
* Because of frequency < 5% of homozygote genotype, these genotypes (TT for CCL5 and GG for 
IFNGR2) were only analysed when combined with heterozygote genotype.
§ Different genotypes of this same SNP are involved in decreased and increased lesion probability. 
† Genotype(s) that are significantly associated with altered local lesion probability in LPM analyses.
See list of abbreviations on page 181
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Discussion
Based on the hypothesis that genetic background may determine spatial lesion patterns, this 
exploratory study combined lesion probability mapping with genetic data of 69 SNPs in 208 
MS patients. To our knowledge, this is the first study that in a large cohort of MS patients 
tests the role of several genes on lesion distribution within the brain. Five SNPs showed a 
locally increased lesion probability in certain brain regions for one genotype, while six SNPs 
showed a decreased lesion probability for one of the genotypes. The most robust finding 
was the increased probability of having a lesion in the left periventricular region next to 
the frontal and to a lesser extent the occipital horn of the ventricles, for the heterozygous 
genotype of rs2227139 (Figures 2e and 2F). This was the only SNP for which a significant 
cluster remained after applying a correction for total brain lesion volume. Rs2227139 is 
located on chromosome 6 within the highly polymorphic major histocompatibility complex 
(MHC) class II region, which is involved in self versus non-self immune recognition.36 These 
genes have consistently been shown to have a major effect on susceptibility to MS and 
other auto-immune diseases36 and may be involved in disease severity as well.15,37 No data 
is available on the effect of this SNP on region-specific differences in the brain. However, 
previously multiple HLA alleles showed effects on several MRI severity markers, such as T2 
lesion volume, T1 hypo-intense lesion volume and atrophy measures,38,39 suggesting a role 
for several HLA alleles in the MS phenotype. These findings highlight the importance of HLA 
genes on MRI severity markers. Future studies on the genetic influence on lesion location 
should preferably include high resolution HLA typing, enabling comparison of the effect of 
different HLA alleles on lesion distribution (taking possible interaction between genes into 
account) and detecting the true causative allele(s).
As can be seen from figures 2 and 3, the SNPs showed altered lesion probability in 
predominantly four regions: the bilateral periventricular white matter next to the frontal 
and occipital tip of the horns of the lateral ventricles. The periventricular clusters are 
distributed in an asymmetrical manner. We have no explanation for these asymmetries, 
which persisted after post-hoc repeated analyses with a lower significance threshold. A 
priori, a genetic influence on this asymmetrical distribution is theoretically unlikely. Another 
study also noted an asymmetrical distribution of MS brain lesions at the individual patient 
level, possibly reflecting a different lineage pattern.9 Although our number of patients is 
relatively high, bias due to, for example, the high number of progressive patients is possible 
and cannot be excluded.
Rs2076530 within BTNL2 (Butyrophilin-like 2-gene) was the only SNP showing significant 
effects for more than one genotype. The AG genotype was associated with an increased lesion 
probability in the periventricular white matter adjacent to the right occipital horn, while the 
GG genotype was associated with a decreased lesion probability in the periventricular white 
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matter adjacent to the left occipital and frontal horn. Both effects were non-conflicting and 
disappeared after correction for total brain lesion volume.
The relation between HLA-DRB1*1501 (the MHC class II allele strongly associated with 
susceptibility to MS)12,40,41 and spatial lesion distribution within the brain was studied in one 
previous report,23 demonstrating no significant influence of the allele. Our results (by using 
rs3135388, a SNP in the MHC region predicting the HLA-DRB1*1501 haplotype with very 
high sensitivity )28 confirmed in a larger sample the negative result of this previous study 
of Sepulcre et al. In a subset of the current patient group, we previously found the HLA-
DRB1*1501 allele to be related to increased lesion loads in the spinal cord but not the brain. 
In the present study on a larger patient group encompassing the former, we confirmed 
that the HLA-DRB1*1501 allele was not related to the total volume of brain lesions,22 and 
importantly, added the new finding that it is also unrelated to their anatomical distribution 
across the brain.
Limitations of this study include the relatively low field strength of the MRI scanners we 
used, which in general leads to lower sensitivity to lesions than current state of the art MRI 
scanners, operating at 3T or above.42
Furthermore, the linear registration method used to warp the lesion masks of individual 
patients to the template, by definition, cannot correct for the variability in ventricular and 
sulcal sizes that is present in MS patients as a result of differences in brain atrophy. Therefore, 
the matching between individual patient’s brains will be imperfect; this discrepancy leads to 
less accurate overlay of corresponding anatomical areas and may explain, to some extent, 
why we only found clusters in the periventricular region and not in areas with a lower 
lesion frequency. In spite of these limitations, we deliberately chose a linear registration 
method (FLIRT), because of the difficulties associated with non-linear registration methods. 
In this study we were limited in the sequences available (dual-echo images only), which 
pose problems for non-linear registration regarding the distinction between periventricular 
lesions and ventricular CSF, because of their similar signal intensities. Second, non linear 
registration could result in displacement of lesions inside the brain, thereby affecting the 
very aspect of the disease that we intended to study (namely lesion distribution). 
The third limitation is the absence of grey matter lesions in our study, since these lesions 
go mostly undetected when using standard MRI techniques.43 From post-mortem studies 
we know that grey matter lesions are extensively present in MS patients43 and it can be 
expected that a different genetic background may influence the lesion distribution between 
the white and grey matter compartment, as well as the anatomical distribution within the 
white and grey matter. 
Total brain lesion volume seems to be an important covariate in LPM analyses.7 Apart 
from the left frontal horn cluster in rs2227139, no clusters retained significance when the 
model was controlled for lesion volume. Thus, the influence of genetic background on 
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spatial lesion distribution, as assessed in the current study, may partly act through total 
brain lesion volume and come to expression in voxelwise analyses especially in regions with 
relatively high frequencies of MS lesions, where differences between groups can become 
statistically significant (i.e., the periventricular white matter). Therefore, in future studies, 
when comparing groups, a correction for total brain lesion volume should be considered. 
The genes investigated in this study are putatively associated with susceptibility or disease 
severity in MS, and we hypothesized that the variation in anatomical distribution of brain 
lesions between MS patients may be partly genetic in nature. Our results suggest that such a 
genetic influence may indeed be present. Independent studies should now be conducted to 
confirm these findings, including studies using alternative methodology in addition to LPM, 
e.g., using pre-defined regions of interest defined on the basis of LPM results, to increase 
sensitivity to detect differences. For the genes with significant results, there are no obvious 
relationships between their functions and spatial MS lesion distribution. However, several 
of the SNPs that were significantly associated with lesion distribution, were also significantly 
associated with the total lesion volume in the brain. The previously reported effect of these 
genes on the overall lesion burden (T2 lesion volume, T1 hypo-intense lesion volume or 
atrophy,38,44,45), acting through their functions in different processes such as mitochondrial 
energy metabolism and inflammation, is likely to generate differences in lesion distribution 
between the genotypes. Our finding that statistically controlling for total brain lesion volume 
removes the observed effects on lesion distribution, suggests that these genes possibly 
exert an effect mainly on the overall lesion burden. However, to fully address this issue, 
a more focused approach should be applied, using both an LPM approach and predefined 
areas of interest (hereby increasing the statistical power) and select more homogenous 
patients to limit the effect of confounding factors. In this context a longitudinal study on 
the spatiotemporal development of new lesions (including T1 hypo-intense lesions and T1 
gadolinium enhancing lesions) would be valuable. Eventually, the insights gained from this 
approach may yield ways of predicting from patients genotype whether they are likely to 
develop lesions in clinically eloquent areas.
Recently, pathway analysis in relation to susceptibility to MS revealed, not surprisingly, 
immune-related pathways.46 However, the same study also detected significant neural 
pathways, implicating a primary neural dysfunction in susceptibility to MS. This pathway 
analysis approach may provide a basis for patient stratification (for instance patients carrying 
a predominantly inflammatory profile versus patients carrying a more neurodegenerative 
profile) and it would be valuable to characterize these patient groups in terms of their lesion 
distribution. Previously, some of the SNPs selected for this study were found related in 
relatively small studies, to a more neurodegenerative profile (CCR 5 and CRYAB),18,45 while 
others have found several HLA alleles associated with a more inflammatory profile.37,38 Such 
profile differences may be able to explain the previously described differences in lesion 
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distribution between T1 gadolinium enhancing lesions (acute inflammatory activity) and T1 
persistent hypo-intense lesions (neurodegenerative activity).9 
Conclusion:
This exploratory study revealed an association between heterozygosity on rs2227139 in the 
MHC class II region and preferential periventricular lesion formation in MS. Other SNPs also 
showed associations between genotype and spatial lesion distribution, which are worth 
studying in future studies using a more focused approach and considering genetic pathways 
in addition to single genes. In these future studies, the potential role of lesion volume 
influencing the relation between genotype and lesion distribution should be explored 
further, as well as the distribution of grey matter lesions, contrast-enhancing lesions, and 
persistent T1-hypointense lesions.
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Supplementary table 1: SNPs included in our analyses. MAF=minor allele frequency in our sample. 
Gene rs-nr Chromosome Polymorphism (major 
allele / minor allele)
MAF
ADAMTS14 * rs4747075 10q22 G/A 0.30
ADAMTS14 rs7081273 10q22 G/C 0.35
ADAMTS14 rs4746060 10q22 C/T 0.09
BTNL2 * rs2076530 6p21.3 A/G 0.24
CACNG4 rs4790896 17q24 A/G 0.38
CCDC46 rs987931 17q24 T/G 0.31
CCL5 rs2280788 17q11.2-q12 C/G 0.02§
CCL5 rs2107538 17q11.2-q12 C/T 0.19
CCR5 rs333 3p21 +/- 0.10
CD24 rs8734 6q21 C 0.00§
CIITA rs3087456 16p13 A/G 0.26
CNTF rs1800169 11q12 G/A 0.12
CRYAB rs14133 11q21-q23 C/G 0.25
CRYAB rs762550 11q21-q23 G/A 0.42
CTLA4 rs231775 2q33 A/G 0.38
CTLA4 rs5742909 2q33 C/T 0.09
EBF1 rs1368297 5q34 T/A 0.38
FAS rs1800682 10q23 T/C 0.46
FAS rs3781202 10q23 C/T 0.41
FAS rs2234978 10q23 C/T 0.31
GABBR1 rs1805057 6p22 C 0.00§
HELZ rs2363846 17q24 C/T 0.50
HLA * rs2395166 6p21.3 T/C 0.48
HLA-DRA rs2213584 6p21.3 A/G 0.42
HLA rs2227139 6p21.3 C/T 0.42
HLA-DRA rs3135388 6p21.3 G/A 0.33
HLA rs9268458 6p21.3 C/A 0.19
HLA * rs6457594 6p21.3 A/G 0.38
HLA-DRA rs2395182 6p21.3 T/G 0.39
HLA-DRA rs2239802 6p21.3 C/G 0.39
HSPB2 rs2234702 11q21-q23 C 0.00§
IFNAR1 rs2257167 21q22 G/C 0.07
IFNGR2 rs9808753 21q22 A/G 0.15
IL1B rs1799916 2q14 A 0.00§
IL1B rs1143627 2q14 A/G 0.35
IL1B rs1143634 2q14 C/T 0.23
IL1RN rs419598 2q12-q14 T/C 0.31
IL1RN 2073 C/T 2q12-q14 C/T 0.31
IL2 rs2069763 4q26-27 G/T 0.34
IL2 rs2069762 4q26-27 T/G 0.26
IL4R rs1801275 16p12 A/G 0.20
IL7R rs11567685 5p13 T/C 0.25
IL7R rs7718919 5p13 G/T 0.13
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Gene rs-nr Chromosome Polymorphism (major 
allele / minor allele)
MAF
IL7R rs11567686 5p13 A/G 0.34
IL10 rs1800896 1q32 A/G 0.45
MC1R rs1805009 16q24 G/C 0.01§
MC1R rs1805006 16q24 C/A 0.01§
MEFV rs28940577 16p13.3 A 0.00§
MOG rs3130250 6p22 G/A 0.20
MOG rs3130253 6p22 G/A 0.11
NDUFA7 rs2288414 19p13.2 G/C 0.03§
NDUFA7 rs561 19p13.2 G/A 0.19
NDUFS5 rs2889683 1p34.2 T/C 0.31
NDUFS5 rs6981 1p34.2 G/A 0.05
NDUFS7 rs2074897 19p13.3 G/A 0.46
NFKBIL1 rs3130062 6p21.3. T/C 0.17
NOS2 rs1137933 17q11.2 G/A 0.24
NOS2 rs2779248 17q11.2 T/C 0.38
NOTCH4 rs367398 6p21.3 G/A 0.18
PDCD1 rs11568821 2q37 G/A 0.11
PITPNC1 rs1318 17q24 A/G 0.22
PITPNC1 rs2365403 17q24 C/G 0.17
PNMT rs876493 17q11-q23 A/G 0.42
PRKCA rs7220007 17q24 A/G 0.48
PRKCA rs887797 17q24 C/T 0.30
PRKCA rs2078153 17q24 G/C 0.23
PRKCA rs3890137 17q24 A/G 0.37
PTPN22 rs2476601 1p13 G/A 0.10
PTPRC rs17612648 1q31 C/G 0.02§
PTPRC rs4915154 1q31 A/G 0.01§
SPP1 rs1126616 4q21 C/T 0.23
SPP1 rs1126772 4q21 A/G 0.19
SPP1 rs2853744 4q21 G/T 0.06
SPP1 rs9138 4q21 A/C 0.24
SPP1 rs4754 4q21 T/C 0.24
TNF rs1800629 6p21.3 G/A 0.21
TNFSF10 rs1131568† 3q26 C/T 0.35
UCP2 rs659366 11q13 C/T 0.40
VDR rs1544410 12q13 G/A 0.44
VDR rs731236 12q13 A/G 0.44
* This SNP deviated from Hardy-Weinberg Equilibrium (p<0.01) 
§ Excluded due to minor allele frequency below 5%.
† Previous rs-number: rs9880164.
See list of abbreviations on page 181
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abstract 
objective: Spinal cord (SC) lesions are frequently found in Multiple Sclerosis (MS), but are 
rare in healthy ageing and cerebrovascular patients. Our aim was analyzing the contribution 
of SC involvement in Clinically Isolated Syndrome (CIS) in diagnosing MS according the 
McDonald 2010 criteria and in predicting conversion to Clinically Definite MS (CDMS). 
Methods: We prospectively followed monofocal, relapsing onset CIS patients with either SC 
or brain symptom onset (including optic neuritis). MRI of the brain and SC were performed 
shortly after onset and patients were followed for 24-119 months (median 64). SC MRI 
findings were assessed for their contribution to the McDonald 2010 diagnostic criteria and 
their effect on conversion to CDMS. 
Results: 121 patients were included (63 spinal-CIS). Based on the brain scan only, 36 patients 
fulfilled the McDonald criteria; by including SC findings 6 additional patients fulfilled these 
criteria. To diagnose one additional non-spinal CIS patient, the number needed to scan is 7. 
In non-spinal CIS patients that did not fulfil McDonald brain MRI criteria (n=42), presence of 
a SC lesion was associated with a higher risk of conversion to CDMS (OR: 14.4 (95% CI: 2.6 
– 80.0) and shorter time to conversion to CDMS (Hazard ratio: 51.4 (95%- CI: 5.5 – 476.3). 
Conclusions: Presence of SC lesions facilitates diagnosing MS and is predictive for conversion 
to CDMS, especially in non-spinal CIS patients that do not fulfill brain MRI criteria. We 
therefore recommend performing a SC scan in non-spinal CIS patients that do not fulfil 
McDonald brain MRI criteria.
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Introduction
Spinal cord (SC) abnormalities on Magnetic Resonance Imaging (MRI) are frequently found 
in clinically definite multiple Sclerosis (CDMS) patients1. In patients presenting with clinically 
isolated syndromes (CIS) the prevalence of SC lesions is lower2,3. In most other neurological 
diseases, especially in cerebrovascular disorders, auto-immune inflammatory disorders and 
also in healthy ageing, SC lesions are rather rare, whereas cerebral white matter changes 
are common4-7.
By introducing MRI criteria, early diagnosis was facilitated and treatment could be started 
early, in an attempt to reduce disability accumulation8-12. SC lesions have been incorporated 
in the MS diagnostic criteria since 200110,11. In the 2010 revisions, SC lesions have become 
increasingly important and now have the same weight as brain lesions12. Despite the 
recognized contribution of SC imaging to the early diagnosis of MS13-17, scanning of the SC 
is not routinely performed in all patients. As a rule, mostly patients presenting with a CIS 
with SC symptomatology, will be referred for a spinal MRI scan to identify the cause of the 
symptoms (demyelination, compression of the SC etc). However, in CIS patients presenting 
with brain symptoms, SC imaging is often not performed, although asymptomatic SC 
involvement is frequent1,18 and may add independent prognostic information by contributing 
to the diagnostic criteria12. 
The aim of this study was to prospectively assess the occurrence of brain and SC lesions in a 
large monofocal CIS cohort, to test the contribution of SC imaging in diagnosing MS applying 
the McDonald 2010 criteria. The second aim was to investigate the impact of presence of SC 
lesions on future conversion to CDMS in patients with SC symptoms (spinal CIS) and brain 
symptoms (non-spinal CIS). 
Methods
Patients
Patients with a monofocal CIS were selected from an ongoing natural history at the VUmc 
Medical Center19. Recruitment for this natural history study started in December 2000 
and lasted until September 2007. Patients with CIS or early MS were only included when 
a demyelinating cause of the complaints was most likely, as assessed by MS-neurologists. 
These patients were invited to participate in this natural history study. Spinal cord and brain 
MRI were obtained at baseline per study protocol from all participants entering the natural 
history study, irrespective of the clinical course of the patient. Of our total cohort of 319 CIS 
/ early MS patients, patients diagnosed with CDMS at entry of the study (n= 102) or with a 
progressive onset (n= 28) were excluded. Of all CIS patients (n= 189) only the CIS patients 
fulfilling the criteria mentioned below were included: 
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1) Patients presenting with a monofocal CIS, suggestive of central nervous system 
demyelination, not attributable to other diseases, without previous neurological episodes 
suggestive of demyelination; symptoms started within 12 months preceding the recruitment 
(27 CIS patients were excluded). Patients with a multifocal onset (signs and symptoms) were 
excluded from further analysis, because they already fulfilled the dissemination in space 
criteria (22 multifocal CIS patients were excluded). 
2) Age between 16 and 60 years at onset of first symptoms. 
3) Availability of an MRI scan of the brain and SC at baseline preferably made on the same 
day, but no more than 3 months apart (13 CIS patients were excluded). 
4) Clinical follow-up of at least 24 months (6 were excluded). 
All patients fulfilling these criteria were enrolled (n= 121)
Standard Protocol approvals, and Patient Consents
Written informed consent was obtained from all patients. The study was approved by the 
Institutional Review board of the VU University Medical Center.
Clinical data
Symptoms at onset were classified according to the presenting symptoms as “spinal-CIS” 
(onset of symptoms originating from the SC) and “non-spinal CIS” (onset of symptoms 
originating from the brain, infratentorial brain region (brainstem and cerebellum) or optic 
nerve). Patients were seen yearly and interviewed for new symptoms and use of disease 
modifying therapy. If new symptoms occurred and patients were seen by a neurologist in a 
different hospital, this neurologist was contacted for information on the signs and symptoms 
of the relapse. Conversion to CDMS was defined as a second episode of new symptoms 
occurring after an interval of at least 1 months and not attributable to other disease21. The 
time from disease onset to conversion to CDMS was calculated in months.
In our analyses the new McDonald 2010 diagnostic criteria for dissemination in space and 
time were applied12. 
MRI 
All patients, irrespective of the onset symptoms, had an MRI scan of the brain and the SC. 
MRI scans of the brain and SC were acquired at baseline either on 1.0 Tesla or 1.5 Tesla MRI 
whole body MRI systems (Siemens Magnetom Impact Expert, Siemens Vision and Siemens 
Sonata) (Siemens AG, Erlangen, Germany). For the brain, we used standard 2D dual-echo 
spin-echo Proton Density (PD) - and T2-weighted images (TR: 2200-3000 ms, TE: 20-30 & 
80-100 ms) and T1-weighted images after administration of intravenous gadolinium (TR 
500-600 & TE 20 ms) with slice thicknesses of 3-5 mm, a maximum gap between slices 
of 0.5 mm, and an in-plane resolution of 1x1 mm2. Lesions on T2 (hyperintense) and T1 
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weighted images (gadolinium-enhancing lesions) were identified by a blinded experienced 
reader (Image Analysis Center) and then outlined using local thresholding software. Lesion 
location was scored using the following regions: periventricular, juxtacortical, infratentorial 
(brainstem and cerebellum). SC scanning included a cardiac-triggered sagittal PD and T2-
weighted dual-echo spin-echo sequence with a slice-thickness of 3mm covering the whole 
SC (TR: 2500 – 3000 ms and TE: 20-30 & 80-100 ms), with a gap between slices of 0.3 mm, 
and an in plane resolution of 1x1 mm, using spinal phased-array coils. The number of focal 
lesions was scored by one experienced reader, being unaware of the clinical condition of 
the patient.
Statistical analyses
The effect of SC scanning on diagnosing MS was evaluated by applying the McDonald 2010 
criteria first without the findings of the SC scan and secondly when including the findings of 
the SC. This allows assessment of whether the SC findings contributed to the DIS and/or DIT 
criteria. The number of patients that needs to be scanned to diagnose one additional MS 
patient was calculated.
To assess our second aim (determining the contribution of SC lesions on conversion 
to CDMS) odds ratios (including 95% confidence-intervals (CI)) were calculated in four 
subgroups: 1. Spinal-CIS fulfilling McDonald MRI criteria at baseline brain scan 2. Spinal-CIS 
not fulfilling McDonald brain MRI criteria at baseline 3. Non-spinal CIS fulfilling McDonald 
brain MRI criteria at baseline and 4. Non-spinal CIS not fulfilling McDonald brain MRI criteria 
at baseline. Furthermore, survival analysis was performed on time to conversion to CDMS 
in the abovementioned four groups. Kaplan-Meier curves were constructed. Cox-regression 
analysis was used to calculate hazard ratios (including 95% CI) for the effect of presence of 
SC lesions on time to conversion to CDMS and corrected for use of DMT before conversion 
to CDMS. Analyses were performed using SPSS for Windows 15.0 (SPSS Inc, Chicago, Illinois).
Results
Patient characteristics
In this study 121 CIS patients were included with a mean age-at-onset of 35 years. The 
mean disease duration at follow up was 5 years and 4 months (range: 2 years - 10 years), 
during which 55 patients (45.5%) converted to CDMS according to the Poser criteria. For 
more details on the patient clinical and MRI characteristics see table 1. In 63 patients, 
the presenting symptoms were attributable to the SC (referred to as “spinal-CIS”) while 
58 patients experienced the first symptoms originating from the brain (“non-spinal CIS”: 
optic nerve, infratentorial region or hemispherical region). The brain MRI showed T2 
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abnormalities in 95% of patients, while 44 patients had gadolinium enhancing lesions in the 
brain (36.4%). In total 82 patients had focal lesions in the SC (67.8%). No patients showed SC 
lesions extending longitudinally over 3 or more segments. The patients with spinal CIS did 
not differ from the non-spinal CIS group in total number of lesions in terms of juxtacortical, 
periventricular or enhancing lesions. However, spinal CIS patients more frequently had SC 
lesions (p=0.001) and a trend towards more frequent infratentorial lesions (p=0.06) (table 
1).
effect of adding SC findings on diagnosing MS using the McDonald 2010 criteria
When we applied the McDonald 2010 criteria, 36 patients fulfilled the criteria for DIS and 
DIT, based on the baseline brain MRI scan only. When the findings of the SC scan were added, 
2 extra patients fulfilled DIS criteria (however still lacked DIT) and 6 additional patients 
fulfilled both DIS and DIT criteria: 2 patients went from not fulfilling DIS and DIT to fulfilling 
both DIS and DIT, 2 patients fulfilled DIS criteria based on the brain scan and after taking into 
account SC findings also fulfilled the DIT criteria and 2 patients fulfilled DIT criteria based 
on the brain scan and now additionally fulfilled DIS criteria when SC findings were added. 
These 6 additional patients were all non-spinal CIS patients, because in the McDonald 2010 
criteria all lesions in the SC in spinal CIS patients are considered symptomatic and therefore 
excluded from contributing to the diagnostic criteria. From our study, the number needed to 
scan in non-spinal CIS patients to be able to early diagnose one more patient with MS is 7.
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Predictive power of the presence of focal SC lesions for conversion to CDMS
In the total CIS group (n=121), during a mean follow-up of 5 years and 4 months, the odds-
ratio of presence of focal SC lesions for conversion to CDMS was 3.53 (95% CI: 1.52 – 8.17) 
compared to patients who do not have SC lesions. The odds-ratio for presence of SC lesions 
for conversion to CDMS in the subgroup spinal-CIS was 1.24 (95% CI: 0.35 – 4.44), while 
in the non-spinal CIS subgroup the odds was 6.48 (95% CI: 2.34 – 17.95). Moreover, the 
Cox-regression (with correction for use of DMT before conversion to CDMS) showed a 
significantly shorter time to conversion to CDMS in patients with SC lesions, compared to 
patients without SC lesions for the total CIS group (n=121) (Hazard ratio: 2.76 (95%-CI: 1.37 
– 5.56; p=0.005) (for survival-curve see Figure 1a). 
Odds-ratios and hazard ratios for the separate subgroups of spinal CIS and non-spinal CIS 
patients with or without an abnormal brain MRI scan, for predicting (time to) conversion to 
CDMS in patients with SC lesions compared to those without SC lesions, are presented in 
table 2. The odds-ratio for presence of SC lesions on predicting conversion to CDMS in the 
non-spinal CIS subgroup that did not fulfil the diagnostic brain MRI criteria was 14.4 (95%-CI: 
(2.60 – 80.03). Only patients with spinal cord lesions in the nonspinal CIS group that did not 
fulfill the McDonald 2010 brain MRI criteria had a significantly shorter time to conversion 
to CDMS, compared with those patients without spinal cord lesions (see figure 1b for the 
survival curve for this group of patients). Please see Figure 2 for an example of an MRI of a 
non-spinal CIS patient with typical MS brain lesions, however lacking spinal cord lesions on 
MRI. This patient did not convert to CDMS during follow-up. 
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Figure 1: Survival-curves on effect of presence of spinal cord lesions on time to conversion to CDMS. 
Figure 1a: Survival-curve (Kaplan Meier) in total group of CIS patients (n=121), significant shorter time 
to CDMS for patients with compared to patients without SC lesions (p=0.005 Cox regression). Figure 
1b: Kaplan Meier curve in non-spinal CIS patients not fulfilling McDonald brain MRI criteria (n=42). For 
colour figure see page 190.
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Figure 2: brain and spinal cord MRIs in patients with and without spinal cord lesions.
MRI of a 36-year-old male that experienced a relapse with brainstem symptoms (an episode of 
sensory disturbances on the left side of his face). The baseline MRI scan of the brain showed multiple 
periventricular lesions (see left upper panel T2 weighted brain images), two infratentorial lesions 
(lower left panel) and a juxtacortical lesion (not shown). No abnormalities were found in the SC (see 
right panels: sagittal T2 weighted and proton-density images). No conversion to CDMS occurred during 
follow-up (4 years).
Discussion
Although SC abnormalities have gained importance in the most recent diagnostic criteria 
when compared to the previous diagnostic criteria for MS, SC scanning is not performed 
in all patients presenting with a CIS. Nowadays, state of the art MRI acquisition techniques 
allow us to image the whole SC with high resolution within a reasonable acquisition time. 
However, in many centers, patients will only be referred for SC MRI when presenting 
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symptoms indicate SC involvement (to rule out other causes). In this study we show however 
that especially in patients not presenting with SC symptomatology, presence of SC lesions 
can both aid in diagnosing MS by contributing to the diagnostic McDonald 2010 criteria, and 
have prognostic value in predicting conversion to CDMS. 
In CIS patients presenting with SC symptomatology (spinal CIS), an MRI scan of the SC will 
be performed almost instantly to assess the cause of SC symptoms. When lesions are found 
consistent with demyelination, a brain scan will be performed to assess dissemination in 
space and time. In our study in this subgroup, presence of focal SC lesions did not aid in 
predicting future conversion to CDMS. To a certain extent this is an artifact of the McDonald 
2010 criteria that ignore all SC lesions in cord-onset patients, while it might be argued that 
some (if 2 or more) are asymptomatic. However, spinal CIS patients in our cohort, with two 
or more SC lesions did not convert more often to CDMS than patients with zero or one SC 
lesion.
By contrast, in patients presenting with brain symptoms (non-spinal CIS), the first procedure 
will be a brain MRI scan. If there is good reason to assume that demyelination is the cause 
of the symptoms, the McDonald 2010 criteria will be applied. In our total CIS cohort, 36 
out of 121 patients (in non-spinal CIS patients 16/58) could be diagnosed with MS after 
a single brain MRI scan. In this group of patients (either spinal-CIS or non-spinal CIS) SC 
lesions did not further contribute to predicting conversion to CDMS. When we added the 
findings of the SC scan in the brain CIS patients that could not be diagnosed with MS (n=42), 
6 additional patients were diagnosed with MS. This means that in this subset for every 7 
MRI scans of the SC 1 extra patient will be diagnosed with MS (number needed to scan = 7).
In addition to a moderate contribution to immediately diagnosing McDonald 2010 MS, we 
found that in the same group of non-spinal CIS patients, presence of SC lesions is a strong 
prognostic factor in predicting conversion to CDMS (see table 2 and Figure 1b). Patients 
with SC lesions in this group have a 14.4 (95%-CI: 2.60 – 80.03) higher risk of converting 
to CDMS, compared to patients that do not have SC lesions. Moreover, patients that have 
SC lesions will experience a second relapse much faster (Hazard ratio: 51.38 (95%-CI: 5.54 
– 476.33). Taken together, in patients with non-spinal CIS presentation, who do not meet 
McDonald criteria on their brain MRI, SC MRI allows for early diagnosis and much more 
adequate future risk estimation. 
Performing additional SC scans in the non-spinal CIS patients somewhat increases the 
burden for the patients and increases the costs. However, it is to be expected that an early 
diagnosis and better prognostificaton of CIS patients might lead to less uncertainty and 
allows an early start of disease modifying therapy. Future studies should analyze these 
combined effects. Moreover, it would be interesting for future studies to assess whether 
SC imaging immediately after onset of non-spinal CIS increases the yield of DIS and DIT 
diagnosis, compared to repeating the brain MRI.
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In a 2008 consensus paper22, absence of SC lesions was considered a minor red flag based 
on the opinion of MS-experts, however this was not based on literature. Our results indeed 
indicate that absence of SC lesions is related to a much lower and delayed conversion to 
CDMS. Even though some of our patients will probably still convert to CDMS in the future, 
we feel that (with a median follow-up of 5 years and 4 months) this is a safe conclusion, since 
literature data show that most conversions to CDMS occur in the first five years23,24. Therefore, 
absence of SC lesions should be considered a warning sign and lead to reconsideration of 
the possibility that this patient might not experience a second relapse or will develop MS. 
As a tertiary referral-center for MS patients, the characteristics of the patients in our study-
cohort might also reflect this. When compared to other studies25,26 our cohort has a lower 
frequency of optic neuritis and a higher frequency of SC onset symptoms. In addition, before 
being entered in this study, patients were carefully assessed by MS expert neurologists, which 
probably resulted in a low rate of patients with cerebrovascular disease being admitted into 
this study. We feel that the yield of one extra diagnosis in our, often complex, population, 
justifies the number of scans needed (=7). However, we do acknowledge that additional 
factors in other hospitals, such as availability of extra scan-time and extra costs need to be 
considered. Before we can generalize our conclusions to other centers, our findings should 
be tested in other cohorts especially in more general neurology practices. 
Interestingly, in the spinal-CIS group “only” 81% showed SC abnormalities, although one 
would expect a percentage near 100%. Twelve patients with a clinically defined spinal cord 
syndrome did not show focal lesions in the spinal cord. Of these twelve patients five converted 
to CDMS during the follow-up. Ten out of twelve showed abnormalities on the initial brain 
MRI scan. This discrepancy between clinical symptoms and imaging parameters might be 
caused because of lack of sensitivity of the SC scan to detect the lesions (considering the 
time between scanning and symptoms) or small lesions escaping detection at the current 
resolution, or diffuse changes not leading to qualitative signal change (normal-appearing 
tissue). Another explanation could be that attribution of symptoms to either brain or SC 
involvement on clinical grounds alone can be difficult. 
While it is already common practice to perform SC MRI in patients with CIS who present with 
SC symptoms, we advocate, based on the findings of this study, to more routinely perform 
SC MRI in patients with non-spinal clinical presentation who do not fulfill McDonald criteria 
on their baseline brain MRI. In these patients SC MRI helps to fulfill diagnostic criteria (1 
extra MS diagnosis from 7 MRIs) and in addition it has pronounced prognostic value, mainly 
because it helps to identify a subgroup that has a very low risk to develop MS. 
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advances in knowledge
	 UCCA (upper cervical cord cross-sectional area) differs between MS subtypes, 
being smaller in the progressive disease courses.
	 Atrophy of the spinal cord is more strongly related to clinical disability than spinal 
cord lesion number.
	 UCCA can be determined from routine 3D brain MRI scans. 
Implication for Patient Care
	 Spinal cord atrophy and diffuse signal increase are helpful in assessing disease 
progression in MS. 
	 Number of affected spinal cord segments is more strongly related to clinical 
disability than the number of SC lesions.
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abstract
Purpose: To study whether spinal cord (SC) atrophy differs between disease types in multiple 
sclerosis (MS), and to determine its contribution to clinical disability over and above other 
MR imaging markers. 
Material and Methods: The institutional review board approved the study; all subjects gave 
written informed consent. Mean upper cervical cord cross-sectional area (UCCA), brain 
and SC lesion loads and brain atrophy were measured in 440 MS patients (311 relapsing-
remitting [RRMS]; 92 secondary-progressive [SPMS]; 37 primary-progressive [PPMS]) studied 
in two different centers. Disability was scored using the Expanded Disability Status Scale 
(EDSS), 25 feet timed-walk test (TWT) and Nine-Hole-Peg (9-HPT) test. UCCA was compared 
between groups using Mann-Whitney U-test. Correlations were assessed using Spearman’s 
rho. Multivariate associations between UCCA and clinical and other MRI parameters were 
assessed using multiple linear regression, adjusted for center.
Results: Mean UCCA in SPMS (79 mm2) and PPMS (77.3 mm2) patients were significantly 
(both p<0.001) lower than in RRMS patients (84 mm2). UCCA was inversely correlated with 
EDSS, the TWT and the 9-HPT (all: rho≤-0.29; p<0.001). The UCCA, number of hypointense 
T1 brain lesions (T1LL), presence of diffuse abnormalities and number of involved segments 
in the SC were found to be significant explanatory factors for clinical disability (R2 =0.564). 
UCCA and brain T1LL were the strongest MRI predictors of EDSS.
Conclusion: SC pathology has a strong impact on clinical disability in MS. MRI derived UCCA 
was found to be the most significant SC predictor on EDSS.
126
Chapter 4.2
Introduction
Multiple sclerosis (MS) is a heterogeneous neurological disease with a diverse spectrum of 
deficits and highly variable outcome. Focal abnormalities in the spinal cord (SC) are present 
in the majority of MS patients1, affecting the cervical region more frequently than the 
thoracic and lumbar regions2,3. 
Structural abnormalities in the SC can be expected to dramatically affect the functional 
outcome of patients, but reports are ambiguous regarding the correlation between the 
number of focal SC lesions and the degree of disability3-6. Patients with primary progressive 
MS have a higher disease burden in the SC and a more pronounced walking disability than 
relapsing onset patients7.
While newer imaging modalities have improved the detection of SC lesions in MS8-11, 
conventional MR-imaging still lacks histopathological specificity3, leading to increased 
attention for quantitative techniques, such as SC atrophy measurement. SC atrophy 
correlates with clinical disability12-14 and is related to disability more strongly than focal 
lesion load15. It is assumed that axonal loss in MS is an important factor for the occurrence 
of atrophy, but whether or not MS-related neurodegeneration may occur in the absence 
of inflammation is unclear16-18. Because SC atrophy tends to occur in the first few years 
of the disease2, quantification of SC volume or cross-sectional area by MRI seems to be a 
potential marker for monitoring the disease course or treatment efficacy in MS. SC atrophy 
has been described in patients with a clinically isolated syndrome (CIS) exhibiting brain 
abnormalities19 as well as in small groups of RRMS patients12,14. In addition SC atrophy 
has been shown to be more pronounced in the progressive forms of the disease than in 
RRMS4,12,20-22, although except by20 most studies have not included a representative large 
number of major disease subtypes. Although atrophy is not limited to the spinal cord in MS, 
but can also be detected in the whole brain and it’s compartment such as grey and white 
matter23.24, large studies focusing on the clinical importance of spinal cord atrophy upon 
other MRI markers, especially brain parameters are lacking25. 
In the current study we used a large cohort of MS patients to investigate, first, whether SC 
atrophy differs between the major disease types; second, whether SC atrophy is associated 
with other conventional SC or brain measures of disease; and third, how SC atrophy is 
related to clinical disability.
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Methods
Subjects
The study was approved by the institutional medical ethics committee. Informed consent 
was obtained from every patient. In total 440 patients were recruited in two centers. 
Patients were diagnosed with MS according to International Guidelines26,27 and classified 
either as relapsing remitting (RR), secondary progressive (SP), or primary progressive (PP) 
MS28. Disability was assessed using the Expanded Disability Status Scale (EDSS) 29 and two 
subtests of the Multiple Sclerosis Functional Composite Measure (MSFC)30; the 25 feet 
timed-walk test (TWT) assessing ambulatory function and the Nine-Hole-Peg test (9-HPT) 
assessing upper limb function. For all patients, use of disease modifying therapy (DMT) 
before start of the study was recorded. 
neuroimaging 
MRI scans were performed on 1.5T MRI Siemens scanners at both study sites. The head 
scan protocol included: a) sagittal MPRAGE (TR/TE/TI [msec]: 9.7-20.8/2-4/300-400; 
1.0mm3 isotropic resolution); b) dual-echo PD/T2w (2000-4000/14-20/80-108; interleaved 
axial 3.0mm thick slices; in-plane resolution 1.0×1.0mm2); c) post-contrast T1w spin-echo 
(467-650/8-17; axial 3.0mm thick slices; in-plane resolution 1.0×1.0mm2). SC scanning 
included a cardiac-triggered sagittal dual-echo PD/T2-weighted sequence, covering the 
whole SC (2500-3000/20-30/80-100; slice-thickness 3mm; 10% gap between slices; in-plane 
resolution 1.0×1.0mm2).
Image analysis
Brain volume normalized for head size (NBV), as well as normalized gray matter volume 
(NGMV) and normalized white matter volume (NWMV) were analyzed in center A using 
SIENAX which allows analysis of brain atrophy state from a single time point after registering 
each individual scan to MNI-152 standard space, using the skull as a scaling constraint31. 
Marking and measurement of T2 hyperintense brain lesions and T1 hypointense brain lesions 
was performed in center B by experienced readers with more than 12 years experience, 
using commercial semi-automatic software (AMIRA 3.1.1; Mercury Computer Systems Inc.). 
Subsequently, volumes were calculated for these lesion categories. Number of enhancing 
lesions were scored on post-contrast T1-weighted images.
For SC images, number of focal lesions as well as number of involved segments and presence 
of diffuse abnormalities were scored by an experienced reader in center A with more than 
3 years of experience. Diffuse abnormalities were defined as poorly delineated areas with 
increased signal intensity compared to signal intensity of spinal CSF on PD-weighted images 
(Figure 1) 32. 
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Figure 1: Sagittal PD (B,D) and T2-weighted (A,C) images of the spinal cord. (A-B) 36 year old male, 
5yrs disease course, relapsing-remitting disease type, EDSS: 2, PD and T2-weighted images reveal a 
focal lesion in the upper cervical cord (arrow) without evidence of diffuse spinal cord abnormalities. 
(C,D) 45 year old female, 13yrs disease course, primary progressive disease type, EDSS: 6; diffuse 
signal hyperintensity indicating diffuse abnormalities of the entire spinal cord, best seen on the 
corresponding PD-weighted image (D, asterix).
Upper SC atrophy was measured by two authors (both with more than 8 years of 
experience) on each available sagittal 3D-T1 brain dataset on which the upper cervical 
cord was visible with sufficient image quality. For the current analysis 18 patients (RRMS, 
n=12; SPMS, n=4; PPMS, n=2) had to be excluded due to insufficient coverage of the upper 
cervical cord within the field-of-view leading to a major signal drop in this area, or image 
artifacts in the cord region due to swallowing or movement. Images were post-processed 
using a semi-automated volumetry method (NeuroQLab, Fraunhofer MEVIS, Germany) 
33,34. Briefly, volumes of interest with a fixed section length of 30mm were placed on the 
sagittal 3D-T1 images starting at the upper border of C2 (Figure 2 and 3). Thereafter, the 
SC was interactively defined by the operator and then separated from surrounding non-SC 
tissue based on an interactive watershed transform. Mislabeled objects not belonging to 
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the SC were removed after visual inspection of the segmentation results. After this initial 
exploratory step, volume computation was performed through an automated histogram 
based partial volume correction and volume results presented in milliliters were calculated. 
The mean upper cervical cord cross-sectional area (UCCA) was then calculated by dividing 
the volume by the section length. 
Intra-rater reproducibility and inter-rater reproducibility were evaluated on 15 MS patients 
randomly selected from the study population. To evaluate the intra-rater reproducibility, 
one investigator repeated the volumetry on the same post-processed dataset twice, blind 
to his first. Similarly, inter-rater reproducibility was assessed by two authors (A,B), who did 
post-processing and volumetry independently on the same datasets.
Figure 2: Sagittal T1-weighted image of the brain illustrating volume-of-interest selection (30mm 
section length) in the cervical cord (A) starting at the upper borders of C2. Representative axial T1w 
with overlaid (red) corresponding segmentation image of (B) a relapsing remitting MS patient (UCCA: 
85mm2) and (C) a primary progressive MS patient (UCCA: 66mm2). For colour figure see page 191.
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Figure 3: Flow chart illustrating the image processing to obtain UCCA from 3D-T1 weighted brain 
images.
Statistical analysis
Analyses were performed using SPSS18 (SPSS, Chicago, USA). Comparisons of the 
demographical data between disease subtypes and among centers were made using Mann-
Whitney U test or Pearson’s x2 test. 
For UCCA reproducibility measures, intra-rater and inter-rater reproducibility were 
expressed by the coefficient of variation (COV), defined as the ratio of the standard deviation 
and the overall mean35. Correlations between UCCA and clinical and MRI parameters were 
performed using Spearman’s rank correlation rho.
Associations between UCCA and clinical and other MRI parameters were first assessed in 
univariate models, statistically adjusted for center. In a multiple linear regression model 
with UCCA as dependent variable, all originally considered independent variables were 
entered together in a combined model and removed one by one using backward stepwise 
selection in order of descending p-values, until the remaining variables were all significant 
at p<0.10. To improve normal distribution a natural log transformation (ln) was used for all 
lesion volumes. To the number of SC segments and SC lesions, a value of 1 was added before 
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applying the natural log transformation. To avoid collinearity in the models, log transformed 
T2 and T1 lesion volumes (lnT2LV, and lnT1LV) were separately used by analyzing two 
different models, one including only lnT2LV, and one including only lnT1LV. Similarly, two 
separate models were conducted for NGMV and NWMV. In the final combined model, for 
each of these pairs only the variable with the most significant b coefficient was entered.
The degree to which clinical and MRI parameters explain EDSS was assessed using multiple 
linear regression. Again, this was done univariately for each variable adjusting for center, 
and subsequently by entering the independent variables together and removing them one 
by one using backward stepwise selection until the remaining variables were significant at 
p<0.10. The same approach was then applied using TWT as the dependent variable.
Results 
Patient characteristics
Patient characteristics
Four hundred and forty patients (287 women and 153 men) were included in the analysis. 
Slightly more than half of the patients (n=225) originated from center B. Descriptive data 
for each center are provided in table 1. The majority of these patients had an RR disease 
type (311 patients; 70.7%); there were 92 (20.9%) SP patients and 37 (8.4%) PP patients. 
Patients enrolled in center A had a higher median EDSS (p<0.001) and a shorter median 
disease duration (p=0.02). Median age of all patients was not different between centers 
(p=0.11). DMT (Interferon beta-1a, interferon beta-1b, glatiramer acetate) was received by 
111 patients in center A, respectively 125 in center B; the proportion did not differ between 
centers. 
table 1: Clinical characteristics of patients separated by center
Center a (n=215) Center b (n=225)
Gender (f:m) 129:86 158:67
Disease type RRMS : 142
SPMS : 49
PPMS : 24
RRMS : 169
SPMS : 43
PPMS : 13
eDSS (median, IQR) 4 (2.5-5) 3 (2-4)
Disease duration in yrs (median, IQR) 9 (4-16) 11 (6-19)
age in yrs (median, IQR) 46 (39-54) 43.8 (36.1-53.4)
IQR: inter quartile range; yrs: years; RRMS: relapsing remitting MS; SPMS: secondary progressive MS; 
PPMS: primary progressive MS
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Brain and SC lesions
For 420 patients an MRI scan of the entire SC was available. The results of the assessment 
of focal and diffuse SC lesions are listed in table 2. SC lesions were present in almost 75% of 
these patients, while nearly all patients (n=440; 99.5%) had T2-abnormalities on the available 
brain MRI scans. Diffuse SC abnormalities were present in 61 (13.9%) patients. In the total 
group of patients a median of 2 SC lesions (IQR: 0-4) was found, with a median number 
of involved segments of 1.75 (IQR: 0-3.5). Number of SC lesions (p=0.03) and number of 
involved segments (p<0.001) in the SC were significantly higher in SPMS compared to RRMS 
patients, while no differences could be established between the other disease types (all: 
p>0.11). Diffuse abnormalities were found more frequently in the chronic disease types 
with the highest frequency in PPMS patients (table 2). 
table 2: Clinical and MRI characteristics of patients separated for disease type.
RRMS (n=311) SPMS (n=92) PPMS (n=37)
Gender (f:m) 222:89 50:42 15:22
age, yrs (median, IQR) 42 (35-48.7) 54.1 (47.4-60.3) 50 (44-56.5)
Disease duration, yrs (median, IQR) 8 (4-14) 18 (13-25.8) 11 (6-19)
eDSS (median, IQR) 2.5 (2-3.5) 5.75 (4-6.5) 4.5 (4-6)
9-HtP_D, sec (median, IQR) 18.7 (16.8-21.4) 25 (21.1-33.6) 22.1 (18.9-28.6)
9-HtP_nD, sec (median, IQR) 19.8 (17.8-22.6) 27.2 (21.4-36.6 25.9 (22.7-37.1)
tWt, sec (median, IQR) 4.4 (3.8-5.3) 8.6 (6.2-17) 7.7 (5.2-13.7)
nbV, ml (median, IQR) 1567 (1506.4-1626.2) 1508 (1460-1555.5) 1564.7 (1473.3-1607.7)
nGMV, ml (median, IQR) 783 (741.7-825.8) 730.4 (684.9-758) 768.7 (731.5-797.5)
nWMV, ml (median, IQR) 775.9 (775.9-812.9) 768.8 (737.8-827.5) 786.7 (773-797.5)
UCCa, mm2 (median, IQR) 84 (78.7-89.3) 79 (72.4-84.9) 77.3 (69-82.5)
no. of SC lesions (median, IQR) 2 (0-4) 3 (1-5) 3 (0-5)
no. of segments SC (median, IQR) 1.5 (0-3) 2.5 (1-4.75) 2.5 (0-4.25)
Presence of diffuse abnormalities 
SC (%)
11.9 17.4 21.6
Use of DMt (%) 56.6 57.6 16.2
IQR: inter quartile range; yrs: years; RRMS: relapsing remitting MS; SPMS: secondary progressive MS; 
PPMS: primary progressive MS; TWT: 25 feet timed-walk test; 9-HPT: Nine-Hole-Peg test (D: dominant 
hand, ND: non-dominant hand) ; NBV: brain volume normalized for head size; NGMV: normalized gray 
matter volume ; NWMV: normalized white matter volume; UCCA: mean upper cervical cord cross-
sectional area; DMT: disease modifying therapy; SC: spinal cord.
Upper cervical cord cross-sectional area and MS subtypes
The intra-rater coefficient of variation (COV) of the method was 0.58%. Inter-rater COV was 
0.99%. Mean UCCA did not differ between centers (p=0.75). For the whole cohort, both 
SPMS and PPMS patients had significantly lower mean UCCA than RRMS patients (both 
p<0.001), while mean UCCA did not differ between SP and PP patients (p=0.30) (table 2). 
Separated by center, similar results were found (Figure 4) except for differences between 
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RRMS and PPMS that reached significance only in center A with sufficient numbers of such 
patients (p<0.001). 
Figure 4: Box-plots for UCCA shown for each center (dark: Center A; light: Center B) and disease 
subtype. Highest UCCA were found in RRMS patients while patients with a progressive phenotype had 
lower UCCA. 
* Significant difference between RRMS and PPMS patients was noted for patients included in Center 
A only.
Correlation between UCCA and clinical disability
In the whole group, UCCA was correlated with all investigated clinical parameters: including 
disease duration, age, EDSS, TWT and HPT. Details are provided in the supplementary 
material (Supplementary table 1). For EDSS subscores, the pyramidal and sensory subscores 
as well as the bowel and bladder subscore were found to be moderate correlated with UCCA. 
Separated by center, findings were similar (Figure 5 and Supplementary table 1).
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Figure 5: Scatterplots of EDSS and UCCA (mm2) separated by center. 
Relationship between SC atrophy and other MRI measures 
UCCA was correlated will all brain MRI parameters in the overall group as well as separately in 
each center, being more significantly correlated to brain atrophy measures (Supplementary 
material: Table E1). In the univariate analysis, adjusted for center NBV, NGMV, NWMV, 
lnT1LV, lnT2LV, presence of enhancing brain lesions and presence of diffuse SC abnormalities 
were each significantly associated with UCCA (table 3). The backward stepwise multiple 
regression analysis, controlling for center, yielded a combined model consisting of the clinical 
variables: disease type, disease duration and gender, and of MRI variables: NBV, NWMV, 
presence of enhancing brain lesions, and presence of diffuse SC abnormalities (table 3). 
Among these, presence of enhancing brain lesions and presence of diffuse SC abnormalities 
were found to be most significantly associated with UCCA. Neither the number of SC lesions, 
nor the number of involved segments of the SC was included the final model. R2 –value for 
the final model was 0.276.
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Associations of MRI measures with disability
Results of the linear regression for EDSS and TWT separately for each center as well as 
univaritely, statistically adjusted for center are provided in the supplementary material 
(Supplementary tables 2 and 3).
Multiple linear regression, controlling for center, with EDSS as the dependent variable 
revealed significant independent predictive value for UCCA, lnT1LV, the presence of diffuse 
abnormalities, and the number of involved segments in the SC, with a R2 –value for the 
final model of 0.564. Among these MRI variables UCCA and lnT1LV were found to be the 
strongest predictors of EDSS based on p-values (table 4). Using TWT as the dependent 
variable, multiple linear regression revealed significant associations with NGMV, presence 
of enhancing brain lesions as well with number of involved SC segments and UCCA (Table 
4). In this model, NGMV and UCCA were found to be the strongest MRI predictors based on 
p-values. R2 –value for the final model was 0.389.
table 4: Multivariate regression for EDSS and TWT, statistically adjusted for center.
eDSS tWt
regression 
coefficient b
SE p-value regression 
coefficient b
SE p-value
ClInICal PaRaMeteRS
Gender a,b - - - -0.13 0.07 0.05
MS subtype Relapsing (RR)=1 vs 
PP and SP=0 a,b
-1.67 0.15 <0.001 -0.72 0.08 <0.001
Age a,b 0.02 0.01 0.001 - - -
Disease duration a,b 0.02 0.01 0.02 0.10 0.004 0.03
Ever use of DMT a,b - - - - - -
MRI PaRaMeteRS
UCCA a,b -0.03 0.01 <0.001 -0.01 0.003 0.007
lnT1LV a,b 0.11 0.03 0.001 - - -
Diffuse abnormalities SC 
(0 absent; 1 present) a,b
0.54 0.17 0.002 - - -
Number of segments SC 
(ln-transformed) a,b
0.25 0.08 0.004 0.1 0.04 0.02
Presence of gadolinium 
enhancing brain lesions a,b
- - - 0.18 0.08 0.02
lnT2LV - - - - - -
NWMV a - - - - - -
NGMV a,b - - - -0.001 0.001   0.006
NBV - - - - - -
Number of SC lesions 
(ln-transformed)
- - - - - -
Superscript letters independent variables that were initially entered in the multivariate models (a: 
EDSS; b: TWT)
RR: relapsing remitting MS; SP: secondary progressive MS; PP: primary progressive MS; DMT: 
disease modifying therapy; UCCA: mean upper cervical cord cross-sectional area; T1LV: volume of 
T1 hypointense brain lesion; SC: SC; NGMV: normalized gray matter volume; NWMV: normalized 
white matter volume; NBV: brain volume normalized for head size; ln: natural log transformation; SE: 
Standard error.
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Discussion
This study demonstrates, in a large cohort of patients, the importance of SC atrophy in 
explaining clinical disability in MS, and shows its relation to focal and diffuse pathology both 
in cord and brain. Specifically, UCCA, the presence of diffuse abnormalities in the SC, and the 
number of segments affected by MR-visible pathology, were found to be the most significant 
MRI predictors explaining physical disability as measured by the EDSS. Furthermore, the 
number of involved SC segments and especially UCCA, were associated with walking abilities 
as expressed by the TWT, confirming the importance of SC pathology regarding ambulatory 
dysfunctions in MS.
This confirms, in a large cohort, previous smaller studies reporting that cord atrophy was 
correlated with clinical disability4,15,22,36,37. Furthermore, SC atrophy was more pronounced 
in PPMS and SPMS, than in RRMS patients confirming findings by Rocca and colleagues20 
who also studied a large patient group. We additionally investigated how the clinical effect 
of SC atrophy compares to that of established MRI measures such as NBV, NGMV and SC 
lesion load. Although UCCA was the most significant MRI predictor of disability, other SC 
parameters were additionally important. The previously observed relation between EDSS 
scores and diffuse SC abnormalities4 was largely confirmed. Moreover, our large group 
allowed us to detect associations between the number of affected SC segments and both 
EDSS and TWT, which has not been observed previously in smaller patient groups3,4,38,39. 
This relation may be understood because lesions in the SC more often cause sensory, limb 
motoric or urinary symptoms than do brain lesions38-40 and they correlate better than do 
brain lesions to the degree of physical disability41. 
The absence of an association between SC atrophy and SC lesion metrics is in line with Rocca 
and colleagues20 and with histopathological studies suggesting that SC atrophy is largely 
independent of lesional tissue loss2. Conversely, the presence of diffuse SC abnormalities 
was associated with more pronounced SC atrophy both in our work and in a previous study4, 
consistent with more severe pathology in diffuse than in focal SC abnormalities42. 
Several MRI studies have investigated possible relations between brain and SC 
pathology4,12,15,39,43-45. When controlling for other variables, brain T2 lesion volumes were not 
associated with UCCA, suggesting that distant pathology e.g. by antegrade degeneration 
due to axonal damage in brain lesions does not seem to be a major contributor of SC 
atrophy. This is in line with previous findings suggesting that SC pathology may develop 
independently from brain pathology4,44,46,47. The brain atrophy measures NBV and NWMV 
however, did exhibit an association with UCCA, suggesting that brain and SC atrophy to 
some degree proceed hand in hand. Interestingly, presence of enhancing brain lesions was 
also associated with UCCA, suggesting that during acute inflammation the SC cross-sectional 
area is larger. This association may actually reflect the effect of local edematous swelling 
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of the SC around acute inflammatory SC lesions, because acute inflammatory activity in 
brain and SC are thought to be strongly correlated39. Unfortunately, we could not test this 
hypothesis in our dataset, because no contrast-enhanced imaging of the SC was available. 
Mean UCCA was associated with clinical dysfunction similarly in both centers, suggesting 
that these findings reflect true disease-related associations that would generalize also 
outside the present study. Most notably, the clinical measures most likely to reflect SC 
damage, i.e. the EDSS subscores for pyramidal, sensory, and bowel and bladder dysfunction, 
as well as the TWT and 9-HPT scores were moderately associated with UCCA. In a smaller 
cohort of MS patients with 20-year disease, Bonati and colleagues similarly found that UCCA 
was independently associated with EDSS as well as with TWT and 9-HPT (48), suggesting 
that these associations are robust in the long-term.
Limitations of our study include the lack of a healthy control group, leaving us unable to assess 
the extent of atrophy especially in RRMS. Future studies should also include CIS patients to 
study whether or not spinal cord atrophy already occurs early in the disease course12,14,19,20. 
A second limitation is the absence of lesion-filling49-51 in the determination of brain atrophy 
measures, which has probably yielded a (limited) degree of underestimation of WM volumes 
due to lesion misclassification52,53, but with the images available no satisfactory automated 
lesion segmentation was feasible, and the cost of manual outlining on 3DT1 for 440 patients 
was considered prohibitive. Third, we used unnormalized UCCA, as recommended by54; 
although several normalization approaches have been suggested54-57, normalization factors 
such as intracranial volume, body mass index and body surface area have shown limited, if 
any, impact on reliability and sensitivity to differences between subjects57. Finally, UCCA was 
derived from brain datasets because appropriate 3D SC sequences had not been acquired 
in the dataset analyzed in the current study. Nevertheless, segmentation of the upper SC 
was successful in 440/458 (96%) of cases, reliability of our measurements was good, and 
SC areas in our cohort were in concordance with literature4,20,22,58. Overall, our study shows 
that measuring upper cervical spinal cord area is feasible using brain datasets, which has 
important implications for clinical studies including treatment trials. Without the additional 
SC scan, total acquisition times can be shorter, reducing both cost and patient burden. 
In conclusion, SC pathology, especially upper cervical SC atrophy, is an important determinant 
of clinical disability in MS, even surpassing brain atrophy in this large-scale cross-sectional 
study.
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5
 Summary and General discussion
This thesis aims to provide more insight in factors explaining parts of the heterogeneity in 
MS, in an attempt to increase the accuracy of the prognosis and diagnosis of individual MS 
patients. We therefore assessed the following two main issues: 1) genetic role in phenotypic 
aspects of MS (especially disability (chapter 2) and lesion distribution (chapter 3)); and 2) 
the role of spinal cord findings in diagnosis and prognosis of MS (chapter 4).
In this final chapter, the main findings of this thesis will be discussed and placed in a broader 
perspective, and finally directions for future research will be discussed.
Genetic susceptibility studies in MS
Since 2007, when the first Genome Wide Association Study (GWAS) aiming to find genes 
related to MS-susceptibility was performed1, the understanding of the genetic background 
in MS susceptibility has increased enormously. Since then, multiple confirmation studies 
based on extensive international collaboration have been performed2-5. Recently, in a 
large cohort of patients (involving almost ten thousand MS patients and more than 17,000 
controls), 24 loci have been replicated6 and 29 new susceptibility loci have been identified. 
But what are the clinical implications of these findings from genetic studies? Can they 
contribute to unraveling the complexity of MS? Indeed, these studies do increase our 
knowledge on the etiologic background of MS. Information from susceptibility studies can 
provide us with information on what processes are involved in starting the disease, or who 
is at risk for developing MS. This may confirm certain hypotheses on the pathological basis 
of MS (i.e. whether it is a primary or secondary neurodegenerative disease). However, the 
current strategy (Genome Wide Association Studies) is now facing the limits of its capacities 
in detecting genes related to MS susceptibility, because the expected effect sizes are too 
small to detect in medium or even large groups of patients. The most recent study included 
ten thousand patients from several countries. In my opinion it is not to be expected that 
further increasing the number of patients will result in many immediately relevant genes. 
Effect sizes are expected to be so small (OR below 1.1), such that no determining influence 
on disease susceptibility is to be expected. The likelihood of discovering a new focus for 
treatment with these low ORs is also expected to be low. In addition, the costs of performing 
a study of this magnitude require huge funding. Moreover, this amount of data will also lead 
to a higher complexity in analyzing it (i.e. increased heterogeneity due to genetic population 
differences). Challenges for the future are to incorporate the current findings from these 
genetic susceptibility studies into more functional or clinical studies leading to further 
understanding of MS pathology and hopefully ultimately leading to new treatment options. 
148
Chapter 5
Genotype-Phenotype associations in MS
In the past decade the emphasis in MS literature has been placed on these susceptibility 
studies. In this thesis, however, we focused on finding genotype-phenotype associations. It is 
not likely that gene identification in MS will lead to genetic counseling or prenatal diagnosis, 
as even full knowledge of the genetic background on MS susceptibility will allow “only” 30% 
accuracy in predicting if a person will develop MS during his lifetime. It is expected that the 
rest of a person’s susceptibility is determined by (mostly unknown) environmental factors. 
Moreover, in the last ten years, several Disease Modifying Therapies (DMTs) have been 
proven helpful in reducing the number of relapses and the number of new MRI lesions in 
the brain, but no cure for MS is to be expected within the near future. Currently, knowledge 
of a possibly increased risk of developing MS during the lifetime of a healthy person (derived 
from already available commercial DNA-arrays) will not lead to the start of disease modifying 
treatment. I expect therefore, that it is only in the way that risk genes reveal details of disease 
triggering events, or that severity genes influence mechanisms driving the tissue damage, 
that genetic information (derived from genotype-phenotype-association studies) has the 
potential to more readily lead to clinical implications (or even therapeutical options). We 
aimed to predict more accurately MS diagnosis and prognosis using genetic variables and 
spinal cord MR findings. Initially, we focused on genotype-phenotype associations to predict 
disease course. We started by taking clinical disability measures as the primary outcome 
parameter (Chapters 2.1, 2.2 and 2.3). Assessing clinical disability remains the most 
important factor in treating MS patients, although clear correlations with the pathological 
processes involved are often lacking. When trying to accurately assess the genetic role in 
disability development (by assessing genotype-phenotype associations), these clinical 
parameters seem to be unsatisfactory. These clinical outcome measures are considered less 
sensitive in reflecting the ongoing MS pathology as can be demonstrated on MRI scans. It 
has been proven that lesion location within the brain and spinal cord lesions have an impact 
on disability. Due to these characteristics, we also took these imaging variables as outcome-
parameters (Chapters 3.1 and 3.2). 
To improve our understanding of genotype-phenotype associations in MS we used several 
strategies. In chapter 2.1 we found that a combination of genes could explain part of the 
disease progression and disability accumulation, while individual effects of the genes 
were not detected (when controlled for multiple testing). We included several outcome 
parameters for disability to increase our confidence in the results (preferably relevant genes 
were associated to more than 1 outcome parameter). Our hypothesis was based on the 
assumption that disability accumulation in MS is determined by several genes with small 
effect sizes. Although the statistical method on combining several genes in predicting 
disease severity seems a promising method, our results need to be confirmed first, ideally 
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using information from the most recent GWAS and recent pathway studies or other 
candidate gene studies on MS phenotype. Our study demonstrates the possible advantage 
of a predictive model over assessing individual genetic effects.
A second strategy, which we applied in chapter 2.2 is to combine genetic studies with studies 
on the mRNA level to gain more functional information, thereby increasing our understanding 
of how genetic polymorphisms exert their effect on the disease. It is generally accepted 
that disease progression and tissue damage are continuously or intermittently supported 
by several mechanisms (which are assumed to be predominantly pro-inflammatory). By 
gaining insight into the functional consequences of a genetic polymorphism supporting 
these tissue damaging mechanisms, we hope to find new possibilities in halting these 
mechanisms. In chapter 2.2 we applied this strategy for the IL7RA risk allele (rs6897932-T), 
that was found to be related to susceptibility to MS. Of this SNP within the IL7R gene, it was 
known from the literature that it had direct consequences on the mRNA level5,7 and also on 
protein functioning. In light of the function of this protein in inflammatory processes and 
the consequences of the polymorphism on protein functioning, we expected that this would 
be a promising gene to affect disease progression. Unfortunately, we could not demonstrate 
this effect neither at the gene-level, nor at the mRNA–level. Our observation that this 
susceptibility SNP within the IL7R gene was not associated with disability parameters, 
was confirmed by several (GWAS) studies2,6,8. These studies on disease phenotype showed 
that disability was associated with genes relatively new to MS literature2. Our study and 
others illustrate that in MS, disease-modifying genes are not necessarily identical to disease 
susceptibility genes8,9. In other diseases this has been shown (e.g. the effect of the ApoEє4-
genotype on Alzheimer’s susceptibility and progression10,11. Probably, genes that are related 
to susceptibility to MS provide information on mechanisms involved in disease initiation 
and are not directly related to mechanisms that are involved in ongoing tissue damage. 
Another possibility is that the genetic effects on disease phenotype are too small to detect. 
However, IL7RA remains an intriguing gene (within a relevant pathway) of which more and 
more functional data is becoming available. The relevance of IL7R in MS susceptibility was 
confirmed by another study in MS patients in 2010, using an IL7/IL7RA pathway approach12. 
Recently, in HIV, polymorphisms in the IL7RA gene were found associated with rapid 
progression to AIDS by using an extreme of outcome strategy13. This study analyzed several 
non-synonymous SNPs and haplotype analysis, demonstrating that different SNPs (on the 
same haplotype) may cause opposing effects on inflammation via mRNA. This elegant 
approach has not yet been applied in assessing the relationship with MS phenotype. 
However, it is worth assessing this to definitively exclude an effect of the IL7R gene on MS 
phenotype. 
In chapter 2.3 we started from the function of the gene and correlated this to a specific 
clinical phenotype. We assessed whether the risk allele of KIF1B (rs10492972) corresponded 
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with the expected functioning of the gene. KIF1B is responsible for axonal transport 
of mitochondria and synaptic vesicle precursors and is related to neurodegeneration. 
Rs10492972 was reported as the first MS susceptibility gene with a known function in 
neurodegeneration (instead of inflammation) in a large study14. We hypothesized that carriers 
of the risk allele might exhibit a disease course with a more neurodegenerative phenotype 
(clinically, and using MRI characteristics). We found no evidence for a determining influence 
of the risk allele on clinical and MRI measures related to neurodegeneration. Our findings 
further strengthen the hypothesis that susceptibility genes need not necessarily be related 
to phenotypic appearances of MS. Our findings are furthermore supported by a recent large 
genotype-phenotype study on MS, that showed that most genes identified as related to 
MS are related to immune system function (overrepresentation of genes that influence 
T-cell maturation) and a relative absence was noted of genes related to neurodegeneration 
independent from inflammation6. Based on these results it was strongly suggested that 
the pathogenesis of MS is mostly related to dysregulation of the immune system. This 
conclusion favours the “primary inflammatory hypothesis” (i.e. auto-immunity). However, 
this hypothesis is still heavily debated based on pathological findings in early MS comprising 
not only early inflammatory, but also meningeal and cortical gray matter pathology15.
Although replication of the association of KIF1B-gene to MS susceptibility is still awaited, 
the KIF-family already is an interesting set of genes and proteins. Both in MS and in other 
auto-immune diseases, other members of the KIF-family have been found to be associated 
with susceptibility16-20. These new studies strengthen the idea that the KIF-family is involved 
in MS, possibly by influencing axonal transport and thereby increasing susceptibility to 
axonal damage, however, the exact mechanism is not clear and should be studied. Possibly 
a pathway approach would be able to provide insight into the relevant mechanisms. 
In 2011 a huge GWAS (7000 MS patients) on MS phenotype did not find a genome-
wide-significant association of any gene with disease phenotype (disability, age at onset, 
MS subtype)6. Despite the extremely high number of patients in this study, no strong 
correlation with a particular gene could be found, indicating that it is not to be expected 
that common variations within the genome will be identified with a large effect on disability 
accumulation. However, this negative study does not imply that disease progression is not 
genetically influenced. One must consider the many difficulties researchers have been faced 
with in their search for genetic predictive markers for disease phenotype in the last decade. 
Not only is it expected (based on familial phenotype studies) that effect-sizes on disability 
accumulation of genes are small, but also, several interaction within genes (gene-gene), and 
between genes and environment (gene-environment and gene-gene-environment) have 
been described, that should ideally be controlled for21,22. Moreover, epistasis and epigenetic 
effects (micro-RNA’s, methylation, etc) and rare variants have not been taken into account 
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in GWAS studies using SNPs. These genetic variants may play an important role in mediating 
genetic effects in MS23,24. GWAS are not able to assess these effects and other genetic 
methods should be used to assess these effects (i.e. sequencing). 
Furthermore, an important complicating factor in genotype-phenotype associations is 
the enormous heterogeneity in MS (variety in subtypes, neurological complaints, rate of 
disability accumulation and lesion distribution throughout the brain and spinal cord). Often 
the contrasts of the outcome parameters (phenotype) are insufficient, thereby decreasing 
the power of the results. The conservative statistical approaches that have been used often, 
are not capable of detecting these subtle differences. This problem highlights the urgent 
call for new statistical approaches that aim to keep adequate power but do not increase the 
number of false positives findings. 
Clinical outcome parameters are often considered less sensitive than certain MRI parameters 
in reflecting the ongoing MS pathology. Clinical measures may underestimate the extent of 
damage to the brain due to functional reorganization, while this can be seen in an earlier 
phase on MRI. It is not well understood whether this variability in MRI parameters reflects 
genetic subgroups of MS patients. In this thesis we aimed to study the genetic role in lesion 
distribution (a uniformly assessed outcome parameter) that may be a clinically relevant25. In 
chapter 3.1 we assessed whether the lesion distribution between the brain and spinal cord 
was influenced by genetic factors, while in chapter 3.2 we assessed whether lesion distribution 
within the brain was associated with a set of candidate genes in MS. We expected a genetic 
role on lesion distribution based on certain demographic hallmarks. The prevalence of spinal 
cord lesions differs between distinct populations (Asian MS patients have more frequently 
spinal cord involvement than “Western-type” MS) 26,27 and between patients (for instance 
some patients exhibit repetitive spinal cord involvement with less brain involvement) 28,29. 
In chapter 3.1 we showed a genetic role on lesion distribution. In our cohort, spinal cord 
lesion number and volume were associated with the HLA-DRB1*1501 genotype (the most 
important susceptibility gene in MS that is possibly related to MS disability features). Our 
findings were recently more thoroughly investigated by an Australian group of researchers 
using high resolution HLA typing (4-digit). They showed a correlation between HLA-DRB1 
alleles (not HLA-DRB1*1501, but DRB1*1104 and DRB1*0701) and lesion numbers in 
different parts of the spinal cord (cervical vs thoracic regions). They also hypothesize that 
regional differences in the levels of expression of MHC Class II antigens and the presentation 
of myelin antigens to the immune system may underlie these effects30. Previously, differences 
in Myelin Basic Protein (MBP) and PLP levels between brain and spinal cord were found 
in healthy controls31. However, this has not been demonstrated in MS patients. Two mice 
EAE models with different MHC strains reported different lesion distribution patterns in the 
central nervous system (spinal cord vs brain parenchyma)32. This was found to be mediated 
via different preferential MOG epitope presentation and ultimately via alternative Th17/Th1 
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ratio32. This study indicates a different mechanism of lesion formation in the brain versus 
spinal cord with a possible indirect role of the MHC class II genes. However, the exact role 
of the MHC class II genes on this mechanism is still unclear and future pathological studies 
of spinal cord lesions and brain lesions, including assessment of local expression profiles 
of MHC Class II molecules, could possibly help us to understand the lesion developing 
mechanisms in the brain and spinal cord and any differences between them. 
In chapter 3.2 we assessed whether lesion location within the brain is genetically influenced. 
We suspected a genetic role because of clinical observations that show a tendency of 
individual patients and relatives to develop relapses, related to pathology in the same 
location28,29,33. Our results suggest that such a genetic influence may indeed be present. The 
most significant association was found for rs2227139. This SNP is located in MHC class II 
region, which is involved in self versus non-self immune recognition. Another recent study 
(in MS patients) showed that carriers of HLA-DR4, DR7 and DR13 have a higher incidence 
of brainstem and cerebellar lesions (and a higher reactivity tot the PLP 184-209 region (a 
component of myelin))34. Some studies (in healthy controls) show that there are natural 
spatial variations in myelin content, which may in turn reflect areas with variable predilection 
for damage in demyelinating disease35. Moreover, in other white matter diseases (Krabbe’s 
disease, late infantile metachromatic leukodystrophy) several predilection sites have been 
identified36-38. Unfortunately, MS lesions can reflect different pathological processes (edema, 
de- and remyelination, gliosis, etc), that can not be distinguished in detail on regular T2-
weighted MRI sequences. Therefore, after this hypothesis-free study, a more focused 
approach using different MRI techniques that are able to detect specific pathologically 
determined lesion subtypes (for instance: T1 black holes (more related to axonal loss) and 
cortical lesions), may increase our understanding of the pathophysiological mechanisms 
involved in lesion distribution and its relationship to (HLA)genes. Careful interpretation of our 
results is furthermore warranted because our results were found in a clinical heterogeneous 
population and should therefore first be confirmed in different MS populations. 
Spinal cord MRI in predicting diagnosis and prognosis of MS
In chapter 4.1 and 4.2 we focus on the predictive capacities of spinal cord lesions and 
cervical spinal cord atrophy on diagnosis and prognosis of MS. In the past, the emphasis has 
been placed on brain MRI scanning in MS. However, we show in our studies that lesions on 
spinal cord MRI can both aid in the MS diagnosis and in the prognosis of a second relapse 
and are therefore of significant clinical relevance. Moreover, cervical spinal cord atrophy 
and diffuse abnormalities are associated with a higher disability (in our study even more 
associated to disability than brain parameters (atrophy or brain lesion volumes). Based on 
the results of our studies, we advise to more frequently perform an MRI scan of the spinal 
cord in order to contribute to a better diagnosis and prognosis of MS patients. 
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We show in our study in chapter 4.1 that presence of spinal cord lesions in CIS patients is 
an important factor in prognosing (time to) a relapse and therefore we advocate to perform 
an MRI scan of the spinal cord early after onset of symptoms especially in brain onset CIS 
patients that do not fulfill the diagnostic criteria. Not only does information of this scan aid 
in diagnosing MS early, but presence of spinal cord lesions is also associated with a short 
interval to the second relapse. Scanning of the spinal cord can be performed easily in most 
hospitals and the burden for patients is minimal (especially when combined with the brain 
MRI scan). Moreover we show in our study that by adding the results from the spinal cord 
MRI scan, an earlier diagnosis could be made. We had to perform a spinal cord MRI scan in 
seven patients to be able to diagnose one extra patient early. Although we think that the 
benefits of an early diagnosis outweigh the costs and burden to the patients, others may 
argue that a yield of 1 in 7 does not justify this extra scan (depending on the local health 
care system). 
The diagnostic criteria39-41, were created to be able to early identify CIS patients that will 
convert to MS. An early diagnosis can reduce uncertainty for the patient and enables an 
early start of disease modifying therapy, that has shown to moderately reduce the number 
of relapses on the short term and may decrease disability accumulation in the long term. 
However, there is no standard test to confirm MS diagnosis. The diagnosis is made based 
on fulfilling the clinical and/or MRI criteria for dissemination in time and space. However, 
to my opinion, diagnosing MS should not only focus on fulfilling these important criteria 
but should also comprise a more accurate prognosis of future relapses and (preferably 
also) future disability. In light of these considerations, maybe the diagnostic criteria should 
be considered as a prerequisite to diagnose MS, however, this process should ideally be 
followed by an effort to provide the most accurate prognosis on disability accumulation and 
prediction of (time to) subsequent relapses. The uncertainty of the extent and timing of 
disability accumulation and relapses are highly relevant for the individual MS-patient. The 
range of disability accumulation and time to first relapse are extremely variable. We know 
that there is a subgroup of officially diagnosed MS patients, that have a “benign” course 
(none or little disability even after 15-20 years). Moreover, we also know that there is a 
subgroup of patients that will not experience a second relapse within 15 years, although the 
MRI has shown dissemination in time. We now can officially diagnose these patients with 
MS using the new diagnostic criteria41. However some of these patients will not benefit from 
the current disease modifying therapies (because no relapse would have occurred with or 
without DMT) and one could argue whether a diagnosis of MS has any consequences for 
the patients and whether the diagnosis increases their quality of life. Therefore, clinical, 
radiological or biomarker studies that focus on increasing the accuracy of prognosing the 
disease course of MS are equally or maybe even more important.
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In chapter 4.2 we evaluated the clinical relevance of cervical spinal cord atrophy and other 
spinal cord and brain parameters on disability. We confirmed in a large multicenter study 
that atrophy of the spinal cord (assessed by mean upper cervical cord area (UCCA)) is 
associated with a higher clinical disability. This variable was found to be the most significant 
variable correlated with disability in addition to clinical parameters. Also other spinal cord 
parameters (extent of focal lesions in the spinal cord and presence of diffuse abnormalities) 
were found related to disability. This study highlights the clinical importance of spinal cord 
findings (especially atrophy and to a lesser extent focal lesions). It was already known that 
brain atrophy is more correlated to disability at the long term when compared to the extent 
of lesions in the brain. Moreover, we applied a technique enabling assessment of the volume 
of the cervical spinal cord using the brain MRI scan, without the necessity of performing an 
extra spinal cord scan. This technique therefore, does not put extra burden on MS patients 
and is therefore easy to apply in clinical practice. 
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Future perspectives
Genotype-phenotype associations
Although GWA-studies have yielded enormous amounts of information about MS 
susceptibility, it has also been shown that it can answer only a limited number of questions 
on the mechanisms involved in MS phenotype, and therefore different strategies are 
needed. In this thesis we used several strategies to overcome some of the difficulties in 
genotype-phenotype correlation research to gain insight into the pathological mechanisms 
involved in MS. 
Recommendations for future research would be to use a pathway-based approach to test 
specific hypotheses42. This strategy reduces the number of genes assessed considerably 
and is expected to assess specific hypothesis on the pathological basis of MS. In 2010 the 
glutamate pathway was assessed by Baranzini et al to assess the hypothesis of glutamate 
toxicity43. The authors composed a model of 70 genes with high relevance to glutamate 
biology (based on protein interaction networks) and correlated it with in vivo glutamate 
levels of MS patients. This study demonstrated that patients carrying a higher number 
of associated alleles from genes in this module showed the highest levels of glutamate 
(assessed via magnetic resonance spectroscopy imaging). Moreover the SNP that was found 
most strongly related to the brain glutamate concentration was also associated with the 
extent of neurodegeneration (as indicated before as a clinically relevant outcome). This 
elegant study demonstrates the genetic role in neurodegenerative processes and highlights 
the opportunities of pathway analysis in assessing MS genotype-phenotype associations. 
Over the years more and more MRI parameters have been used as indirect outcome 
parameters. These MRI parameters (new lesion development or lesion location) might be 
more sensitive and objective than clinical outcome measures and may provide more direct 
linkage to pathophysiological mechanisms (gadolinium enhancing lesions are considered to 
reflect recent inflammatory MS lesions, while black holes represent chronic axonal loss). In 
other neurological diseases recently new imaging techniques display a higher pathological 
specificity: PIB-PET scans performed in Alzheimer’s patients are for instance capable of 
revealing amyloid-beta depositions in the brain44. In MS, proton magnetic resonance 
spectroscopy ((1)H-MRS) measuring whole brain N-acetyl-L-aspartate (a neural marker) has 
recently proven to be a sensitive and stable marker even in small MS patient groups and 
might be incorporated in future studies45. Other high-end MRI measures, such as subtle 
abnormalities in normal appearing white matter in connectivity measures: Diffusion Tensor 
Imaging (DTI) or Magnetization transfer ratio (MTR) have recently shown to be, more specific 
than standard (T2-weighted) MRI measures, related to, pathological processes (microglial 
activiation) 46. 
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Finally, recent studies have shown that grey matter (cortical and subcortical) involvement 
(lesions and atrophy) is a frequent finding and can be demonstrated in vivo using specific 
MRI settings (e.g. Double Inversion Recovery (DIR)). Pathologically, these grey matter lesions 
show clear differences when compared to white matter lesions. It would be interesting to 
assess the genetic influence on the development of (heterogeneity in) these grey matter 
lesions (and atrophy), as cortical pathology is considered to be an important pathologic 
correlate of disability (cognitive impairment) 47.
These recent developments increase our knowledge on the pathological basis of MRI 
findings. When these results are confirmed in different data sets, this may ultimately enable 
us to assess, in vivo, the genetic role on distinct MS pathological processes. Future endo-
phenotyping based on these specific MRI findings are an important strategy to dissect the 
pathological (genetic) basis of MS, without the necessity of including more than 10,000 
patients in a study. For all future endo-phenotyping it remains important to use variables 
with a strong contrast (for instance by selecting the extremes of outcome). 
Moreover, MS cohorts should be large and clinically and paraclinically (for instance by MRI) 
well defined and preferably longitudinally followed during their MS course. Confirmation in 
different populations remains essential, due to the high chance on false positive findings in 
this field. 
Based on our findings (chapter 3.1 and 3.2) and on recent findings of others48-50, the 
HLA –region remains an intriguing gene-region. HLA molecules play an important role in 
antigen binding and presentation and T cell repertoire determination51 (associated with 
auto-immune inflammation) and would therefore be a logical candidate not only in MS 
susceptibility but also in determining MS phenotype52,53. Recently, alleles at the HLA-DRB1 
locus have quite convincingly been shown to affect clinical disease severity54,55. Some 
HLA-DRB1 alleles additionally have been found to influence disease severity as assessed 
by MRI outcomes56,57. Thorough investigations using high-resolution HLA genotyping (and 
correction for interactions within the HLA-region), might yield important information on 
several phenotypical characteristics of MS.  
In addition to the genetic and imaging strategies mentioned in this thesis, future studies 
incorporating epigenetics23,24,58 and studies taking (gene-gene and gene-environment) 
interactions into account, are promising. Previous studies have shown that when building an 
algorithm to predict MS susceptibility, predictive accuracy will increase when environmental 
factors are also taken into account59,60. 
Spinal cord imaging:
Based on the findings in this thesis, we advise to more frequently perform an MRI scan 
of the spinal cord in patients with a clinical brain onset, that do not fulfil the diagnostic 
criteria. Presence of spinal cord lesions in this group of patients can aid in diagnosing MS, 
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but moreover highly predictive of a short time to relapse. Confirmation studies are awaited. 
New imaging techniques of the spinal cord probably will lead to a higher detection rate 
of spinal cord lesions and the presence of diffuse abnormalities in the spinal cord61. The 
effect of this higher sensitivity of lesion detection on diagnosis and prognosis in CIS patients 
should be assessed.
In the future, new diagnostic criteria, maybe with incorporation of cortical lesions or 
lesions in the corpus callosum are expected as they may play a role in prognosing MS62,63. 
However, we expect that spinal cord findings will remain an important part of these criteria. 
It is extremely important that our findings should be assessed in a more general neurology 
practice, since the diagnostic criteria are developed in MS specialized centers. A study 
in 2008 in Ireland showed a considerable gap between the clinical diagnosis of MS and 
compliance with the previous diagnostic criteria64. The new criteria have been simplified 
and it would be valuable to test the accuracy of the 2010 criteria in the general neurology 
practice.
We furthermore showed in our studies that atrophy of the spinal cord is clinically highly 
associated with disability. Possibly, atrophy of the spinal cord can be used as an outcome-
parameter in trials assessing the effect of DMT on disability accumulation (and may reflect 
the neurodegenerative process). To assess this, future studies should involve longitudinal 
cohort-studies to assess the association of decreasing UCCA overtime in relation to disability 
accumulation. Maybe, this parameter can be used as a relevant outcome parameter when 
assessing the influence of DMT on prevention of disability.
Prediction of disease course and disability is extremely important and research should focus 
on this topic since the therapies available for MS today are not able to cure MS, but only 
seem to slow down the disease. An accurate selection of patients that could benefit from 
these therapies is essential. In this thesis we aimed to explain the role of genetics and spinal 
cord pathology (as two examples of (endo)phenotyping) in MS diagnosis and prognosis. 
In the last five years the knowledge of the genetic role in MS has grown enormously due 
to new techniques and it is expected that genetic information can provide highly valuable 
information on disease mechanisms in MS. However, the challenge lies in translating these 
genetic findings to the individual patient. Currently, this translation to the individual patient 
is not possible yet, but to my opinion unraveling the genetic basis of disease phenotype 
is essential in understanding and predicting MS disease course. Spinal cord MRI scans 
are already regularly performed by neurologists for diagnostic purposes, but our findings 
indicate that it is also of clinical relevance for prognosing MS and we advocate a broader 
field of application.
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Most likely a combination of clinical, radiological and biomarker studies (including genetics) 
at the start of the disease could increase our understanding of MS and will lead to a more 
accurate prediction of disease course for the individual patient in the future. The ultimate 
future goal is to build a clinical algorithm, integrating the different risk factors (clinical, 
genetic and using early MRI variables) to be able, early in the disease, to predict long-term 
disability for individual MS patients.
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GenetISCHe en RaDIoloGISCHe MaRkeRS VooR De PRoGnoSe en DIaGnoSe Van 
MUltIPle SCleRoSe
Multiple Sclerose (MS) is een aandoening van het centrale zenuwstelsel (hersenen en 
ruggenmerg) waarbij er schade optreedt aan de myelineschede (de isolerende laag om de 
zenuwen) en de axonen (de zenuwuitlopers) . Meestal begint de ziekte met aanvalsgewijze 
uitvalsverschijnselen. Deze verschijnselen zijn erg gevarieerd: bv krachtsverlies of 
gevoelsstoornissen van armen of benen, problemen met het zien, blaasproblemen, 
geheugen- of concentratieproblemen en vermoeidheid. De ziekte begint vaak (ongeveer 
90%) met een episode van neurologische klachten (klinisch geïsoleerd syndroom, Clinically 
Isolated Syndrome (CIS)), die meestal daarna weer verdwijnen of in lichte mate aanwezig 
blijven. Bij het merendeel van de patiënten wordt dit later gevolgd door opnieuw episodes 
van neurologische klachten (“relapsing remitting” beloopsvorm). De diagnose kan worden 
gesteld als er op basis van de klinische verschijnselen aangevuld met MRI parameters wordt 
voldaan aan disseminatie in tijd (meerdere episodes van opvlammingen klinisch (door 
nieuwe terugval met neurologische klachten) of radiologisch (nieuwe ontstekingen zichtbaar 
op MRI hersenen) en plaats (ontstekingen op tenminste 2 voor MS karakteristieke lokaties in 
het centrale zenuwstelsel (klinisch danwel radiologisch aangetoond). Echter na enige tijd van 
terugvallen, met deels of volledig herstel, ontwikkelt de ziekte zich vaak tot een langzaam 
progressieve ziekte, waarbij de klachten geleidelijk aan steeds erger worden zonder duidelijke 
opvlammingen van de ziekte. De snelheid waarin dit proces zich voltooid (en MS patiënten 
geïnvalideerd raken) verschilt enorm: zo zijn er patiënten die binnen een jaar na de diagnose 
reeds rolstoel-gebonden zijn, terwijl andere MS patiënten soms tot 30 jaar na de diagnose 
vrij weinig tot geen blijvende klachten hebben. Het voorspellen van het ziektebeloop in 
de individuele patiënt is tot op heden niet mogelijk. Er bestaat tevens momenteel geen 
genezende behandeling voor MS. Er zijn wel ziekte-modulerende therapieën voorhanden, 
welke met name de hoeveelheid terugvallen verminderen, echter het langetermijneffect op 
het voorkomen van progressieve klachten is nog niet uitgekristalliseerd. Patiënten met een 
snel progressief ziektebeloop hebben naar alle waarschijnlijkheid het meeste baat bij deze 
therapieën, terwijl patiënten met een gunstiger beloop (benigne MS) misschien geen effect 
zullen merken (en mogelijk wel “onnodige” bijwerkingen van deze medicijnen ondervinden). 
Het is belangrijk om met name vroeg in de ziekte een betere voorspelling te geven van het 
verwachte ziektebeloop. Niet alleen vanwege bovengenoemde reden met betrekking tot 
de behandeling, maar ook vanuit het perspectief van de, vaak jonge, patiënt, om zo de 
mate van onzekerheid met betrekking tot de prognose te verkleinen. Uiteindelijk hopen 
we, door de kennis over factoren die van invloed zijn op ziekteprogressie te vergroten, dat 
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er nieuwe behandelstrategieën worden gevonden om de ziekteprogressie te vertragen of 
te voorkomen en de juiste patiënten te selecteren voor behandeling met medicatie met 
mogelijk ernstige bijwerkingen. 
Tot nu toe zijn er slechts een beperkt aantal klinische variabelen gevonden die gecorreleerd 
zijn aan een sneller en ernstiger ziektebeloop van MS: de leeftijd waarop de eerste klachten 
ontstaan, progressieve vs. het relapsing remitting subtype, en de frequentie van klinische 
“relapses” vroeg in de ziekte. Echter uitbreiding van deze markers is essentieel voor een 
betere voorspelling van het ziektebeloop. Onze hypothese is dat genetische factoren en 
radiologische factoren vroeg in de ziekte, hierin zouden kunnen bijdragen om een deel 
van de variatie in MS te kunnen verklaren (hierbij hebben we ons met name gericht op 
ziekteprogressie en afgeleiden hiervan). Kunnen we op basis van genetische en radiologische 
factoren (in combinatie met bekende klinische factoren) subtypes onderscheiden met een 
bepaalde prognose? Er zijn in eerdere studies overeenkomsten gevonden in het ziektebeloop 
van meerdere MS patiënten binnen 1 familie. Deze bevindingen suggereren een genetische 
rol. Tevens zijn er radiologische studies beschreven waarin er een verband werd gevonden 
van (verandering in) afwijkingen op de MRI van de hersenen in het begin van de ziekte en 
het ziektebeloop tot 20 jaar na de eerste MRI scan. Tenslotte is bekend dat er een associatie 
bestaat tussen de hoeveelheid afwijkingen in het ruggenmerg met meer neurologische 
klachten (zoals loopproblemen en blaasproblemen).
Zowel genetische als radiologische factoren (zoals zichtbaar op MRI scans van hoofd en 
ruggenmerg) zouden dus vroeg in de ziekte waardevol kunnen zijn bij het verhogen van 
de accuratesse van de ziekte-voorspelling. Beide biomarkers kunnen bijdragen aan een 
betere voorspelling van het ziektebeloop op basis van hun eigen karakteristieken. Zo zullen 
genetische variabelen een bepaalde predispositie aan kunnen tonen voor een bepaald 
ziektebeloop, waarbij genetische variabelen een voordeel hebben dat deze niet veranderen 
gedurende de ziekte en daarmee dus al vanaf het begin van de ziekte betrouwbaar te 
bepalen zijn. Radiologische variabelen daarentegen (zoals veranderingen in het ruggenmerg 
afgebeeld middels MRI) veranderen gedurende de ziekte en zijn daarmee een goede 
afspiegeling van de activiteit tijdens (het begin van) de ziekte. Tevens visualiseren ze de 
aangedane delen van het centrale zenuwstelsel en kunnen daarmee bepaalde symptomen 
verklaren.
Het doel van dit proefschrift is om meer inzicht te geven in enkele factoren die mogelijk 
van invloed zijn op de bijna oneindige klinische en radiologische variatie binnen Multiple 
Sclerose teneinde de nauwkeurigheid van de prognose en diagnose van MS patiënten te 
verhogen. Hierbij hebben we ons gebaseerd op de volgende twee hoofdvragen: 
1. Bestuderen van de rol van enkele genen op bepaalde klinische en radiologische variatie 
binnen MS (waaronder met name de mate van handicap van MS patiënten en de verdeling 
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van de laesies (onstekingshaarden) zoals zichtbaar op MRI van de hersenen en ruggenmerg).
2. Bestuderen van de rol van ruggenmerg-afwijkingen (zichtbaar op de MRI van het 
ruggenmerg) op de diagnose en prognose van MS. Hierbij hebben we zowel naar focale 
afwijkingen gekeken als atrofie (afname van het volume) van het ruggenmerg. 
Na de algemene introductie in hoofdstuk 1 proberen we in hoofdstuk 2 het ziektebeloop te 
voorspellen aan de hand van een aantal genetische factoren. In hoofdstuk 2.1 hebben we 
onderzocht of we de mate van handicap van individuele MS patiënten konden voorspellen 
op basis van de combinatie van meerdere genetische variaties in aanvulling op het effect 
van bekende klinische parameters. Hiertoe hebben we een DNA chip gebruikt waarop 
80 genetische variaties werden onderzocht, die eerder beschreven waren als mogelijk 
gerelateerd aan MS. We vonden dat de genetische variaties afzonderlijk geen significant 
effect hadden op de mate van handicap van patiënten later tijdens de ziekte, tevens was 
er geen effect op de ziekteduur op het moment dat ze een hulpmiddel nodig hadden bij 
het lopen. Echter, een combinatie van genetische variaties laat wel een verhoging van de 
nauwkeurigheid van de prognose zien ten opzichte van alleen klinische variabelen. 
In hoofdstuk 2.2 hebben we specifiek naar 1 bepaald gen gekeken: het Interleukine 7 
receptor-alfa gen. Een variatie (single nucleotide polymorfisme (SNP)) in dit gen is de laatste 
jaren duidelijk geassocieerd met het risico op het ontwikkelen van MS. Deze specifieke 
variatie binnen dit gen leidt tevens tot functionele veranderingen op mRNA niveau, wat zou 
kunnen leiden tot een veranderde functie van het eiwit zelf. Gezien deze veranderingen op 
het mRNA niveau was onze hypothese dat dit gen (betrokken bij ontstekingsprocessen) ook 
een rol zou kunnen spelen bij processen betrokken bij ziekteprogressie. Hier vonden we 
echter geen aanwijzingen voor in onze studie.
Tenslotte hebben we in hoofdstuk 2.3 onderzocht of het KIF1B gen een rol speelt bij het 
neurodegeneratieve fenotype van MS. De variatie (rs10492972) in het KIF1B gen is de enige 
SNP in een gen dat geassocieerd is met een hoger risico op het ontwikkelen van MS, waarbij 
het eiwit een directe rol speelt in neurodegeneratie (de overige genen die betrokken zijn bij 
een hoger risico op MS zijn vooral geassocieerd met inflammatoire (ontstekingsgerelateerde) 
processen). Onze hypothese was dat MS patiënten die het met MS geassocieerde allel dragen 
meer neurodegeneratieve kenmerken hebben. Echter, in onze patiëntenpopulatie vonden 
we geen effect van dit gen op klinische en radiologische afgeleiden van neurodegeneratie 
(respectievelijk ziekte-ernst na langere tijd en de snelheid van hersenvolume afname). De 
hoofdstukken hiervoor genoemd geven aan (gesterkt door andere studies) dat de genen die 
geassocieerd zijn met het ontwikkelen van MS niet dezelfde zijn als de genen die betrokken 
zijn bij processen tijdens de ziekte die de ziekte-ernst bepalen.
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In hoofdstuk 3 hebben we gekeken naar de genetische invloed op de verdeling van laesies 
binnen het centrale zenuwstelsel. De lokatie van de laesies is een van de parameters die 
direct en indirect de ziekte-ernst kunnen bepalen. Sommige laesies in klinisch belangrijke 
gebieden zullen veel klachten geven, terwijl er ook nieuwe laesies op bepaalde plaatsen 
in het centrale zenuwstelsel op de MRI zichtbaar kunnen zijn, zonder dat deze klachten 
heeft gegeven bij de patiënt. We verwachten een genetische invloed gebaseerd op eerdere 
demografische studies. In hoofdstuk 3.1 hebben we onderzocht of de laesie-verdeling 
tussen de hersenen en het ruggenmerg beïnvloed wordt door genetische invloeden. Onze 
studie laat zien dat het HLA-DRB1*1501 genotype (het genotype waarvan reeds bekend is 
dat het een vier keer verhoogde kans geeft op het ontwikkelen van MS) geassocieerd is met 
een hoger aantal en groter totaal volume van de ruggenmerg laesies. 
In hoofdstuk 3.2 hebben we tevens onderzocht of de laesieverdeling in de hersenen zelf 
onder invloed staat van genen. We vonden dat een bepaalde variatie binnen het MHC klasse 
II gen (rs2227139) geassocieerd is met een hogere kans op het hebben van een laesie op 
de MRI ter plaatse van de rechter voorhoorn. Nog tien andere genetische variaties waren 
borderline-significant geassocieerd met het ontwikkelen van laesies op specifieke plaatsen 
in de hersenen. Hoewel uiterst interessant dienen deze bevindingen verder worden 
onderzocht door andere onderzoeksgroepen. 
In hoofdstuk 4 onderzochten we de klinische relevantie van ruggenmerg-afwijkingen 
(laesies in het gehele ruggenmerg en het volume van het cervicale ruggenmerg) op het 
diagnosticeren van MS en op het voorspellen van de ernst van de ziekte. In het verleden 
heeft de nadruk gelegen op de MRI scan van de hersenen. Onze studie in hoofdstuk 4.1 
laat zien dat de aanwezigheid van laesies in het ruggenmerg zowel kunnen helpen bij het 
vroeg stellen van de diagnose MS in CIS patiënten, als ook op het voorspellen van de tijd 
tot een volgende klinische episode van klachten. Naar aanleiding van onze studie adviseren 
we om vaker een ruggenmerg MRI scan te maken om zo sneller de diagnose te stellen en 
om accurater een prognose te geven. Dit zou kunnen leiden tot minder onzekerheid bij 
patiënten in de vroege fase. 
In hoofdstuk 4.2 laten we tevens zien dat niet alleen laesies relevant zijn in de prognose 
van MS patiënten, maar dat ook het volume van het cervicale ruggenmerg (ruggenmerg ter 
plaatse van de nek) zeer gerelateerd is aan de mate van invaliditeit. Een lager volume van 
het cervicale ruggenmerg is geassocieerd met een hogere mate van invaliditeit.
Concluderend, is het nauwkeurig voorspellen van het ziektebeloop van MS patiënten erg 
belangrijk, mede ook gezien de recente ontwikkelingen op het gebied van nieuwe ziekte-
modulerende medicatie die binnenkort zeer waarschijnlijk op de markt zullen komen. 
Een nauwkeurige selectie van patiënten die mogelijk baat zou kunnen hebben bij deze 
therapieën is uiterst belangrijk. Meest waarschijnlijk zal de combinatie van klinische 
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gegevens, radiologische bevindingen en resultaten van biomarker studies (incl. genetische 
informatie) in de toekomst kunnen leiden tot een betere voorspelling van de prognose van 
individuele MS patiënten.
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Prof. Dr. J.J. Heimans, beste Jan, bedankt voor de bereidheid om zitting te nemen in de 
promotie-commissie en voor de kans om de opleiding tot neuroloog te volgen. 
Prof. Dr. R.Q. Hintzen, beste Rogier, dank voor de vlotte samenwerking tijdens ons KIF1B 
manuscript en voor de bereidheid om zitting te nemen in de promotie-commissie.
Dr. N.F. Kalkers, beste Nynke, jij stond aan het begin van mijn onderzoekstijd. Mede door 
jouw verhalen ben ik enthousiast geraakt voor MS-onderzoek. Ik waardeer het zeer dat 
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Collega’s:
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list of abbreviations
25-TWT: 25 feet timed walk test 
9-HTP:  Nine-Hole-Peg test (D: dominant hand, ND: non-dominant hand)
ADAMTS14:  a disintegrin and metalloproteinase with thrombospondin motif, type 1   
 motif 14
BTNL2:  butyrophilin-like 2 
CACNG4:  calcium channel, voltage-dependent, gamma subunit 4 
CIS: clinically isolated syndrome
CCDC46:  coiled coil domain containing 46 
CCL5:  chemokine (C-C motif) ligand 5 
CCR5:  chemokine (C-C motif) receptor 5 
CIITA:  class II, major histocompatibility complex, transactivator 
CNS: central nervous system
CNTF:  ciliary neurotrophic factor 
CRYAB:  Alpha B crystallin
CTLA4:  cytotoxic T-lymphocyte-associated protein 4
DMT: disease modifying therapy
EBF1:  early B-cell factor 1
EDSS: Expanded Disability Status Scale
FAS:  TNF receptor superfamily, member 6
GABBR1:  gamma-aminobutyric acid (GABA) B receptor, 1
GLM: General Lineal Model
GWAS: genome-wide association study
HELZ:  helicase with zinc finger
HLA:  human leucocyte antigen
HLA-DRA:  human leucocyte antigen DR alpha
HSPB2:  heat shock protein Beta 2
HWE: Hardy-Weinberg equilibrium
IFNAR1:  interferon (alpha, beta and omega) receptor 1
IFNGR2:  interferon gamma receptor 2 (interferon gamma transducer 1)
IL1B:  interleukin 1, beta
IL1RN:  interleukin 1 receptor antagonist
IL2:  interleukin 2
IL4R:  interleukin 4 receptor
IL7R:  interleukin 7 receptor
IL10:  interleukin 10
IQR : interquartile range
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KIF1B: kinesin family member 1B
Ln: natural log transformation
LPM: lesion probability mapping
MAF : minor allele frequency
MC1R:  melanocortin 1 receptor
MEFV:  mediterranean fever
MOG:  myelin oligodendrocyte glycoprotein
MRI: magnetic resonance imaging
mRNA: messenger ribo nucleic acid
MS: Multiple Sclerosis
ms: millisecond
MSFC: Multiple Sclerosis functional composite
MSSS: Multiple Sclerosis severity score
NBV: brain volume normalized for head size
NDUFA7:  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7
NDUFS5:  NADH = (Nicotinamide adenine dinucleotide) dehydrogenase    
 (ubiquinone) Fe-S protein 5
NDUFS7:  NADH dehydrogenase (ubiquinone) Fe-S protein 7
NFKIBL1:  nuclear factor of kappa light polypeptide gene enhancer in B-cells   
 inhibitor-like 1
NGMV: normalized gray matter volume
NWMV: normalized white matter volume
NOS2:  nitric oxide synthase 2
NOTCH4:  Notch homolog 4
PASAT: paced auditory serial addition test
PD:  proton density
PDCD1:  programmed cell death 1
PITPNC1:  phosphatidylinositol transfer protein, cytoplasmic 1
PNMT:  phenylethanolamine N-methyltransferase
PP: primary progressive
PRKCA:  protein kinase C, alpha
PTPN22:  protein tyrosine phosphatase, non-receptor type 22
PTPRC:  protein tyrosine phosphatase, receptor type, C
RR: relapsing remitting
SC: spinal cord
SD:  standard deviation
SE: standard error
SP: secondary progressive
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SPP1:  secreted phosphoprotein 1 / osteopontin
T1LV: volume of T1 hypointense brain lesions
TE: echo time
TR:  repetition time
TNF:  tumor necrosis factor
TNFSF10:  tumor necrosis factor (ligand) superfamily, member 10
UCCA: mean upper cervical cord cross-sectional area
UCP2:  uncoupling protein 2
VDR:  vitamin D (1,25- dihydroxyvitamin D3) receptor
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Colour figures
A
Chapter 3.2. Figure 1: Lesion frequency map for our group of 208 MS patients, indicating for every 
voxel the lesion frequency throughout our patient sample, showing a range from 1% (n=2 patients 
having a lesion in that voxel) through the maximum of 33% (n=69). 
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Chapter 3.2. Figure 2: Association between increased lesion probability and genotype. Each row shows 
results for the comparison of one genotype compared to the other two. a: CC genotype of rs2107538 
within the CCL5 gene (chemokine (C-C motif) ligand 5). b: AA genotype of rs9808753 within IFNGR2-
gene (IFNGR2: interferon gamma receptor 2). C: AG genotype of rs2076530 within Butyrophilin-like 
2 gene (BTNL2) (MHC class II associated). D: AG genotype of rs876493 (within phenylethanolamine 
N-methyltransferase-gene). e: CT genotype of rs2227139 (within MHC class II region). F: CT genotype 
of rs2227139 (within MHC class II region), when statistically controlled for total T2 brain lesion volume.
Images show several axial slices of the T2-weighted template (the same slices in each case), with color 
overlay (indicating p-values) of the clusters in which local lesion probability was significantly increased. 
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Chapter 3.2. Figure 3: Association between decreased lesion probability and genotype. Each row shows 
results for the comparison of one genotype compared to the other two. a: CT genotype of rs3781202 
(within FAS-gene: TNF receptor superfamily, member 6). b: TT genotype of rs2234978 (within FAS-
gene: TNF receptor superfamily, member 6). C: GG genotype of rs2076530 within Butyrophilin-like 2 
gene (BTNL2) (MHC class II associated). D: AA genotype of rs762550 within Alpha B crystallin gene. e: 
GG genotype of rs2074897 within NDUFS7-gene (NADH dehydrogenase (ubiquinone) Fe-S protein 7). 
F: CC genotype of rs659366 within UCP-2 gene (Uncoupling protein 2). 
Images show several axial slices of the T2-weighted template (the same slices in each case), with color 
overlay of the clusters in which local lesion probability was significantly decreased.
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Chapter 4.1. Figure 1: Survival-curves on effect of presence of spinal cord lesions on time to 
conversion to CDMS. 
Figure 1a: Survival-curve (Kaplan Meier) in total group of CIS patients (n=121), significant shorter time 
to CDMS for patients with compared to patients without SC lesions (p=0.005 Cox regression). Figure 
1b: Kaplan Meier curve in non-spinal CIS patients not fulfilling McDonald brain MRI criteria (n=42). 
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Colour figures
A
Chapter 4.2. Figure 2: Sagittal T1-weighted image of the brain illustrating volume-of-interest selection 
(30mm section length) in the cervical cord (A) starting at the upper borders of C2. Representative axial 
T1w with overlaid (red) corresponding segmentation image of (B) a relapsing remitting MS patient 
(UCCA: 85mm2) and (C) a primary progressive MS patient (UCCA: 66mm2). 
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